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ABSTRACT 
Combined Biosynthetic and Synthetic Production of Valuable Molecules: A Hybrid 
Approach to Vitamin E and Novel Ambroxan Derivatives 
Bertrand T. Adanve 
Chapter 1. Introduction 
Synthetic chemistry has played a pivotal role in the evolution of modern life.  
More recently, the emerging field of synthetic biology holds the promise to bring about a 
paradigm shift with designer microbes to renewably synthesize complex molecules in a 
fraction of the time and cost. Still, given nature’s virtuosity at stitching a staggering 
palette of carbon frameworks with ease and synthetic chemistry’s superior parsing 
powers to access a greater number of unnatural end products, a hybrid approach that 
leverages the respective strengths of the two fields could prove advantageous for the 
efficient production of valuable natural molecules and their analogs.  
To demonstrate this approach, from biosynthetic Z,E-farnesol, we produced a 
library of novel analogs of the commercially important amber fragrance Ambrox®, 
including the first synthetic patchouli scent. Likewise, we produced the valuable 
tocotrienols from yeast-produced geranylgeraniol in a single step, the first such process 
of its kind. The novel acid catalyst system that allowed for this unique regioselective 
cyclization holds promise as an asymmetric proton transfer tool and could open the door 
to facile asymmetric synthesis of vitamin E and other molecules.  
Chapter 2. Z,E-Farnesol Biosynthesis 
To produce the scarce and costly Z,E-farnesol biosynthetically, we over-
expressed the four reported Z,E-FPPS (from acid-fast bacteria M. tuberculosis, T. fusca, 
C. glutamicum, and C. efficiens) into E. coli and the two with the best reported kinetics
(those from M. tuberculosis and T. fusca) into yeast. Though our engineered yeast strains 
did not produce any detectable Z,E-farnesol, they surprisingly produced high titers of 
E,E-farnesol. In E. coli, the Z,E-FPPS from M. tuberculosis led to the best production 
titers of Z,E-farnesol (8.0 mg/L in flasks and 2.9 mg/L at bench scale), allowing us to 
produce and isolate 50 mg of the material. 
Chapter 3. Novel Ambroxan Analogs from Biosynthetic Farnesol 
In a first demonstration of the hybrid approach where the biosynthesized 
intermediate is not part of the target molecule’s biosynthetic pathway, microbe-produced 
Z,E-farnesol was homologated and subsequently cyclized with the halonium donors 
BDSB and IDSI to yield halo-benzohydrofurans, the 3 carbon halogenated versions of the 
commercially relevant 9-epi-Ambrox®. From this halogenated intermediate, the known 
compound was derived along with a library of novel analogs with improved organoleptic 
properties, among which the first synthetic patchouli scent.  
Chapter 4. Geranylgeraniol Biosynthesis 
We engineered yeast with a set of fusion enzyme constructs, including a first of 
its kind triple fusion enzyme construct, which led to geranylgeraniol (GGOH) production 
with no squalene side product despite no repression of squalene synthase (ERG9). With 
this triple fusion-engineered strain, we produced 27 mg of isolated GGOH in a very 
rudimentary, homemade fermenter. 
Chapter 5. Tocotrienols in Single Step from Biosynthetic Geranylgeraniol 
In a second demonstration of the hybrid biosynthetic synthetic approach, we 
coupled the yeast-derived geranylgeraniol with trimethylhydroquinone to produce the 
potent vitamin E α-tocotrienol in a single step C–C coupling with concomitant 
regioselective cycloetherification of the most proximal vinyl, which constitutes the 
shortest synthesis of the tocotrienol. Likewise, we synthesized the three other members of 
the tocotrienol family.  
Chapter 6. Novel Chiral Acid for asymmetric proton transfer: Adanve acids applied 
to Chiral vitamin E synthesis 
We developed a new class of chiral Bronsted acids (Adanve acids), materials that 
are highly tunable, easy to synthesize, and easy to handle as well as recover. In a 
preliminary exploration of the ability of these chiral acids to induce asymmetric proton 
transfer, we investigated their usage to impart asymmetric formation of chromans, 
namely the important vitamin E family. Our early findings suggest that a host of factors 
play a role in the ability of this novel acid catalyst system to induce asymmetric chroman 
formation.  
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1.1   The Eminence of Synthetic Chemistry and Its Limitations 
Over the course of the past two centuries, synthetic chemistry has played a 
profound role in the development of society, impacting nearly every component of 
modern life. Its power to create molecules has grown tremendously, and there remain at 
present few known organic molecules that synthetic chemistry has not conquered through 
its immense sophistication and ingenuity. Even incredibly complex natural products like 
Taxol (1) and Brevetoxin were synthetically assembled in the mid-1990s.1-3  
The potential of synthetic chemistry was first ushered in by Friedrich Wohler in 
1828 when he synthesized urea (2).4 1903 then saw the first commercial total synthesis 
with Gustaf Komppa’s industrial production of camphor (3). This achievement 
crystallized the notion that chemical synthesis, with its convenience and scale in 
producing complex molecules from the assembly and manipulation of simpler building 
blocks, could supplant natural source extraction for the production of much needed 
molecules.  
This paradigm shift was welcomed, for direct extraction from natural sources was 
often fraught with challenges such as short supply, difficulty in isolating reasonable 
amounts of material as well as costs associated with purification and product shipment 
from one end of the world where the natural source is found to the other end where the 
product is consumed. For instance, Carothers’ synthesis of nylon at Dupont in 19305 
offered a convenient alternative to natural rubber, which was hitherto produced through 
the collection of latex sap from rubber trees in tropical zones. The triumph of synthetic 
chemistry became even more pronounced in the second half of the last century, which 
saw an explosion in the sophistication with which organic molecules were synthetically 
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assembled beginning with Woodward’s syntheses of many complex natural products 
including quinine (4), strychnine, cortisone, reserpine, chlorophyll, and vitamin B12.6,7 
Expanding this Woodwardian era with their seminal achievements,6-8 chemists like 
Corey, Barton, Stork, Eschenmoser, and Nicolaou further augmented our understanding 
of the fundamental principles governing chemical structures and reactivities, 
consolidating the awesome power of synthetic chemistry to make any molecule, from 
therapeutics to polymers, through a vast arsenal of chemical reactions, synthetic 
strategies, and analytical tools. The impact and influence of synthetic chemistry has yet to 
wane. To the contrary, it remains vibrant and dynamic with many young chemists’ foray 
into the field armed with novel synthetic tools, new ideas for functionalization 
chemistries, and a deeper knowledge of biosynthetic tactics.  
Figure 1: Examples of natural products produced by synthetic chemistry 
Furthermore, the advantages of synthetic chemistry go beyond simply providing a 




































improvements to natural products by enabling access to analogs with better 
pharmacokinetics and toxicity profiles, a crucial benefit since natural products are not 
always optimized for human biochemistry. Synthetic chemistry can also bring about 
completely novel compounds with unique, advantageous properties that do not occur in 
nature, as was the case with Kevlar and Teflon, materials from Dupont that continue to 
find wide applications in many areas of human life.  
Nevertheless, despite synthetic chemistry’s untold merits and vast potential to 
continue its impact on the future, some limitations remain. First, synthesis can be time-
consuming, often constituting the rate-limiting step in nearly all biomedical 
investigations. Second, it typically relies on petrochemical-based precursors and highly 
expensive reagents and catalysts. Third, even when a key molecule of interest has been 
identified, if it is of even a moderate degree of complexity it is unlikely that it can be 
made efficiently on scale, let alone in environmentally benign ways. As an example of 
the state of the art, a recent effort by process chemists at Novartis showed that more than 
50 g of the bioactive natural product discodermolide could be synthesized in 39 overall 
steps in an industrial environment, but only through a Herculean effort involving 43 
chemists, 17 large-scale chromatographies and 20 months of overall time.9-12  
1.2   The Emergence of Synthetic Biology and Its Limitations 
Given these limitations of synthetic chemistry, and in particular the value of 
complex natural products for the development of novel medicines, unique materials, 
cosmetics, perfumes, and sundry other applications, synthetic biology appears well 
poised to be a natural and significant complement to synthetic chemistry. Just as synthetic 
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chemistry provided a favorable alternative to the extraction of organic molecules from 
their natural source at great cost in the 19th and 20th centuries, synthetic biology holds the 
promise to bring about another paradigm shift, a more renewable one, in how organic 
compounds are produced for mass consumption.   
Until recently, biology was an observation-analysis only science, much like 
chemistry before the advent of synthetic methods. But a deeper understanding of the 
“stimulus-DNA-RNA-Peptide” relationship, more sophisticated molecular biology tools 
for genome manipulation, advances in the elucidation and construction of metabolic 
pathways spurred by the appreciation that natural products were biosynthesized according 
to the rules of organic chemistry, and breakthroughs in the various -omics technologies 
have conferred a synthetic echelon to the biology field.    
Increasingly, innovations in this branch of biology, synthetic biology, hint to a 
future where microbes are reprogrammed as adaptive diagnostic and remedial tools that 
seek and destroy pathogens inside the body. In this future, not only are microbes 
engineered with logic gates effectively turning them into living computers, but they are 
also, owing to their ease of culture and exponential reproduction rates, foundries inside of 
which valuable organic molecules—fuels, therapeutics, polymers—are produced in a 
cheap, convenient, and renewable fashion. One could point out that the use of microbes 
as living foundries for the synthesis of important molecules began in 1928 when 
Alexander Fleming discovered that Penicillium rubens produced an anti-bacterial 
(penicillin) when grown under certain conditions. But it was not until synthetic and 
molecular biology methods were engaged to evolve better strains of the fungi that enough 
penicillin could be produced to satisfy demand.  
5
Figure 2. Examples of natural products produced by synthetic biology 
Getting a microbe to efficiently produce a compound that it does not already 
produce natively demands the expertise of metabolic engineering, a field that was 
essentially born in the 1990’s.13 It does not suffice to simply introduce the genes of a 
xenobiotic pathway into the microbial host—lest toxic intermediates accumulate and kill 
the cell, negatively interfering with target production. Instead, one must take a more 
intricate, global, and synergistic approach where all genes on the metabolic pathway are 
controlled with respect to one another to maintain flux balance so that sufficient titers of 
the target molecule can be produced without disrupting endogenous homeostasis. Other 
crucial considerations include the types of carbon source fed to the organisms, growth 
conditions, protein modifications, and techniques for product detection and isolation.  
Some of these concepts are already being put to practice. For instance, 1,3-propanediol 
(7) was successfully produced in titers reaching 3.5 g/L/h;14 amorphadiene (8) was
produced in yields of over 40 g/L,15,16 taxadiene (9) at 1.08 g/L,17 sclareol (10) at 1.5 
g/L,18 and many others including polyketides such as the promising anti-cancer 
epothilone19 and biofuels like butanol.20 This rapid progress in the metabolic engineering 
















Still, significant challenges remain to tap the field’s full potential, with two of the 
most notable issues being that key enzymes in the biosynthetic pathways of target 
molecules are often missing and engineering redox partners-requiring P450 enzymes for 
the oxygenation steps is arduous.21,22 In fact, to date no report of the functional 
expression of more than one P450 enzyme exists, and even successful single P450 
expressions often come at the price of significantly lower titer yields.17,23 This latter 
challenge is perhaps the most significant considering that the majority of bioactive 
natural products are decorated with an assortment of functionally critical oxygen-based 
groups. 
Furthermore, it is imperative to appreciate that the goal is not always to make the 
same molecule as nature given that synthetically derived analogs often exhibit superior 
properties to the natural compound. For instance, with the penicillins, it was ultimately 
(+)-6-Aminopenicillinic acid (11), the core of the molecule, which was biosynthesized 
and then synthetically modified into novel antibiotics (12) with greater efficacies against 
gram-negative bacteria and beta-lactamase producing organisms.24 This model sheds 
deep light on valuable solutions for 21st century science.  
1.3   The Hybrid Biosynthetic and Synthetic Approach 
With the current limitations of the two fields in mind and the appreciation that 
synthetic chemistry enhances synthetic biology, for my Ph.D thesis, I aimed to leverage 
the respective strengths of synthetic biology and synthetic chemistry in a combined 
“jigsaw” strategy to produce complex natural and unnatural organic molecules in an 
efficient and sustainable manner (Figure 3).  
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Figure 3. Schematic representation of the hybrid approach 
For molecules necessitating several oxygenations, the hybrid approach seeks to 
biosynthesize an advanced intermediate with one or two chemical handles that are 
strategically positioned to aid in the functionalization of additional positions by way of 
synthetic chemistry, thus enabling rapid generation of the target natural product and a 
manifold of analogs.  






















































11: (+)-6-Aminopenicillinic acid 12: penicillin analogs
13: Baccatin III 1: Taxol


















Previously, others have demonstrated similar combined semi-biosynthetic 
approach to produce several key molecules such as penicillin, taxol, artemisin, Δ7-
Dafacronic acid, and polyketide derivatives.23-27 In each case, fermentation in biological 
hosts is used to produce an advanced intermediate and subsequent organic 
transformations are implemented to yield the final product. Figure 4 depicts the reported 
semisyntheses of penicillins, taxol, and artemisinin.  
In contrast to this general strategy, we aimed to leverage nature’s approach for 
building varied, versatile carbon frameworks and mesh it with synthetic chemistry’s 
parsing and combinatorial abilities to access a greater number of natural and unnatural 
end products (Figure 3). Importantly, this approach does not necessitate that these 
compounds occur as natural biosynthetic intermediates in the pathway towards the target 
molecule. By contrast, in this strategy, optimization of biosynthetic production of 
relatively few molecules can result in the efficient semi-biosynthetic production of many. 
Moreover, this hybrid approach calls for the examination of any material up for 
production to discern an intermediate step where it is optimal for either synthetic biology 
or synthetic chemistry to be involved, a strategy which requires synthetic biology as well 
as synthetic chemistry expertise. Lastly, this approach may sometime require the 
invention of novel chemistry (as is the case with our single step synthesis of tocotrienols 
described later in this thesis).  
Figure 5 demonstrates how the hybrid approach could be applied to Taxol (1), the 
valuable but scarce anticancer agent. To begin, yeast would be engineered to produce 
Taxadien-5,10-diol (16) in high titers. Subsequently, this intermediate would be isolated 
and its 5-hydroxyl enlisted to install the oxetane ring with concomitant generation of the 
9
4-hydroxyl. C13 would be readily oxidized as it is allylic to give compound 17. 
Subsequently, the 4-hydroxyl would be recruited to direct the oxidation at C2, and the 10-











Figure 5. Possible taxoid therapeutics production by the hybrid approach 
 
given that SAR studies have indicated that the 7-hydroxyl and 1-hydroxyl are not 
required for activity, and that a hydroxyl instead of a ketone at C9 improve anti-cancer 
activity, a modified beta-lactam tail could be affixed to 18 to produce less oxygenated, 
unnatural taxoid analogs such as 19 that could have better activity than Taxol (1). 
Alternatively, 18 could be taken to Baccatin III (13) after oxidation of C1 and C7, after 
which, upon affixing of the appropriate beta-lactam tail, we arrive at Taxol (1) and 
Taxotere® (20).  
While it would have been rewarding to apply the hybrid approach to a complex 







































































with great commercial and therapeutic value, were better fits for a first proof-of-principle 
demonstration.   
 
1.4   The Hybrid Biosynthetic and Synthetic Approach Applied to 9-epi-Ambrox®  
        and tocotrienols 
In a first demonstration of the hybrid approach where the intermediate produced is 
not found on the target molecule’s biosynthetic pathway, and the target molecule itself is 
not a natural product, we engineered S. cerevisiae and E. coli to produce 2-Z,6-E-farnesol 
(Z,E-FOH, 21). Then, using chemical synthesis, we converted this versatile precursor to 
the valuable tricyclic labdane ether fragrance 9-epi-Ambrox® (22) and a library of novel 
analogs with improved ambergris-type organoleptic properties, including, to our 
knowledge, the first synthetic patchouli scent. 
 
Figure 6. Demonstrated hybrid approach to 9-epi-Ambrox® and analogs 
 
In a second demonstration of the hybrid approach, we engineered S. cerevisiae to 
produce the diterpene geranylgeraniol (GGOH, 23), which we subsequently coupled with 
trimethylhydroquinone to produce the potent vitamin E tocotrienols (24) in a single step 



























vinyl group in what constitutes the shortest synthesis of α-tocotrienol to date (Figure 7A). 
Likewise, we synthesized three other members of the tocotrienol family. In the latter 
case, the necessary use of a meta-directing group to prevent over-alkylation of the 
additional open arene positions led to a great proportion of the obtained product being the 
uncyclized 3-geranylgeranyl-hydroquinone acetates. We selectively cyclized these 
products to tocotrienols with a Bronsted acid version of the original acid catalyst system 
at room (Figure 7B).  
Finally, we explored the ability of the novel acid catalyst system that allowed for 
the single step tocotrienol synthesis to effect asymmetric proton transfer as applied to 

















Figure 7. (A) Demonstrated hybrid approach to tocotrienols (B) Mild regioselective cyclization 




1.5   Conclusion 
Synthetic chemistry has played a pivotal role in the evolution of modern life by 
providing a reliable alternative to the extraction of important molecules from natural 
sources, offering novel synthetic materials with advantageous properties such as life-

















































z = H, F
n = 1 - 3










R1, R2 = Me, Me (α); Μe, H (β); H, Me (γ); H, H (δ)
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improved understanding of biological systems and our enhanced ability to engineer living 
organisms, the emerging field of synthetic biology holds the promise to bring about 
another paradigm shift with designer microbes to renewably synthesize complex 
molecules in a fraction of the time and cost. Still, given nature’s virtuosity at stitching a 
staggering palette of carbon frameworks with ease and synthetic chemistry’s superior 
parsing and combinatorial powers to access a greater number of unnatural end products, a 
hybrid approach that leverages the respective strengths of the two fields could prove 
advantageous for the efficient production of valuable natural molecules and their analogs.  
To demonstrate this approach, I will describe in this thesis how, from biosynthetic 
Z,E-farnesol, a library of novel analogs of the commercially important amber fragrance 
Ambrox® were produced. Likewise, the valuable tocotrienols were generated from yeast-
produced geranylgeraniol in a single step, the first such process of its kind. The novel 
acid catalyst system that allowed for this unique regioselective cyclization holds promise 
as an asymmetric proton transfer tool for other applications, opening the door for facile 
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2.1   Introduction 
 Plant secondary metabolites constitute a vast and diverse group of molecules that 
have been evolved for millions of years to fulfill a range of purposes including defense, 
signaling, growth, and reproduction. Astoundingly, these metabolites are all derived from 
a common precursor, acetyl CoA—one could go even further back through glucose to 
carbon dioxide and water—showcasing nature’s virtuosity for stitching together 
monomers to yield a wide array of molecular structures. Figure 1 illustrates this natural 
complexity.  
      
 
Figure 1. Nature’s synthetic pathway to diverse architectures from a single starting point. 
 
 
For hundred of years, key classes of these secondary metabolites have found 
crucial human applications. Given their large biodiversity, desirable properties, and 
extensively studied biosynthesis and chemical reactivity, terpenes lend themselves 
fittingly to the hybrid approach described in the preceding chapter.  
With over 55,000 members, terpenes constitute the largest and most diverse 
family of secondary metabolites, finding use in numerous human applications including 































building block, isoprene, which can be derived from the prokaryotic methylerythritol 
phosphate (MEP) pathway or from the eukaryotic mevalonate (MVA) pathway.1-3 
Isoprene is then stitched together in a head to tail synthesis as dimethylallyl 
pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP) to yield a linear 
isoprenoid. This linear molecule can be hydrolyzed to yield prenyl alcohols, or it can be 
cyclized by different cyclases into a vast palette of carbocyclic frameworks that in turn 
can undergo rearrangements and functionalization, largely at the hand of P450 enzymes, 
to yield a staggering diversity of terpenoid molecules. Sesquiterpenes (15 carbon 
terpenes) are the most diverse class in the terpene family, comprising over 10,000 
members. Many key therapeutics such as artemisinin (1), fuels such as farnesane (2), and 
fragrances such as selinene (3) are sesquiterpenes.  
 
 






























































In our hybrid approach to 9-epi-Ambrox® (5), we aimed to employ Z,E-farnesol 
(4, Z,E-FOH), the 2-cis,6-trans isomer of the common sesquiterpene progenitor farnesol 
as our starting material. Given the cost and difficulty in obtaining Z,E-FOH ($1,000 per 
mg from commercial sources, seven synthetic steps from geraniol),4,5 we aimed to 
engineer S. cerevisiae (yeast) and E. coli for cheap and renewable production of this 
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Terpenoid production in heterologous hosts is typically achieved by first 
enhancing the pool of IPP and DMAPP by overexpressing the MEP or MVA pathways.6-8 
With the MVA pathway in yeast, overexpression of the rate-limiting hydroxymethyl-Co-
A reductase (HMG1) often combined with repression of ERG9 (squalene synthase, which 
diverts FPP and GGPP to ergosterol synthesis) is often sufficient to achieve this goal.9 
Then, overexpression of the appropriate isoprenoid diphosphate synthases and cyclases 
allows for the condensation of the 5-carbon monomers and their cyclization to reach the 
desired structure. However, the ERG9 repression or mutation approach requires 
supplemention of the fermentation media with ergosterol, an essential component of yeast 
cell membranes. 
In our case, in addition to overexpression of the MEP pathway (E. coli) and 
HMG1 enzyme (yeast), we required a Z,E-FPPS that would catalyze the formation of 
Z,E-farnesylpyrophosphate, which in turn would be hydrolyzed by endogenous 
phosphatases such as DPP1 to yield our desired Z,E-FOH (4).  
 
Figure 5. Strain design for Z,E-FOH production in engineered microbes. A) MEP in E. coli. B) 
MVA in S. cerevisiae. 
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2.2.  Z,E-farnesylpyrophosphate synthases (Z,E-FPPS) 
Naturally, most organisms, including yeast and E. coli, possess native 
farnesylpyrophosphate synthases (FPPS) that catalyzes the formation of the trans,trans- 
farnesyl isomer. With the exception of the long-chain (C40–C200) isoprenoid synthases 
that catalyze the formation of Z isoprenoids,10,11 few Z-FPP synthases have been 
identified. To date, only four Z,E-FPPS have been cloned, all from acid fast bacteria (M. 
tuberculosis, T. fusca, C. glutamicum, and C. efficiens).12,13  
To achieve production of the target Z,E-FOH in our host strains, we imported all 
four known Z,E-FPPS into E. coli strains and the two Z,E-FPPS with the best reported 
kinetics13 (those from M. tuberculosis and T. fusca) into yeast. The heterologously 
expressed Z,E-FPPS relies on the endogenous 5-carbon terpene precursors IPP and 
DMAPP as building blocks for assembly of Z,E-FOH. While E,E-farnesyl pyrophosphate 
(E,E-FPP) is a substrate for several downstream processes in yeast as well as E. coli, we 
anticipated that Z,E-farnesyl pyrophosphate (Z,E-FPP) would not be diverted into 
downstream biosynthetic processes due to the altered geometry about the double bond.     
  
2.3  Z,E-farnesol in E. coli 
 In E. coli over-expressing a subset of the B. subtillis MEP pathway, the Z,E-FPPS 
from M. tuberculosis (Rv1086) led to the best Z,E-FOH production (8.0 mg/L in flasks 
and 2.9 mg/L at bench scale production). In flasks, the Rv1086-engineered strain also 
produced E,E-FOH at 2.1 mg/L. Interestingly, the level of E,E-FOH production (0.037 
mg/L) was much lower at bench scale comparatively to the decrease in Z,E-FOH titers, 
suggesting that the large scale conditions were more conducive to greater ratios of Z,E-
FOH product. 
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 Of the other Z,E-FPPS-engineered strains, only uppS1 (C. glutamicum) led to 
Z,E-FOH production (0.77 mg/L) and some E,E-FOH (0.10 mg/L). Ce1055 (C. efficiens) 
produced only E,E-FOH (0.76 mg/L) while Tfu0456 (T. fusca) also produced only E,E-
FOH but at 0.054 mg/L (Figure 6).  
 





















While we were not too surprised that the Ce1055 and uppS1-engineered strains 
did not produce much Z,E-FOH given their less favorable kinetics, we were puzzled that 
the Tfu0456-engineered strain did not produce any Z,E-FOH in our hand not only 
because of its more favorable Kcat/Km,13  but also because our collaborators at Acidophil, 
LLC (who constructed the E. coli strains for us) reported that the Tfu0456-engeneered 
strain had the second highest production of Z,E-FOH to the Rv1086-engineered strain 
(Figure 7). That our fermentation of the same Tfu0456-engeneered strain leading to no 
Z,E-FOH could be explained by the differences in colonies tested (see Section 2.5 of this 
Chapter) or other fermentation condition differences, as we encountered all of these 
challenges in our fermentation of the Rv1086-engeneered strain. Solubility and folding 
issues could also play a role. These latter factors, i.e. differing kinetics, solubility and 
folding, could also explain why the differing Z,E-FOH production levels between the 
four Z,E-FPPS-engineered strains, suggesting that Rv1086 may have the best properties 
for expression in E. coli.   
As such, we selected the E. coli strain engineered with Rv1086 for bench scale 
production. We found that a combination of 10–20% decane content by volume and a 
water bath to maintain constant 29.5 ºC temperature were helpful for Z,E-FOH 
production at this scale in our rudimentary fermentor (vide infra). Unlike previous 
hypotheses that the decane overlay helps prevent the loss of volatile farnesol,14 we 
believe that given farnesol’s high boiling point (284 ºC) a more likely explanation for the 
positive effect of decane on farnesol prodution is that it helps extract the farnesol product 
out of the cell, which prevents the deleterious effects that overproduction of prenyl 
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alcohols has on the organism.15 Surfactants in general were found to have the same effect 
and enhanced prenyl alcohol production in microbes when added to the fermentation 
media.15 As such, we evaluated isopropyl myristate as a possible additive, but the more 
volatile decane made it more suitable for product processing.  
During the course of our fermentations, an independent report16 was published 
where E. coli was engineered with Rv1086 (Z,E-FPPS from M. tuberculosis) to produce 
Z,E-FOH. In this report, they achieved production by fusing Rv1086 to ispA (native E,E-
FPPS), hypothesizing that the GPP (geranylpyrophosphate) produced by the native ispA 
was engaged by Rv1086. We found that this fusion was not necessary, and that the Z,E-
FPPS on its own could drive Z,E-FPP production in E. coli as evidenced by Z,E-FOH 
production.  
 As described in the next section, we did engage the fusion strategy in yeast, albeit 
one different from the reported ispA–Rv1086.  
 
2.4   Z,E-farnesol in yeast 
To achieve Z,E-FOH production in yeast, we chose to focus our efforts on Z,E-
FPPS from M. tuberculosis (Rv1086) and T. fusca (Tfu0456) given that they were 
reported to have the two highest Kcat/Km out of the four known Z,E-FPPS. For the 
background strain, we chose ATCC200589, which has been reported to produce E,E-
FOH in titers of 2.2 mg/L when engineered with a truncated version of HMG1 (tHMG1) 
lacking the regulatory domain (Δ1192–1266).17 Our hypothesis was that Z,E-FPPS in a 
background strain with a large pool of IPP and DMAPP would be beneficial to Z,E-FOH 
production.  
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However, when we over-expressed Z,E-FPPS Rv1086 and Tfu0456 in the 
ATCC200589/tHMG1 background, we detected no production of Z,E-FOH in either 
resulting strains (Figure 8) but saw squalene (~2.5 mg/L) and E,E-FOH (<0.3 mg/L) 
production. Additionally, we introduced double fusion constructs of Rv1086 and Tfu0456 
with DPP1, hoping to take advantage of the enhanced substrate channeling effect (see 
Chapter 4 for a more in-depth discussion of fusion strategies) that we have seen in other 
cases. We found that none of these double fusion engineered strains produced our desired 
Z,E-FOH, but that the combination ATCC200589/tHMG1/DPP1-Tfu0456 surprisingly 
led to high levels of E,E-FOH production (20.3 mg/L, Figure 8) with ten-fold lower 
squalene (Figure 8) than the background ATCC200589/tHMG1. This outcome could be 
due to the over-expressed DPP1 in the fusion construct hydrolyzing E,E-FPP to produce 
















Figure 8. Z,E-FPPS-engineered yeast produced E,E-FOH (mg/L) 
 
In our fermentations of ATCC200589/tHMG1/DPP1-Tfu0456, we observed a 
significant side product peak at retention time of ~9.90 min that possessed a similar mass 
spectra and retention time (~9.90 min) to a side product peak in our synthetic Z,E-FOH 
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standard (see Figure S5 in the experimental section). Although this unidentified side 
product peak was also present at lower levels in the background strain 
ATCC200589/tHMG1, the fact that we observed the same peak in our initial E. coli-
Rv1086 fermentations without decane and its disappearance when we employed a 20% 
decane by volume additive suggest that it could be a degradation product of FOH, with 
Z,E-FOH being more prone to this degradation given its lower stability. Unfortunately, 
we could not test whether increased decane levels in the ATCC200589/tHMG1/DPP1-
Tfu0456 fermentation would lead to detectable Z,E-FOH given that the strain’s growth 
was severely impaired when more than 5% decane was added. Alternative surfactants 
that are more compatible to yeast growth but also conducive to rapid GC-MS 
quantification could be helpful in the future to solve this problem (isopropyl myristate is 
compatible with yeast survival but not GC quantification in our hands). It is also possible, 
given that we only tested one codon-optimized version of our constructs, that different 
codon optimizations of the Z,E-FPPS could lead to Z,E-FOH production in yeast.  
 
2.5   High-ATCC200589/tHMG1: A Yeast Background Strain For Terpenoid 
Production 
When we over-expressed tHMG1 under the strong, constitutive promoter TEF1 in 
ATCC200589, the result was increased production of E,E-FOH, geranylgeraniol 
(GGOH), and squalene as compared to the starting strain which only produced E,E-FOH 
to barely detectable levels (Figure 8). Out of 6 independent colonies of 
ATCC200589/tHMG1 screened, 2 produced a 10-fold higher titers of E,E-FOH, GGOH, 
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Figure 9. Prenyl alcohol production in ATCC200589-derived strains. **Data is plotted 
on a log scale. In brackets at the end is the number of independent replicates. Error bars 
represent one standard deviation. 
 
 
These results (Figure 9) suggest that colonies obtained from the same 
transformation can exhibit large differences in production, possibly due to imbalances in 
pathway flux as a result of differences in plasmid copy numbers and/or mutations. As 
such, when engineering cells for heterologous production, it may be beneficial (even 
necessary) to screen a large number of colonies for the desired phenotype.  
The E,E-FOH production titer for the high-ATCC200589/tHMG1 strain was 17.4 
mg/L, which is twice the level of production previously reported in the same background 
strain over-expressing  with a different tHMG1 construct and expression plasmid.17 The 
























































































































































































































ATCC200589/tHMG1 may represent a good background strain for the heterologous 




2.6   Bench Scale Production Optimizations Without Appropriate Fermenter
 Interestingly, the Z,E-FOH titer yields of our Rv1086-engineered E. coli 
decreased by an order of magnitude when going from production in flask to bench scale 
production in 6-liter jars when typically an increase by several orders of magnitude have 
been reported by others with scaled up fermentation.18,19 
Our lower yields are likely due to our less than ideal fermentation conditions. For 
example, we used compressed air instead of oxygen, we had no pH control, or any of the 
other trappings found on modern fermentors. It is likely that our strains would fare much 
better in better fermentation conditions with more favorable aeration, pH, mixing, 
nutrients, and evaporation control. 
 
2.7   Titer Yield Calculation 
We calculated our production titer yields based on mg/L of growth media and not 
on mg/L of the organic extract. Moreover, we did not adjust our titer yields to account for 
the efficiency of the extraction process. It is known that a significant portion of prenyl 
alcohols remain bound within the cell membrane even with the addition of a surfactant to 
the fermentation culture.15 In light of this fact, our actual production titer yields could in 




2.8   Conclusion 
In summary, we expressed the four reported Z,E-FPPS (from acid-fast bacteria M. 
tuberculosis, T. fusca, C. glutamicum, and C. efficiens) into E. coli and the two with the 
best reported kinetics (those from M. tuberculosis and T. fusca) into yeast for 
biosynthetic production of Z,E-FOH. Though our engineered yeast strains did not 
produce any detectable Z,E-FOH, they surprisingly led to high titers of E,E-FOH. In E. 
coli, Rv1086 led to the best production titers of Z,E-FOH, allowing us to produce and 
isolate 50 mg of the biosynthetic material.  
While our immediate goal is to employ Z,E-FOH in the synthetic production of 9-
epi-Ambrox, our successful heterologous expression of Z,E-FPP holds promise for 
parallel biosynthetic production of Z-type terpenenoids.  
**I would like to note that the following people contributed to the work in this chapter:
Caroline Patenode: E. coli–Z,E-FPPS fermentation (including bench scale set-up).  
Yao Zong Ng: Yeast–Z,E-FPPS strain construction and fermentation. 
Acidophil, LLC: E. coli–Z,E-FPPS strain construction and initial fermentation. 
Erik Aznauryan and Pedro Baldera-Aguayo helped with S. cerevisiae cloning and early 
fermentation trials. 
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2.10   Experimental Section 
Culture media 
E. coli 
LB media was made from Miller powdered mix (broth:10285, plates:10283), TB media was 
made from BD-Difco powdered mix (243820). 99% glycerol (G5516), D-(+)-glucose (G7021), 
ampicillin sodium salt (A0166) and spectinomycin dihydrochloride pentahydrate (S40014) were 
purchased from Sigma-Aldrich. 
 
S. cerevisiae 
YPD media (1L): 10g BD Bacto Yeast Extract (212750), 20g Bacto Peptone (211677), dH2O to 
950mL, autoclave; when cooled to 50ºC add 50mL 40% glucose. For yeast SC selective media, 
see Table S4 and S5.  
 
Strain construction 
E. coli  
E. coli BL21 (DE3) cells were made competent using CaCl220 and transformed with plasmid pA8 
(carrying an IPTG-inducible subset of the B. subtillis MEP pathway) and with one of four 
plasmids carrying various Z,E farnesol pyrophosphate synthases (Z,E-FPPases) under an IPTG-
inducible promoter. The four Z,E-FPPases were derived from various species of bacteria and 
codon-optimized for expression in E. coli: M. tuberculosis/RV1086 (pFPP2), T. fusca/Tfu0456 
(pFPP3), C. efficiens/CE1055 (pFPP4) and C. glutamicum/uppS1 (pFPP5). E. coli transformants 
were selected on LB plates containing 50mg/L spectinomycin (for pA8) and 100mg/L ampicillin 
(for pFPPs).  
 
S. cerevisiae 
The yeast (Saccharomyces cerevisiae) strain ATCC200589 was obtained from the American 
Type Culture Collection, Rookville. The other strains used in this study (see Table S1) were 
constructed by transforming various plasmids (see Table S2) into the background strain 
ATCC200589. Yeast transformation was performed by electroporation at 1500V. The 
transformants were cultivated on SC agar plates or liquid media lacking specific amino acids to 
select for the auxotrophic markers on the plasmids. 
 
Plasmid construction 
E. coli  
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Four Z,E-FPPases previously identified in four species of bacteria (M. tuberculosis:RV1086, T. 
fusca:Tfu0456, C. efficiens:CE1055, and C. glutamicum:uppS1)13 were codon-optimized for 
expression in E. coli and synthesized commercially by DNA 2.0 Inc. Each of the four Z,E-
FPPases was amplified by PCR (see Table S3) to add NcoI and XhoI restriction sites on the 5’ 
and 3’ ends respectively. The resulting amplicons and pTrc2B vector were digested with NcoI 
and XhoI, and the construct inserted via InFusion cloning (Clontech), to create the four IPTG-
inducible Z,E-FPPase expression plasmids pFPP2, pFPP3, pFPP4 and pFPP5. The cloning mix 
was transformed into electrocompetent E. coli TG1 cells and selected on LB/ampicillin agar 
plates. This cloning was performed by our collaborator Acidophil LLC. 
Plasmid pA8 containing the B. subtilis MEP pathway was also constructed by Acidophil. It 
consists of a pCL1920 backbone21 with a replication origin from pSC1010 and carrying a 
spectinomycin resistance cassette. It contains the B. subtilis MEP genes dxs, dxr, ispD, ispF, 
ispG, ispH and idi, which were codon-optimized for E. coli expression. The genes were cloned 
under the IPTG-inducible pLac promoter. B. subtilis genes were chosen due to the higher flux 
through the MEP pathway in B. subtilis compared to E. coli.22 
 
S. cerevisiae  
The general strategy adopted for the construction of yeast expression plasmids (see Table S2) 
was: (1) PCR of the individual parts (see Table S3 for primers), (2) overlap/fusion PCR (external 
primers AN409 and AN412 for all plasmids except pAN127) to create a transcriptional unit (TU) 
composed of the promoter, ORF and terminator, (3) Gibson assembly to insert the TU into the 
cut plasmid backbone, and (4) transformation of the Gibson mixture into E. coli TG1 cells for 
selection on LB/ampicillin plates and amplification prior to transforming into S. cerevisiae. 
pAN96 was constructed by Gibson assembly of the vector pRS41623 digested with SacI and 
KpnI, PCR products of the promoter and terminator, as well as synthetic double-stranded gene 
fragments (gblock-1 and gblock-2, Integrated DNA Technologies) coding for yeast codon-
optimized Tfu0456 containing an N-terminal His6-tag and TEV cleavage site. pAN99 was 
constructed via the same strategy but using gblock-3 and gblock-4 coding for yeast codon-
optimized Rv1086 containing an N-terminal His6-tag and TEV cleavage site. pAN193 and 
pAN194 were constructed by Gibson assembly of the vector pRS426 digested with SacI and 
KpnI and the PCR amplified transcriptional units from pAN96 and pAN99 respectively (primers 
AN409 and AN412) (see Table S3). 
The plasmids pAN137 and pCP51 containing the enzyme fusions were constructed by Gibson 
assembly of SacI and KpnI-digested pRS426 with a fusion PCR product containing the promoter, 
N-terminal His6-tag and TEV cleavage site, DPP1, GGGS linker, Rv1086 or Tfu0456 and 
terminator amplified from pAN99/pAN96 respectively. For these two plasmids, the N-terminal 
His6-tag and TEV cleavage site were created by primer extension (primers AN466 and AN467) 
followed by a second round of PCR with the primers AN468 and AN469. The plasmids pAN138 
and pAN141 were constructed by Gibson assembly of SacI and KpnI–digested pRS426 with a 
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fusion PCR product containing the promoter, Z,E-FPPases amplified from pAN96/pAN99 
respectively, GGGS linker, DPP1 and terminator. 
 
Small scale production trials 
E. coli  
E. coli farnesol production was performed in sterilized, baffled, 125mL Erlenmeyer flasks 
(Corning 4444-125) with culture caps (KimKap 73665-25) in an incubator shaker (New 
Brunswick, Innova 43R). On Day 1, a single colony was inoculated into a 14mL Falcon culture 
tube containing 3mL LB with 100mg/L ampicillin and 50mg/L spectinomycin. The culture was 
shaken at 37°C and 230 rpm for 15 hours. On Day 2, 0.5mL of the saturated overnight culture 
was added to 50mL of LB with 1% glycerol, 100mg/L ampicillin and 50mg/L spectinomycin. 
The flasks were grown at 30°C and 230 rpm until they reached an optical density (OD600) of 
approximately 1.5 (4-6 hrs) as determined by a 1:10 dilution of the culture in LB media. OD600 
measurements were carried out in a SpectraMaxPlus 384 spectrophotometer using 1.5mL 
cuvettes (VWR, 97000-586). At this point, IPTG was added (0.2mM) to induce expression of the 
MEP pathway components and Z,E-FPPase. An overlay of 4.5mL of decane (95%, Sigma 
30570) was added at the time of induction. The culture was harvested on Day 3 after 24 hours 
post-induction.  
 
S. cerevisiae  
Yeast prenyl alcohol production was performed in sterilized, 50mL Erlenmeyer flasks (VWR) in 
an incubator shaker (New Brunswick, Innova 43R) at 30ºC and 230 rpm for a total of 7 days. On 
Day 1, 0.3 mL of saturated, overnight culture grown in appropriate selective media was added to 
2.7mL of SC or YPD media. On Day 2, 3mL of YPD and 150µL of decane (to a final 
concentration of 2.5%) were added. On Day 3, 4mL of YPD and 100µL of decane were added. 
Cultures were harvested after incubation for 7 days. 
 
Bench scale production 
Bench scale E. coli–based production was performed in a Bellco 6L Low Profile Vertical 
Sidearm Bioreactor vessel. Filtered air was supplied via a sidearm sparger, and vented via two 
exit ports equipped with moisture traps (see Fig.S6). The 6L vessel was placed in a water bath to 
maintain the temperature at 29.5°C. Mixing of the broth was achieved by the sparged air. There 
was no control of dissolved oxygen, pH, nutrient availability or culture volume. Bench scale 
production was attempted only with the FPP2/A8 E. coli strain. 
On Day 1, a single colony was inoculated into a 14mL Falcon culture tube containing 3mL LB 
with 100mg/L ampicillin and 50mg/L spectinomycin, and grown at 37°C and 230 rpm for 8 
hours. The 3mL culture was then used to inoculate 25mL of the same media and incubated for 15 
34
hours at 37°C and 230 rpm. On Day 2, the 25mL overnight culture was added to 2.5L of TB 
broth and 1% glycerol (autoclaved at 250°F for 45 minutes on Day 1) in a 6L vessel, along with 
400µl of Sigma Antifoam-400, 100mg/L ampicillin and 50mg/L spectinomycin. The culture was 
grown until it reached an OD600 of approximately 0.3 (4-6 hours), at which time 0.2mM IPTG 
was added to induce expression of the Z,E-FPPase RV1086 and MEP pathway components. 
375mL of decane was added to the 6L vessel at the time of induction to form an overlay. Pulses 
of glycerol (25mL, 1% of final vol) were added at 8 and 16 hours post-inoculation. At 24 hours 
post-inoculation, 1L of TB media containing the aforementioned concentrations of IPTG and 
antibiotics was added to replace media lost from the 6L vessel. A further 250mL of decane was 
also added at this time to replenish the overlay. The content of the 6L vessel was collected and 
extracted with ethyl acetate at 48 hours post-induction. 
 
Prenyl alcohol extraction 
E. coli 
Small scale flask fermentations were transferred into a 50mL falcon tube. The inside of the flask 
was rinsed with 5mL of ethyl acetate (99.5%, Sigma 437549), and combined with the fermented 
broth. 1mL of brine was added to aid separation. The tube was vortexed vigorously for 4x30 
seconds. The tube was then centrifuged at 3200 rpm for 10 minutes and the top organic layer was 
filtered and transferred to a glass GC-MS vial for analysis. 
Bench scale fermentations were transferred into a 2L separation funnel in batches of 1L. 500mL 
of ethyl acetate and 20mL of brine were added to each batch in the funnel, and the contents 
shaken vigorously. Separation was allowed to occur and the aqueous layer was removed and re-
extracted once more as above. The organic layer was transferred into centrifuge tubes and spun 
at 4000 rpm for 10 minutes to break the emulsion. The organic layers were concentrated under 
reduced pressure and the residue dissolved in hexane (99%, Sigma 32293) for GC-MS analysis. 
50 mg of Z,E-FOH was isolated from these concentrates following drying (MgSO4) and 
purification on silica gel.  
 
S. cerevisiae  
1mL of the final culture broth was removed for pH and OD600 measurements. The remainder of 
the culture (~8.4mL) was transferred into a 15mL falcon tube containing 1mL of brine. 2mL of 
hexane was used to rinse the flask and added to the falcon tube. The tube was shaken vigorously 
and then placed horizontally in an incubator shaker (230 rpm) for 1 hour to mix. The mixture 
was centrifuged at 3200 rpm for 10 min and the top hexane layer was filtered and transferred into 
a glass GC-MS vial for analysis. 
 
Analysis of prenyl alcohols 
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Z,E-FOH, E,E-FOH, nerolidol, GGOH and squalene were analyzed using a ThermoFinnigan 
PolarisQ GC-MS (Agilent J&W column, #CP8907, VF-1ms 15m X 0.25mm x 0.25µm). GC-MS 
runs were carried out with the following method: MS: ion source 225ºC, EI/NICI, mass range 
50-600. GC: helium gas, 1.2 ml/min, inlet temperature 225ºC, initial column temperature 50ºC,
hold 2.5 minutes, raise at 17ºC/min to 285ºC, hold 3.5 minutes.
E. coli
For quantitative analysis of E. coli fermentations, cis-nerolidol (96%, Sigma 72180) was used as 
an internal standard. A standard concentration curve was created by graphing the ratio of the TIC 
area of the E,E-farnesol (96%, Sigma 277541) peak to the TIC area of the 25mg/L cis-nerolidol 
peak for a range of E,E-farnesol concentrations (Fig.S7). To determine the concentration of Z,E-
FOH in the biosynthesis extracts, each sample was dosed to achieve a final concentration of 
25mg/L cis-nerolidol. The equation of the linear regression of the standard curve was used to 
calculate the concentration of Z,E-FOH.16 All production values were back calculated and 
reported as mg/L of culture media. Specifically, the total amount of extracted Z,E-FOH was 
calculated by multiplying the determined concentration by the volume of the extract. This was 
then divided by the total volume of culture to determine production yield in mg/L of media. 
S. cerevisiae
For quantitative analysis of prenyl alcohols, undecanol was used as an internal standard. The 
ratio of the selected ion peak area (67 mass fragment) of 25mg/L undecanol to that of 25 mg/L of 
authentic standards was used as a standard ratio. The amount of prenyl alcohol in a sample was 
determined by comparison of this ratio to the ratio in a sample spiked with 25mg/L undecanol. 
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Figure S1. Z,E-FOH and E,E-FOH production in E. coli 
Graph showing the yield of Z,E-FOH and E,E-FOH from engineered E. coli strains containing one of four 










Figure S2. GC-MS traces of E. coli fermentations 
(A) Gas chromatographs of extract from FPP2 (M. tuberculosis FPPase) flask fermentation in 
decane (top) and synthetic Z,E-FOH standard in decane (below). Corresponding mass spectra 
below. Peak (i) denotes the Z,E-FOH product of the FPP2 strain. Peak (iii) denotes the 
synthesized Z,E-FOH, and peak (ii) denotes a potential degradation product of Z,E-FOH. RT of 
Z,E-FOH is ~12.12 min. RT of the Z,E-FOH side peak is ~12.05 min. These runs were 
performed with a different GC column compared to all other traces in this report, hence the 
different retention times. 
A 
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Figure S2. GC-MS traces of E. coli fermentations 
(B) Gas chromatographs of extract from FPP2 
bench-scale production in hexane (top) and the 
synthetic Z,E-farnesol standard (below) in hexane. 
Corresponding mass spectra below. Peak (i) denotes 
the added cis-nerolidol standard. Peak (ii) denotes 
the biosynthesized Z,E-FOH. Peak (iv) denotes the 
synthesized Z,E-FOH, and peak (iii) denotes the 
side peak as in (A). RT of cis-nerolidol in hexane is 
~8.87 min. RT of standard Z,E-FOH in hexane is  
~9.98 min. RT of Z,E-FOH side peak in hexane is 













Figure S2. GC-MS traces of E. coli 
fermentations 
(C) Gas chromatographs of extracts from 
E. coli strains containing the other Z,E-
FPPases: 1) FPP5 (C. glutamicum); 2) 
FPP4 (C. efficiens); 3) FPP3 (T. fusca); 
4) Mix of farnesol isomers (Sigma, 
W247804) in decane; 5) Synthesized 
Z,E-FOH standard in decane. 
Corresponding mass spectra below.  
Peaks (i), (iv), and (vi) denote the added 
cis-nerolidol. Peaks (ii) and (vii) denote 
biosynthesized Z,E-FOH. Peaks (iii), (v) 
and (viii) denote EE-FOH. RT of cis-
nerolidol in decane is ~8.76 min. RT of 
standard Z,E-FOH in decane (peaks (ix) 
and (xi)) is ~9.81 min. RT of standard 































Figure S3. NMR of biosynthetic Z,E-FOH from E. coli 
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Figure S4. Prenyl alcohol production in S. cerevisiae 
Small scale production trials of engineered yeast strains showing the yields of various prenyl 
alcohols (side peak, E,E-FOH, NOH, GGOH and squalene). Data is plotted on a log scale. In 






































































































































































































































Figure S5. GC-MS traces of S. cerevisiae fermentations 
 (A) GC chromatographs of: 1. Extract from small scale fermentation trial of CP-51. 2. Extract 
from small scale fermentation trial of ATCC200589/tHMG1 (AN-ZE1-T7). 3. Synthetic Z,E-
FOH standard. 4. Authentic E,E-FOH standard (96%, Sigma 277541). The undecanol internal 
standard is present in each trace at retention time (RT) ~ 7.68 min. RT of the unidentified side 
peak is ~ 9.90 min. RT of Z,E-FOH is ~ 9.99 min. RT of E,E-FOH is ~10.12 min. (B) Mass 






Figure S6. Schematic of bench-scale production vessel 
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Figure S7. E,E-FOH calibration curve for quantification of Z,E-FOH 
y = 78.829x - 53.682 
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Ratio of area of EE-farnesol peak to nerolidol peak 
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Table S1. E. coli and yeast strains used in this study 
Name Genotype/Plasmids-insert Source 
FPP2/A8 DH5(DE3)/pA8/pFPP2 This study 
FPP3/A8 DH5(DE3)/pA8/pFPP3 This study 
FPP4/A8 DH5(DE3)/pA8/pFPP4 This study 
FPP5/A8 DH5(DE3)/pA8/pFPP5 This study 
ATCC200589 MATalpha can1 leu2 trp1 ura3 aro7 ATCC 
AN-ZE1-T7 ATCC200589/pAN127-tHMG1 This study 
AN-ZE5-T1 ATCC200589/pAN127-tHMG1/pAN193-Tfu0456 This study 
AN-ZE5-T2 ATCC200589/pAN127-tHMG1/pAN194-Rv1086 This study 
CP-51 ATCC200589/pAN127-tHMG1/pCP51-DPP1-Tfu0456 This study 
EA-3 ATCC200589/pAN127-tHMG1/pAN137-DPP1-Rv1086 This study 
EA-14 ATCC200589/pAN127-tHMG1/pAN138-Tfu0456-DPP1 This study 
AN-ZE2-T3 ATCC200589/pAN127-tHMG1/pAN141-Rv1086-DPP1 This study 
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Table S2. Plasmids used in this study 
Name Origin Marker Transcriptional Unit (Promoter-ORF-Terminator) Details 
pA8 pSC101, E coli SpecR 
pLac-(dxs, dxr, ispD,ispF, idi, 
ispH) –T1 
E. coli codon-optimized MEP
components from B. subtilis
pFPP2 pBR322, E coli AmpR pTrc-RV1086-rrnBt 
E. coli codon-optimized Z,E-
FPPase from M. tuberculosis
pFPP3 pBR322, E coli AmpR pTrc-Tfu0456-rrnBt 
E. coli codon-optimized Z,E-
FPPase from T. fusca
pFPP4 pBR322, E coli AmpR pTrc-CE1055-rrnBt 
E. coli codon-optimized Z,E-
FPPase from C. efficiens
pFPP5 pBR322, E coli AmpR pTrc-uppS1-rrnBt 
E. coli codon-optimized Z,E-
FPPase from C. glutamicum
pAN127 2µ, yeast TRP1 TEF1p-tHMG1-ACT1p Truncated tHMG 
pAN96 
CEN, 
yeast URA3 PGK1p-Tfu0456-ADH1t Codon optimized Tfu0456 
pAN99 
CEN, 
yeast URA3 PGK1p-Rv1086-ADH1t Codon optimized Rv1086 
pAN193 2µ, yeast URA3 PGK1p-Tfu0456-ADH1t Codon optimized Tfu0456 
pAN194 2µ, yeast URA3 PGK1p-Rv1086-ADH1t Codon optimized Rv1086 
pAN137 2µ, yeast URA3 PGK1p-DPP1-Rv1086-ADH1t Fusion of DPP1-Rv1086 
pAN138 2µ, yeast URA3 PGK1p-Tfu0456-DPP1-ADH1t Fusion of Tfu0456-DPP1 
pAN141 2µ, yeast URA3 PGK1p-Rv1086-DPP1-ADH1t Fusion of Rv1086-DPP1 
pCP51 2µ, yeast URA3 PGK1p-DPP1-Tfu0456-ADH1t Fusion of DPP1-Tfu0456 
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Table S3. Primers and dsDNA gene fragments (gblocks) used in this study 
Name Plasmid Template Sequence (5’ – 3’) 
AN569 pAN127 TEF1p-F 
CACTAAAGGGAACAAAAGCTGGAGCTATAGCTTCAAA
ATGTTTCTACTCC 
AN387 pAN127 TEF1p-R 
GTTTTCACCAATTGGTCCATAAACTTAGATTAGATTGC
TATGCT 
AN388 pAN127 tHMG1-F 
TAGCAATCTAATCTAAGTTTATGGACCAATTGGTGAA
AACTGAAG 
AN401 pAN127 tHMG1-R 
TACGCGCACAAAAGCAGAGATTAGGATTTAATGCAGG
TGACGG 
AN402 pAN127 ACT1t-F TCACCTGCATTAAATCCTAATCTCTGCTTTTGTGCGCG 










AN413 pAN96 PGK1p-R 
ATGATGATGGTGCATTTGTTTTATATTTGTTGTAAAAA
GTAGATAATTAC 







































AN410 pAN99 PGK1p-R 
GTGATGATGATGCATTTGTTTTATATTTGTTGTAAAAA
GTAGATAATTAC 




























AN411 pAN99 ADH1t-F 
TCTTACGGTCGATAAGCGAATTTCTTATGATTTATGAT
TTTTAT 



























AN471 pAN137 DPP1-R 
TAATCTCCATAGAACCACCACCCATACCTTCATCGGA
CAAAGGATG 
AN472 pAN137 Rv1086-F 
AGGTATGGGTGGTGGTTCTATGGAGATTATTCCTCCA
AGATTGAA 
AN473 pAN137 Rv1086-R 
CATAAGAAATTCGCTTATCGACCGTAAGATCTATGAC
G 
AN474 pAN137 ADH1t-F 
CTTACGGTCGATAAGCGAATTTCTTATGATTTATGATT
TTTAT 
AN480 pAN138 PGK1p-R 
GTGATGATGATGGTGCATTTGTTTTATATTTGTTGTAA
AAAGTAGATAATTAC 
AN481 pAN138 Tfu0456-F 
CAACAAATATAAAACAAATGCACCATCATCATCACCA
CG 
AN482 pAN138 Tfu0456-R 
CTGTTCATAGAACCACCACCACAACCAAAACGTCTTT
GTCTGAC 
AN483 pAN138 DPP1-F 
TTGGTTGTGGTGGTGGTTCTATGAACAGAGTTTCGTTT
ATTAAAACG 
AN431 pAN138/pAN141 DPP1-R 
AAATCATAAATCATAAGAAATTCGCTTACATACCTTC
ATCGGACAAAGG 
AN432 pAN138/pAN141 ADH1t 
TCCTTTGTCCGATGAAGGTATGTAAGCGAATTTCTTAT
GATTTATGATTTTTAT 
AN475 pAN141 PGK1p-R 
GTGGTGATGATGATGCATTTGTTTTATATTTGTTGTAA
AAAGTAGATAATTAC 
AN452 pAN141 Rv1086-F 
CAACAAATATAAAACAAATGCATCATCATCACCACCA
TGG 
AN476 pAN141 Rv1086-R 
CTGTTCATAGAACCACCACCTCGACCGTAAGATCTAT
GACGAG 
AN477 pAN141 DPP1-F 
CTTACGGTCGAGGTGGTGGTTCTATGAACAGAGTTTC
GTTTATTAAAACG 
AN478 pCP51 DPP1-R 
GTAAACCCATAGAACCACCACCCATACCTTCATCGGA
CAAAGGATG 











R pFPP2 XhoI-R AGCTGCAGATCTCGACTCGAGTTAGCGGCCGTA 
optEC-
























































Ceff_RWR pFPP4 XhoI-R AGCTGCAGATCTCGACTCGAGTTACTTGCCGAAAC 
optEC-






























Cglu_RWR pFPP5 XhoI-R AGCTGCAGATCTCGACTCGAGTTACTTACCGAAGC 
optEC-



























Table S4. Yeast synthetic-dropout media recipe  
Ingredient Amount to 100mL 
2X (13g/L) Yeast Nitrogen Base (YNB) from BD-
Difco (291940) 
50mL 
40% Glucose 5mL 
20X amino acid 5mL 
1% Histidine (if required) 0.2mL 
1% Leucine (if required) 0.9mL 
1% Tryptophan (if required) 0.2mL 
0.2% Uracil (if required) 1.0mL 




Table S5. Amino acid preparation 
20X amino acid mix To 500mL Sigma-Aldrich Catalog Code 
Adenine sulfate 0.2g S/A-8626 
Arginine HCl 0.2g S/A-5006 
**Aspartic acid 1.0g S/A-9256 
Glutamic acid 1.0g S/G-1251 
Isoleucine 0.3g S/I-2752 
Lysine HCl 0.3g S/L-5626 
Methionine 0.2g S/M-9625 
Phenylalanine 0.5g S/P-2126 
Serine 4.0g S/S-4500 
**Threonine 2.0g S/T-8625 
Tyrosine 0.3g S/T-3754 
Valine 1.5g S/V-0500 
Autoclave all and add ** when cooled, then sterile filter 
   
Selective amino acids To 200mL Sigma-Aldrich Catalog Code 
1% Histidine 2g S/H-8125 
1% Leucine 2g S/L-8000 
1% Tryptophan 2g S/T-0254 
0.2% Uracil 0.4g S/U-0750 
























Novel 9-epi-Ambrox® Analogs from Biosynthetic Z,E-farnesol 
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3.1   Introduction to Ambrox® 
The tricyclic lambdane ether Ambrox® [registered trademark of Firmenich SA, 
also known as Ambroxan (Henckel)] is a prized fragrance with a worldwide production 
volume of 50 tons per year, costing $500 per kilogram to purchase commercially. The 
story of Ambrox® (1) is another example of the power of synthetic chemistry to 
supersede natural extraction, specifically in this case, essentially saving the sperm whale 
(Physeter macrocephalus) from extinction.  
Ambrox® (1) is an oxidative-degradation product of Ambergris, itself a metabolic 
excretion of the sperm whale.1-3 Ambergris, from the French ambre gris, has been valued 
by many cultures since the ancient world for its fine organoleptic properties. The famous 
English poet Alexander Pope said in 1720, “Praise is like Ambergris. A little whiff of it is 
very agreeable.” The great demand for ambergris led to the overhunting of the whale, 
prompting a ban on whaling to protect the species from extinction. One could speculate 
that even with this ban on whaling, that the sperm whale could still be illegally hunted for 
its ambergris, were it not for synthetic chemistry’s providing of an alternative for the 
procurement of Ambrox®, the sought-after degradation product of ambrein (main 
constituent of ambergris).  
Ambrox® was first chemically synthesized from sclareol (2) by chemists at 
Firmenich SA in 1950.4,5 Since then, it has been derived from many starting materials 
including sclareolide (3, current starting material for industrial production), abietic acid 
(4), thujone (5), nerolidol (6), farnesol (7), and β-ionone (8) [9].2,6-8  
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Figure 1. Synthetic Ambrox® production from diverse starting materials 
Furthermore, extensive research programs were instituted to find more powerful 
analogs of Ambrox®. These structure-activity relationship studies revealed that 9-epi-
Ambrox (9) and the unsaturated analog Superambrox® (10) are, at present, the strongest 
of the ambergris-type odorants.2,8-11 
Figure 2. Potent synthetic Ambrox® analogs 
However previously reported syntheses of these ambrox analogs are limited by 
low yield and long synthetic routes.2,8-11 Additionally, the majority of reported Ambrox 






































western region of the molecule essentially unexplored. To address these challenges, we 
sought to prepare 9-epi-Ambrox through a polyene cyclization of biosynthetically derived 
Z,E-farnesol (11). Moreover, by utilizing a halonium-promoted variant of that 
cyclization, a chemical handle would be introduced at position 3 of the Ambrox molecule 
that can be used for subsequent functionalization and for the preparation of novel labdane 
analogs, in addition to any useful properties afforded by the halogen motif itself. 
 
            
Figure 3. Hybrid approach to 9-epi-Ambrox® and analogs 
 
 
With biosynthetic Z,E-FOH in hand (see Chapter 2), we developed a 
homologation process that maintained the desired cis geometry at position 3 of the 
product Z,E-homo-FOH.  
 
3.2   Farnesol Homologation 
Critically, the homologation of Z,E-FOH to Z,E-homofarnesol (13) required a 
two-step reduction of the nitrile (12), first with DIBAL-H (an intractable reaction to 
which we found a unique solution with the use of silica to liberate the aldehyde) and then 
NaBH4 (Figure 4A), as attempted alkaline hydrolysis of the nitrile led to cis-trans 













11: Z,E-Farnesol (--)-9-epi-Ambrox & novel analogs
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Figure 4. homologation chemistry. A) Four step homologation from biosynthetic Z,E-FOH B) 




Based on previous reports demonstrating the conversion of nerolidol (18, NOH) 
to homofarnesol (figure 4C),12 we also explored deriving Z,E-homo-FOH (13) from E,E-
farnesol (14). Modifying the previously reported method by the addition of a vanadium 
oxide catalyst allowed for the synthesis of a mixture of homofarnesyl amides 15 and 16 
in 57% yield from E,E-FOH. Although 13 can be reached in just a single additional step, 
in our hands, this route yields E,E- homo-FOH (17) as the major product over the desired 
Z,E-homo-FOH (13), requiring purification to separate the target compound from its 
isomeric partner (Figure 4B-C) at the amide stage. Thus, this demonstrates the 
importance of our biosynthetic production of Z,E-FOH to allow for the synthesis of pure 
Z,E-homo-FOH. However, if from a standpoint where a mixture of the homologated 
material is not an issue, say for the production of isomeric mixture of Ambrox®, then the 












































3.3   Cyclization to Halo-hydrobenzofurans 
We next explored polyene cyclization of Z,E-homo-FOH (13) using the 
previously developed halonium-based reagents BDSB (bromodiethylsulfonium 
bromopentachloroantimonate, Et2SBr•SbBrCl5) and IDSI (iododiethylsulfonium 
iodopentachloroantimonate).13-15 These halonium-donating reagents can be employed for 
efficient polyene cyclization that introduces a halogen handle into the polycyclic 
frameworks. By subjecting Z,E-homo-FOH to BDSB and IDSI in nitromethane at -20 ºC, 
we obtained 3-Bromo-9-epi-Ambrox (20-Br) and 3-Iodo-9-epi-Ambrox (20-I), 
respectively, in 41% and 40% yield. The use of a TMS protecting group (19) improves 
the yields of 20-Br and 20-I respectively to 65% and 64%. These products only have a 
slight scent, but can be readily converted to fragrant analogs including 9-epi-Ambrox (9).  
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3.4   Derivatization 
9-epi-Ambrox was readily prepared in 99% yield by radical-mediated reduction of the 
iodo-derivative, while 2,3-ene- 9-epi-Ambrox (22) was generated in 88% yield by 
subjecting 20-I to DBU in pyridine. Unfortunately, attempted nucleophilic substitutions 
at the alkyl halide led predominantly to 22, so we therefore elected to generate further 
Ambrox analogs through derivetization of the olefin in 22, namely epoxidation with 
mCPBA that yielded epoxide 23. These transformations demonstrate that a diversity of 
molecules can be derived from just a single cyclization product and precursor polyene. 
 
 
3.5   Discovery of Novel Structure and Ambergris-type Scent 
Interestingly, in the IDSI promoted reaction of 13, a side product with a 
detectable fragrance was obtained, which we found to be the iodinated 
octahydrobenzofuran derivative 21-I. The addition of 10% toluene to the reaction mixture 
led to increased yields (20%) of 21-I. Given its mild scent but instability (decomposes 
when left standing at room temperature), we decided to make the less sterically 
demanding beta epimer through IDSI promoted cyclization of E,E-homo-FOH (17). This 
process led to 25 in higher yields, and the compound has a very potent Ambrox-like 
scent.16 To date, the consensus has been that the three axial methyl groups of the 
Ambrox® structure were responsible for conferring the characteristic ambergris scent.9 
This understanding is known as the tri-axial rule.  
Nevertheless, 25 along with its derivatives 26 and 27 break the tri-axial rule yet 
retain strong fragrant properties. This may indicate that factors other than the three axial 
methyl groups are responsible for conferring the characteristic ambergris scent. As such, 
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Figure 6. Potent new Ambrox®-type scents that break the tri-axial rule 
 
 
3.6   Inspiration for a Synthetic Patchouli Scent 
Taking inspiration from 25 and 26, materials that break the triaxial rule and yet 
are strongly odorant, we decided to make the core of these molecules. Thus we prepared 
homo-geraniol (28), which was subjected to BDSB and IDSI to produce halo-hydrofurans 
29 and 30 in 94% and 93% yield, respectively. Interestingly, 29, 30, and their derivative 
31 possess patchouli scent,16 making these compounds the first synthetic patchouli 
odorant to our knowledge and potential patchouli replacer/extender. Furthermore, it is 
interesting to note the shared hexahydrobenzofuran core between the 26, 31, and 
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Further derivatization and/or functional group permutations on this core could 
prove beneficial. It would also be interesting to synthesize single-point stereochemical 
epimers of 29, 30, and 31 to determine which one is more responsible for the strong 
patchouli fragrance. Testing for biological activity is another attractive possibility for 
further study.  
Figure 7. Shared structural motif between Firmenich’s Superambrox® and our novel analogs 
3.7   Conclusion 
In conclusion, we demonstrated the concept of “jigsaw” semi-biosynthesis 
through the production of a series of novel Ambrox® analogs from biosynthetic Z,E-
farnesol. In contrast to previous demonstrations of semi-biosynthesis, we show that it is 
possible to access natural product scaffolds via biosynthetically derived molecules that 
are not intermediates in the natural pathway. Importantly, in the approach applied here, a 
single biosynthetically derived intermediate carries sufficient functionality and 
complexity that allows for functionalization to complex natural and unnatural products, 
but does not carry an overly specific and restrictive architecture to limit its utility to a 








derivatization shown in Figures 5 and 6, one could imagine far more molecular scaffolds 
being obtained from this or similar biosynthetically derived molecules. This combined 
approach could be applied to other classes of molecules in a non-natural pairing of 
chemical synthesis and synthetic biology to efficiently produce natural products and their 
homologues.  
We would like to note that 18.5 mg of 20-Br was derived, by way of 13, from 
biosynthetic Z,E-FOH (11). All of our other 9-epi-Ambrox® analogs were derived from 
13 produced by chemical means.  
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3.9 Experimental Section 
 
General procedures:  Unless otherwise stated, all reactions were carried out under argon 
atmosphere with dry solvents under anhydrous conditions. Reagents were purchased from 
commercial vendors at the highest available purity and used without further purification.  
Dry dichloromethane (DCM), diethyl ether (Et2O), and tetrahydrofuran (THF) were 
purchased from Sigma-Aldrich; nitromethane was stored over 3 A molecular sieves for 2 
days before use. All reactions were stirred magnetically and monitored by TLC 
performed on 0.25 mm E. Merck silica gel plates (60F-254) using UV light as the 
visualizing agent or cerium ammonium molybdate (CAM) and heat as the developing 
agent. Silica gel (SiliCycle 60, academic grade) was used to carry out flash column 
chromatography. Unless otherwise recorded, yields refer to purified materials with 
spectroscopically (1H and 13C NMR) homogeneity. NMR spectra were recorded on 
Bruker DRX-300, DRX-400, and DRX-500 instruments calibrated using residual 
undeuterated solvents as internal reference. Multiciplicities were represented by the 
following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of 
doublet, ddd = doublet of doublet of doublet, m = multiplet, br = broad. IR spectra were 
recorded on a Perkin Elmer Spectrum Two® FT-IR spectrometer, and High-resolution 
mass spectra (HRMS) were recorded in the Columbia University Mass Spectral Core 
facility on a Waters XEVO G2XS QToF mass spectrometer using electrospray ionization 
(ESI), atmospheric solids analysis probe (ASAP) and atmospheric pressure chemical 
ionization (APCI) techniques.   
 
Abbreviations: DCM = dichloromethane, MgSO4 = Magnesium sulfate, Et2O = diethyl 
ether, TMHQ = trimethylhydroquinone, (NH4)2SO4 = Ammonium sulfate, NH4Cl = 
ammonium chloride, EtOH = ethanol, MeOH = methanol, DI = distilled, HCl = hydrogen 
chloride, RT = room temperature, DCE = 1,2-dichloroethane, EtOAc = ethyl acetate, 
DMFDMA = N,N-dimethylformamide dimethyl acetal     (VO(OSiPh3)3) = 
Tris(triphenylsiloxy)vanadium oxide, I2 = iodine,    TLC = thin layer chromatography,   
CAM = cerium ammonium molybdate, FOH = farnesol, hFOH = homofarnesol,  
 
 
A. Cation-π Cyclization precursors preparation 
Z,E-Homofarnesol (13) from biosynthetic Z,E-farnesol (11): Starting from 45 mg 
(0.20 mmol) Z,E-farnesol (15) produced from engineered E. coli, 30.4 mg (0.13 mmol, 
64%) of Z,E-farnesyl cyanide (12) is prepared as previously reported.17, 18 Subsequently, 
12 (30.4 mg, 0.13 mmol, 1 equiv) is dissolved in 0.5 mL of dry dichloromethane and 
cooled to -78oC. 0.2 mL (0.2 mmol) of a 1M solution of DIBAL in dichloromethane is 
then added drop-wise and the reaction mixture stirred for 1 hour. Saturated aqueous 
Rochelle salt (1 mL) is then added and the resulting mixture stirred for another hour at 
which point, 0.5 mL of aqueous ammonium chloride (NH4Cl) is added and the organic 
phase is isolated. The aqueous phase is further extracted with dichloromethane (2 x 6 
mL), and the pooled organic layers are washed with sodium bicarbonate and brine. The 
organic phase is then treated with 4 g of silica, filtered and evaporated to yield 21.3 mg 
(69.4%) of Z,E-homofarnesyl-aldehyde. This material (21.3 mg, 0.091 mmol, 1 equiv) is 
then dissolved in methanol (0.5 mL) and cooled to 0oC before the addition of 7 mg (0.18 
69
mmol, 2 equiv) of sodium borohydride dissolved in 0.5 mL of methanol. The reaction 
mixture is stirred at room temperature for 30 minutes, quenched with 1 mL of aqueous 
NH4Cl, and extracted with dichloromethane (3 x 2 mL). After drying the organic layers 
over magnesium sulfate and removing solvent under vacuum, 21 mg (96%) of Z,E-
homofarnesol (13) is obtained as a clear oil. Rf = 0.3 (silica gel, 20% EtOAc:hexanes); 
IR (film) 𝝂max 3324 (br), 2964, 2917, 2857, 1667, 1445, 1377, 1046, 834, 559 cm-1; 1H 
NMR (500 MHz, CDCl3) δ 5.15 – 5.04 (m, 3H), 3.58 (t, J = 6.6 Hz, 2H), 2.26 (td, J = 
7.4, 0.9 Hz, 2H), 2.09 – 2.00 (m, 6H), 1.99 – 1.93 (m, 2H), 1.85 (br s, 1H), 1.71 (2 s, 3H), 
1.66 (s, 3H), 1.59 (s, 3H), 1.58 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 139.0, 135.7, 
131.6, 124.6, 124.2, 121.0, 62.8, 40.0, 32.3, 31.7, 27.0, 26.8, 26.0, 23.8, 17.9, 16.2; 
HRMS (ASAP) calcd for C16H29O+ [M + H]+ 237.2218, found 237.2214.   
 
 
Alternative Homologation chemistry  
[2,3] sigmatropic rearrangement with DMFDMA 
E,E-Farnesol (1 g, 4.5 mmol, 1 equiv) and VO(OSiPh3)3 (180 mg, 0.2 mmol, 0.05 equiv) 
are added to 10 mL of xylenes. The reaction mixture is refluxed for 30 minutes, then 
DMFDMA (4.8 mL, 36 mmol, 8 equiv) is added and the reaction flask is fitted with a 
Dean-Stark apparatus filled with xylenes, 3A molecular sieves (MS), and 6 mL 
DMFDMA. After refluxing overnight, xylenes is evaporated and the remaining residue is 
applied to silica gel to obtain 703 mg (57%) of a mixture of Z,E-homofarnesyl-N,N-
dimethylamide (15) and E,E-homofarnesyl-N,N-dimethylamide (16), which are separated 
on silica gel (20% EtOAc:Hexanes) into 282 mg of 15 and 421 mg of 16.   
 
One also arrives at 15 and 16 in 90% yield by replacing E,E-Farnesol and VO(OSiPh3)3 
with nerolidol (18) in the preceding procedure (see ref. 12, Buchi et al.). 
 
Z,E-Homofarnesyl-N,N-dimethylamide (15): Rf = 0.41 (silica gel, 40% 
EtOAc:hexanes); IR (film) 𝝂max 2965, 2917, 2855, 1648, 1492, 1444, 1392, 1263, 1134, 
836 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.31 (t, J = 6.6 Hz, 1H), 5.13 – 5.02 (m, 2H), 
3.04 (d, J = 6.7 Hz, 2H), 2.97 (s, 3H), 2.91 (s, 3H), 2.11 – 1.99 (m, 7H), 1.98 – 1.90 (m, 
2H), 1.72 (s, 3H), 1.65 (s, 3H), 1.58 (s, 3H), 1.57 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
172.2, 138.4, 135.7, 131.6, 124.5, 124.0, 117.9, 40.0, 37.6, 35.7, 33.5, 32.5, 26.9, 26.4, 
26.0, 23.7, 17.9, 16.2; HRMS (ASAP) calcd for C18H32NO+ [M + H]+ 278.2484, found 
278.2484.   
 
E,E-Homofarnesyl-N,N-dimethylamide (16): Rf =  0.32 (silica gel, 40% 
EtOAc:hexanes); IR (film) 𝝂max 2964, 2917, 2854, 1647, 1492, 1443, 1392, 1262, 1134, 
835 cm-1; 1H NMR ((500 MHz, CDCl3) δ 5.24 (t, J = 6.1 Hz, 1H), 5.06 – 4.93 (m, 2H), 
2.99 (d, J = 6.5 Hz, 2H), 2.92 (s, 3H), 2.85 (s, 3H), 2.06 – 1.92 (m, 6H), 1.92 – 1.84 (m, 
2H), 1.59 (s, 3H), 1.57 (s, 3H), 1.51 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 172.1, 
138.1, 135.2, 131.3, 124.4, 124.0, 117.0, 39.8, 39.7, 37.4, 35.6, 33.9, 26.8, 26.5, 25.8, 
17.8, 16.6, 16.1; HRMS (ASAP) calcd for C18H32NO+ [M + H]+ 278.2484, found 
278.2491.   
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Homofarnesyl-N,N-dimethylamide reduction to homofarnesol: 
15 (600 mg, 2.21 mmol, 1 equiv) is dissolved in 6 mL of dry tetrahydrofuran (THF) and 
cooled to 0oC with stirring. A 1M solution of Lithium triethylborohydride (LiBEt3H) in 
THF (8.7 mmol, 4 equiv) is subsequently added, and the reaction mixture is stirred as it 
warms to room temperature. 100 mL of aqueous NH4)2SO4 is then added along with 50 
mL of brine and the reaction mixture is extracted with diethyl ether (3 x 50mL). The 
organic layers are pooled, dried over magnesium sulfate (MgSO4) and concentrated. The 
residue is purified by flash column to give 477 mg (92%) of Z,E-homofarnesol (13). 
Physical spectra of 13 thus produced is identical to that of the material produced using 
the nitrile homologation method detailed above.  
 
E,E-Homofarnesol (17)”4” is obtained in 93% yield by subjecting 16 to LiBEt3H as 
above.  Rf = 0.3  (silica gel, 20% EtOAc:hexanes); IR (film) 𝝂max 3324 (br), 2964, 2917, 
2857, 1667, 1445, 1377, 1046, 834, 559 cm-1; 1H NMR (500 MHz, CDCl3) δ 5.14 – 5.04 
(m, 3H), 3.57 (t, J = 6.6 Hz, 2H), 2.26 (q, J = 6.8 Hz, 2H), 2.12 – 1.90 (m, 10H), 1.71 (d, 
J = 1.1 Hz, 1H), 1.66 (s, 4H), 1.62 (s, 2H), 1.58 (s, 8H); 13C NMR (125 MHz, CDCl3) δ 
138.9, 138.9, 135.6, 135.5, 131.6, 131.5, 124.6, 124.3, 124.1, 121.0, 120.2, 62.8, 62.6, 
40.1, 40.0, 32.2, 31.8, 31.7, 27.0, 26.8, 26.7, 26.0, 24.0, 18.0, 16.4, 16.3, 16.2; HRMS 
(ASAP) calcd for C16H29O+ [M + H]+ 237.2218, found 237.2217.   
 
E,E-Homogeraniol and Z,E-homogeraniol (28): First, a homogeranyl-N,N-
dimethylamide (S1) is prepared as a mixture of isomers by the reaction of linalool with 
DMFDMA {clear oil,  Rf = 0.35 (E,E) and 0.44 (Z,E) (silica gel, 40% EtOAc:hexanes); 
IR (film) 𝝂max 3397 (br), 2965, 2923, 1643, 1447, 1394, 1132, 830 cm-1; 1H NMR (500 
MHz, CDCl3) δ 5.25 – 5.19 (m, 1H), 5.04 – 4.95 (m, 1H), 3.00 – 2.95 (m, 2H), 2.91 (s, 
3H), 2.86 – 2.82 (2 s, 3H), 2.04 – 1.91 (m, 4H), 1.65 (d, J = 1.1 Hz, 1H), 1.6 – 1.54 (2 s, 
5H), 1.53 – 1.48 (2 s, 3H); 13C NMR (125 MHz, CDCl3) δ 172.3, 172.2, 138.2, 138.1, 
131.9, 131.6, 124.2, 124.1, 117.7, 117.0, 39.7, 37.5, 35.6, 33.9, 33.3, 32.3, 26.6, 26.3, 
25.8, 23.5, 17.8, 17.7, 16.5; HRMS (ASAP) calcd for C13H24NO+ [M + H]+ 210.1858, 
found 210.1861.} 
Subsequently, this material was reduced with LiBEt3H to furnish 28 as a mixture of 
isomers.  Light oil, Rf =  0.33 (silica gel, 20% EtOAc:hexanes);  IR (film) 𝝂max 3679, 
3348 (br), 2965, 2922, 1441, 1219, 1051, 1016, 833 cm-1; 1H NMR (500 MHz, CDCl3) δ 
5.16 – 5.04 (m, 2H), 3.75 (dd, J = 13.5, 6.8 Hz, 1H), 3.60 (t, J = 6.4 Hz, 1H), 2.31 – 2.20 
(m, 2H), 2.12 – 2.02 (m, 3H), 1.99 (dd, J = 15.2, 7.2 Hz, 1H), 1.72 (s, 1H), 1.70 (s, 1H), 
1.68 (s, 3H), 1.64 (s, 1H), 1.63 – 1.60 (3 s, 4H), 0.91 (t, J = 7.8 Hz, 1H), 0.73 (dd, J = 
15.6, 7.8 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 139.2, 139.1, 137.6, 137.6, 132.2, 
132.0, 131.9, 131.7, 124.6, 124.5, 124.5, 124.3, 121.3, 121.1, 120.4, 120.2, 63.6, 63.4, 
62.9, 62.7, 40.1, 40.1, 32.3, 32.3, 31.8, 31.7, 30.9, 30.8, 27.0, 27.0, 26.9, 26.8, 26.0, 23.8, 
23.8, 18.0, 17.9, 16.5, 16.4, 8.2; HRMS (ASAP) calcd for C11H21O+ [M + H]+ 169.1592, 
found 169.1594.       
 
 
Cyclization Catalysts—BDSB and IDSI: The halonium donors BDSB 
(bromodiethylsulfonium bromopentachloroantimonate) and IDSI 
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(bis(diethyliodosulfonium)chloride hexachloroantimonate) were synthesized according to 
the method described by Snyder et al. (refs. 13 - 15). The IDSI preparation method was 
modified by lowering the volume of DCE such that the concentration of I2 was 0.5 M. 
This modification improved the product yield to 95%.  
 
3-Bromo-9-(-)-epi-Ambroxide (20-Br)—representative procedure of the Cation-π 
cyclization to halo-octahydrobenzofurans derivatives:   
50 mg (0.213 mmol, 1 equiv) of 13 is dissolved in 21 mL of nitromethane and cooled to -
20oC under argon. To this vigorously stirring mixture, a solution of BDSB (127.4 mg, 
0.235, 1.1 equiv) in 0.5 mL of nitromethane is quickly added. The resulting mixture is 
left to warm to 0oC with stirring over 10 minutes and then 10 mL each of 5% aqueous 
sodium sulfite (Na2SO3) and sodium bicarbonate (NaHCO3) are successively added and 
the mixture is stirred vigorously at room temperature for 30 minutes or until all reddish 
coloration has disappeared. 20 mL of brine is then added to the mixture before it is 
extracted with dichloromethane (3 x 20 mL). The pooled organic fractions are washed 
with brine (30 mL), dried over magnesium sulfate, and evaporated to yield 27.4 mg 
(41%) of 20-Br after column purification (4% EtOAc:hexanes) as a colorless oil that 
crystallizes into a white solid when stored at 0oC.  
An alternative method to synthesize 20-Br in higher yield is to protect the free alcohol of 
13 with a trimethyl silyl (TMS). The TMS-protected homofarnesol (19) was prepared 
by dissolving 13 (25 mg, 0.11 mmol, 1 equiv) in nitromethane (0.4 mL), adding 
bis(trimethylsilyl)amine (HMDS) (19 mg, 0.12 mmol, 1.1 equiv) and stirring at room 
temperature for 30 minutes. At this point, 3 Å MS (2 beads) is added to the reaction flask 
to soak up the ammonia side product, the reaction diluted with more nitromethane (9 
mL), cooled to -20oC and BDSB directly added to produce 20-Br (21.9 mg, 64%).  
Clear oil that crystallizes when stored at 0oC. Rf = 0.22 (silica gel, 15% EtOAc:hexanes);   
IR (film) 𝝂max 3706, 3680, 3665, 2970, 2940, 2922, 2866, 2075, 1322, 1055, 1032 cm-1; 
1H NMR (500 MHz, CDCl3) δ 3.97 (dd, J = 12.7, 4.2 Hz, 1H), 3.85 (td, J = 9.0, 2.9 Hz, 
1H), 3.77 (dd, J = 16.7, 8.4 Hz, 1H), 2.25 (ddd, J = 26.3, 13.3, 3.7 Hz, 1H), 2.11 – 1.86 
(m, 4H), 1.69 – 1.41 (m, 8H), 1.37 (s, 3H), 1.36 – 1.21 (m, 5H), 1.14 (s, 3H), 1.10 (s, 
3H), 0.94 (s, 3H), 0.88 (s, 1H), 0.84 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 80.7, 69.4, 
64.3, 58.9, 47.6, 39.9, 39.7, 36.4, 35.8, 31.2, 31.1, 29.1, 27.8, 23.8, 22.2, 18.7; HRMS 
(ASAP) calcd for C16H27BrO+ [M+] 315.1324, found 315.1303.  
 
Note that from biosynthetically derived 13 (21 mg, 0.089 mmol), 18.5 mg of 20-Br was 
derived. For all other halonium induced cyclization to produce the halogenated Ambrox® 
and novel derivatives, additional 13 was derived by the chemical means described above.  
 
3-Iodo-9-(-)-epi-Ambrox (20-I): By replacing BDSB with IDSI in the procedure for 20-
Br, 20-I was produced from 13 in 55% yield. Colorless oil;  Rf = 0.22 (silica gel, 15% 
EtOAc:hexanes);  IR (film) 𝝂max 2938, 2871, 1460, 1378, 1125, 998, 846, 650, 430 cm-1; 
1H NMR (500 MHz, CDCl3) δ 4.21 (dd, J = 13.0, 4.1 Hz, 1H), 3.84 (td, J = 9.2, 2.9 Hz, 
1H), 3.76 (dd, J = 16.7, 8.4 Hz, 1H), 2.45 (ddd, J = 26.6, 13.3, 3.6 Hz, 1H), 2.30 – 2.23 
(m, 1H), 2.05 – 1.95 (m, 1H), 1.94 – 1.85 (m, 2H), 1.74 – 1.65 (m, 2H), 1.61 – 1.52 (m, 
4H), 1.50 – 1.16 (m, 2H), 1.14 (s, 3H), 1.08 (s, 1H), 1.07 (s, 3H), 0.98 (s, 1H), 0.97 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 80.7, 64.3, 58.9, 53.9, 46.3, 41.7, 39.4, 36.7, 35.9, 
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34.1, 33.8, 29.1, 27.8, 23.3, 23.1, 21.6; HRMS (ASAP) calcd for C16H28IO+ [M + H]+ 
363.1185, found 363.1185.    
 
5-Iodo-4,4-dimethyl-4-homogeranyl-octahydro-9-epi-benzofuran (21-I): was 
recovered in 8% yield from the reaction of 13 with IDSI. The addition of toluene (10% 
volume of nitromethane) to the reaction mixture prior to IDSI addition increases the yield 
of 21-I (20%). Colorless oil; faint ambroxide scent; Rf = 0.31 (silica gel, 15% 
EtOAc:hexanes);  IR (film) 𝝂max 2964, 2925, 2876, 1448, 1379, 1133, 1002, 937, 678 cm-
1; 1H NMR (500 MHz, CDCl3) δ 5.07 (t, J = 7.0 Hz, 1H), 4.36 (dd, J = 11.3, 4.9 Hz, 1H), 
3.88 – 3.75 (m, 4H), 2.33 – 2.20 (m, 3H), 2.03 – 1.94 (m, 6H), 1.69 (s, 4H), 1.62 (s, 4H), 
1.37 (s, 6H), 1.21 (s, 4H), 1.20 – 1.12 (m, 3H), 1.10 – 0.92 (m, 5H); 13C NMR (125 
MHz, CDCl3) δ 132.0, 124.5, 80.5, 63.9, 51.6, 46.0, 39.5, 36.3, 34.9, 28.6, 26.9, 26.0, 




9-(-)-epi-Ambroxide (9): 85 mg (0.235 mmol, 1 equiv) of 20-I was dissolved in 3.5 mL 
of toluene along with tris(trimethylsilane)silane (117 mg, 0.47 mmol, 2 equiv) and 
azobisisobutyronitrile (11.5 mg, 0.07 mmol, 0.3 equiv) and the reaction was heated at 
95oC for 3.5 hours to yield 53.33 mg (99%) of 41 after concentration and silica gel 
purification (10% EtOAc:hexanes). Clear oil, pleasing scent,  Rf = 0.36 (silica gel, 15% 
EtOAc:hexanes);  IR (film) 𝝂max 3706, 3680, 3665, 2968, 2940, 2866, 2075, 1346, 1056, 
1013, 841 cm-1; 1H NMR (500 MHz, CDCl3) δ 3.84 (td, J = 9.0, 3.0 Hz, 1H), 3.76 (q, J = 
8.3 Hz, 1H), 2.03 (dq, J = 12.1, 9.3 Hz, 1H), 1.94 – 1.85 (m, 1H), 1.69 – 1.47 (m, 5H), 
1.42 – 1.37(m, 2H), 1.36 (s, 3H), 1.30 – 1.09 (m, 6H), 1.08 (s, 3H), 0.88 (s, 3H), 0.80 (s, 
3H), 0.17 – 0.04 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 81.2, 64.4, 59.3, 47.0, 42.6, 
39.0, 36.3, 36.1, 33.9, 33.2, 29.1, 28.0, 23.1, 22.1, 20.7, 18.8; HRMS (ASAP) calcd for 
C16H29O+ [M + H]+ 237.2218, found 237.2216.   
 
2,3-ene-9-(-)-epi-Ambrox (22): To 20-I (100 mg, 0.28 mmol, 1 equiv) in 0.5 mL of 
toluene was added DBU (0.43 mL, 2.8 mmol, 10 equiv). The reaction mixture was heated 
at 85oC for 6 hours, then brine (5 mL) and NH4Cl (7 mL) were added, and it was 
extracted with ether (3 X 10 mL). The pooled organic layers were dried over MgSO4, 
evaporated, and purified over silica (10% EtOAc:hexanes) to yield 57 mg (88%) of 22 as 
a clear oil.  
22 was also obtained as the single product when 20-I is heated (85oC) with NaOH in 
DMSO for a few hours.  
Clear oil, pleasing ambroxide-like scent, Rf = 0.3 (silica gel, 15% EtOAc:hexanes);  IR 
(film) 𝝂max 3715, 3673, 2938, 2866, 1454, 1379, 1055, 723 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 5.44 (ddd, J = 9.9, 6.0, 1.5 Hz, 1H), 5.32 (dd, J = 10.1, 2.8 Hz, 1H), 3.87 – 3.80 
(m, 1H), 3.76 (q, J = 8.4 Hz, 1H), 2.08 – 1.86 (m, 3H), 1.81 – 1.39, (m, 9H), 1.37 (s, 3H), 
1.36 – 1.20 (m, 2H), 1.10 (s, 1H), 1.09 (s, 3H), 1.02 (s, 1H), 0.96 (s, 3H), 0.94 (s, 1H), 
0.88 (s, 1H), 0.85 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 138.0, 121.8, 80.9, 64.1, 57.2, 
43.9, 38.5, 35.3, 34.9, 34.8, 32.0, 29.7, 27.2, 23.4, 23.2, 21.6; HRMS ((ASAP) calcd for 
C16H27O+ [M + H]+ 235.2062, found 235.2061.   
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2,3-Epoxy-9-(-)-epi-Ambrox (23): 22 (26 mg, 0.11 mmol, 1 equiv) was dissolved in 1.5 
mL of DCM along with NaHCO3 (49 mg, 0.55 mmol, 5 equiv) and cooled to 0oC with 
stirring. 29.6 mg (0.17 mmol, 1.5 equiv) of m-Chloroperoxybenzoic acid (mCPBA) was 
then added and the reaction was stirred at room temperature for 3 hours. Then the mixture 
was washed with Na2SO3 (2 x 3 mL), NaHCO3 (4 x 3 mL) and brine (3 mL) to yield 23 
as a clear oil after drying over MgSO4 and evaporation. NMR showed presence of m-
benzoic acid contaminants even following several aqueous NaHCO3 washed—however, 
23’s sensitivity to silica gel, further purification was not attempted. Rf = 0.12 (silica gel, 
15% EtOAc:hexanes);  IR (film) 𝝂max 2942, 2874, 1768, 1466, 1387, 1216, 945, 826 cm-
1; 1H NMR (500 MHz, CDCl3) δ 3.85 (td, J = 9.8, 3.9 Hz, 1H), 3.78 (q, J = 8.4 Hz, 1H), 
3.29 – 3.21 (m, 1H), 2.84 (t, J = 3.8 Hz, 1H), 2.61 – 2.34 (m, 1H), 2.12 – 1.53 (m, 10H), 
1.52 (s, 2H), 1.45 (s, 1H), 1.39 (s, 1H), 1.36 (s, 2H), 1.32 – 1.19 (m, 4H), 1.16 – 0.91 (m, 
14H), 0.85 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 86.7, 85.6, 64.0, 62.0, 61.6, 57.3, 
55.3, 53.1, 52.4, 39.6, 39.4, 38.4, 38.0, 36.0, 35.3, 34.5, 33.4, 32.6, 29.7, 28.3, 28.3, 26.8, 
26.6, 25.6, 22.8, 21.0, 20.0; HRMS (ASAP) calcd for C16H27O2+ [M + H]+ 251.2011, 
found 251.2013.   
 
 
3-Iodo-Ambrox (24): was obtained as a mixture with its 9-epi isomer by the reaction of 
E,E-homofarnesol (17) with IDSI. Clear oil,  Rf = 0.22 (silica gel, 15% EtOAc:hexanes);  
IR (film) 𝝂max 2937, 2870, 1460, 1378, 1126, 998, 846, 650, 431 cm-1; 1H NMR (300 
MHz, CDCl3) δ 4.30 – 4.16 (m, 1H), 3.97 – 3.71 (m, 2H), 2.57 – 2.36 (m, 1H), 2.35 – 
2.21 (m, 1H), 2.06 – 1.83 (m, 2H), 1.77 – 1.63 (m, 2H), 1.53 (s, 3H), 1.48 – 1.39 (m, 2H), 
1.37 (s, 2H), 1.15 (s, 1H), 1.11 – 1.03 (3 s, 5H), 1.00 – 0.96 (2 s, 3H), 0.90 (s, 2H); 13C 
NMR (125 MHz, CDCl3) δ 78.2, 78.0, 74.3, 74.1, 73.1, 72.7, 72.0, 71.6, 71.5, 69.6, 68.8, 
68.4, 68.0, 67.9, 67.8, 67.2, 67.1, 66.9, 66.5, 66.4, 65.2, 64.9, 63.8, 63.8, 63.7, 63.7, 63.3, 
63.3, 63.2, 61.8; HRMS (ASAP) calcd for C16H28IO+ [M + H]+ 363.1185, found 
363.1188. 
 
5-Iodo-4,4-dimethyl-4-homogeranyl-octahydro-benzofuran (25): was obtained as a 
single isomer (35% yield) as a side product of the reaction of E,E-homofarnesol (17) with 
IDSI to yield 25 (toluene was added to promote this side product generation). Clear oil; 
potent ambroxide and patchouli scent, Rf = 0.31 (silica gel, 15% EtOAc:hexanes);  IR 
(film) 𝝂max 2963, 2925, 2875, 1449, 1379, 1133, 1002, 938, 678 cm-1; 1H NMR (300 
MHz, CDCl3) δ 5.10 (t, J = 7.1 Hz, 1H), 4.27 (dd, J = 12.7, 4.5 Hz, 1H), 3.93 – 3.66 (m, 
3H), 2.49 – 2.36 (m, 1H), 2.26 (ddd, J = 16.8, 13.6, 4.0 Hz, 1H), 2.01 – 1.71 (m, 8H), 
1.69 (s, 3H), 1.63 (s, 3H), 1.55 (s, 2H), 1.49 – 1.29 (m, 5H), 1.15 (s, 3H), 1.11 – 1.00 (m, 
3H), 0.95 (s, 3H), 0.90 – 0.79 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 132.3, 124.0, 
79.7, 64.8, 50.3, 44.6, 43.4, 41.2, 40.9, 35.3, 26.0, 25.7, 21.8, 20.9, 18.2, 15.2; HRMS 
(ASAP) calcd for C16H28IO+ [M + H]+ 363.1185, found 363.1182.    
 
4,7-dimethyl-4-homogeranyl-hexahydrobenzofuran (26): was derived from 25’s 
reaction with DBU according to the procedure outlined for the preparation of 22. Clear 
oil; potent patchouli scent with a note of saffron; Rf = 0.3 (silica gel, 15% 
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EtOAc:hexanes);  IR (film) 𝝂max 2962, 2922, 2874, 1635, 14512, 1374, 1035, 1001, 728 
cm-1; 1H NMR (500 MHz, CDCl3) δ 5.58 (ddd, J = 9.9, 5.8, 1.9 Hz, 1H), 5.39 (dd, J = 
9.9, 2.0 Hz, 1H), 5.06 (t, J = 7.1 Hz, 1H), 3.96 – 3.89 (m, 1H), 3.88 – 3.73 (m, 2H), 2.21 
(dd, J = 15.9, 5.9 Hz, 1H), 2.14 (s, 1H), 2.10 (s, 1H), 2.00 – 1.77 (m, 7H), 1.66 (s, 3H), 
1.58 (s, 3H), 1.42 (s, 1H), 1.39 – 1.23 (m, 6H), 1.06 (s, 3H), 0.96 (s, 3H), 0.90 (s, 1H), 
0.82 (d, J = 3.5 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 136.6, 131.6, 125.1, 124.2, 
79.8, 65.0, 50.7, 44.9, 40.2, 39.5, 26.0, 24.0, 23.3, 21.1, 20.7, 17.9; HRMS (ASAP) calcd 
for C16H2O+ [M + H]+ 235.2062, found 235.2060.   
  
5-Iodo-4,4-dimethyl-4-methylpentanyl-octahydrobenzofuran (27): 25 (20 mg, 0.0552 
mmol, 1 equiv) was dissolved in 1 mL of methanol (MeOH) along with 6 mg (0.00552 
mmol, 0.1 equiv) of 10 wt% palladium on carbon. A balloon filled with hydrogen was 
then affixed to the reaction, and, after stirring overnight at room temperature, the reaction 
mixture was filtered through a celite plug to yield 18 mg (90%) of 27 as a clear oil after 
evaporation. Rf = 0.33 (silica gel, 15% EtOAc:hexanes);  IR (film) 𝝂max 3707, 3680, 
2951, 2867, 1455, 1381, 1055, 1032, 1010 cm-1; 1H NMR ((300 MHz, CDCl3) δ 4.25 
(dd, J = 12.6, 4.5 Hz, 1H), 3.93 – 3.65 (m, 4H), 2.47 – 2.36 (m, 1H), 2.25 (ddd, J = 27.1, 
13.5, 3.9 Hz, 2H), 1.98 – 1.17 (m, 26H), 1.14 (s, 6H), 1.11 – 0.96 (m, 5H), 0.94 (s, 4H), 
0.89 (s, 4H), 0.87 (s, 4H), 0.85 – 0.78 (m, 2H); 13C NMR (125 MHz, CDCl3) δ 79.6, 
64.8, 50.3, 45.0, 43.7, 41.2, 40.9, 39.7, 35.3, 28.1, 25.6, 23.0, 22.9, 21.0, 20.9, 20.6; 
HRMS (ASAP) calcd for C16H30IO+ [M + H]+ 365.1341, found 365.1330.    
 
5-Iodo-4,4,7-dimethyloctahydrobenzofuran (29): made by the reaction of 28 with IDSI 
according to the procedure detailed for the preparation of 20-I. Interestingly, the yield 
was much higher at 94%. 29 is a clear oil with strong patchouli scent; Rf = 0.35 (silica 
gel, 15% EtOAc:hexanes);  IR (film) 𝝂max 2964, 2873, 1454, 1375, 1139, 1063, 1049, 
945; 1H NMR (500 MHz, CDCl3) δ 4.40 (dd, J = 11.5, 3.8 Hz, 1H), 4.08 (dd, J = 12.9, 
4.4 Hz, 1H), 3.91 – 3.76 (m, 5H), 2.43 – 2.36 (m, 1H), 2.27 – 2.09 (m, 4H), 2.05 – 1.80 
(m, 6H), 1.75 – 1.39 (m, 8H), 1.35 (s, 3H), 1.20 (s, 3H), 1.12 (s, 4H), 1.06 (s, 3H), 1.03 
(s, 4H), 0.97 (s, 4H); 13C NMR (125 MHz, CDCl3) δ 80.3, 79.3, 65.0, 64.1, 54.7, 53.5, 
49.3, 45.7, 41.3, 39.1, 37.6, 36.0, 35.8, 34.3, 32.8, 31.0, 29.2, 28.4, 27.2, 26.1, 20.3, 20.0; 
HRMS (ASAP) calcd for C11H20IO+ [M + H]+ 295.0559, found 295. 0562. 
 
5-bromo-4,4,7-dimethyloctahydrobenzofuran (30) “18”: made from 28’s reaction with 
BDSB in 93% yield. Clear oil with strong patchouli scent, Rf = 0.35 (silica gel, 15% 
EtOAc:hexanes);  IR (film) 𝝂max 2960, 2873, 1456, 1376, 1153, 1127, 1067, 1041, 1001, 
783, 583; 1H NMR (500 MHz, CDCl3) δ 4.23 (dd, J = 11.0, 3.8 Hz, 1H), 3.95 – 3.75 (m, 
9H), 2.28 – 2.21 (m, 2H), 2.16 – 1.79 (m, 15H), 1.76 – 1.46 (m, 8H), 1.35 (s, 3H), 1.17 
(s, 3H), 1.13 (s, 7H), 1.09 – 1.06 (2 s, 9H), 0.95 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 
80.2, 79.2, 66.2, 65.3, 64.2, 63.2, 56.3, 54.8, 39.6, 39.1, 37.7, 34.5, 33.2, 31.6, 30.7, 29.0, 
28.9, 27.3, 25.7, 25.1, 20.4, 17.3; HRMS (ASAP) calcd for C11H19BrO+ [M+] 247.0697, 
found 247.0698.  
 
4,4,7-Trimethylhexahydrobenzofuran (31): was derived from 29’s reaction with DBU 
according to the procedure detailed for the preparation of 22. Clear oil; woody, clary 
75
sage, sclareol scent; Rf = 0.38 (silica gel, 15% EtOAc:hexanes);  IR (film) 𝝂max 3716, 
3673, 2958, 2954, 2863, 1646, 1265, 1058, 1032, 1014 cm-1; 1H NMR (500 MHz, 
CDCl3) δ 5.53 – 5.46 (m, 1H), 5.42 – 5.37 (m, 1H), 3.96 – 3.91 (m, 1H), 3.88 – 3.76 (m, 
1H), 3.72 – 3.64 (m, 1H), 2.23 – 2.09 (m, 2H), 1.99 – 1.72 (m, 4H), 1.69 (dd, J = 12.9, 
7.3 Hz, 1H), 1.34 (s, 1H), 1.07 – 1.03 (2 s, 5H), 1.02 (s, 1H), 0.96 (s, 2H); 13C NMR (125 
MHz, CDCl3) δ 138.4, 135.9, 122.9, 122.5, 80.5, 79.7, 65.0, 64.4, 54.2, 53.7, 40.3, 36.4, 
35.0, 34.7, 32.5, 31.3, 29.6, 29.0, 28.7, 23.9, 21.7, 20.8; HRMS (ESI) calcd for C11H17O+ 
[M – H]+ 166.1436, found 166.1057 (fragmentation made it difficult to observe the 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.1   Introduction    
Totalling over 7,000 members, diterpenes are a diverse class of terpenoids with 
important properties.1 Molecules such as Prostratin (2, anti-HIV activity), Totarol (3, 
antibacterial), and the famous Taxol® (4, anti-cancer) all belong to the diterpene family.  
 
 
Figure 1. Examples of diterpenes. 
 
The biogenesis of diterpenes follows the same model discussed in Chapter 2; in 
other words, they are generated from the head to tail condensation of the universal 5-
carbon building blocks isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate 
(DMAPP) into farnesyl pyrophosphate (FPP), to which is added an additional IPP unit to 
make the 20-carbon geranylgeranyl pyrophosphate (GGPP). GGPP then undergoes 
further transformations at the hand of cyclases, reductases, and oxygenases to afford 
more complex diterpenes.  
The hydrolysis product of GGPP, geranylgeraniol (GGOH, 1), is a crucial raw 
material in the synthetic production of vitamin A and E in addition to its widespread use 
in the cosmetic industry as an ingredient in perfumes.2,3 GGOH has also been shown to 


















































Figure 2. Single step hybrid approach to tocotrienols 
 
While GGOH can be produced by synthetic means (see figure 3),1,5 we aimed to 
engineer yeast to produce GGOH to serve as the renewable starting material in our single 
step synthesis of the tocotrienols (5, figure 2). As with other terpenoids (see Chapter 2), 
GGOH production in yeast is typically achieved by over-expressing the terpenoid 
pathway enzymes HMG1 (hydroxymethyl-Co-A reductase, rate-limiting enzyme in the 
mevalonate pathway), ERG20 [farnesyl diphosphate (FPP) synthase] and BTS1 
[geranylgeranyl diphosphate (GGPP) synthase] often combined with repression of ERG9 
(squalene synthase), which diverts FPP and GGPP to ergosterol synthesis (Figure 4). 
Overproduced GGPP is then hydrolyzed by endogenous phosphatases such as DPP1. 
   
 
Figure 3. Synthetic approaches to GGOH production 
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R1, R2 = Me, Me (α); Μe, H (β); H, Me (γ); H, H (δ)
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Figure 4.Triple fusion construct-engineered S. cerevisiae 
4.2   Double Enzyme Fusion Exploration 
Recently, enzyme fusions have been employed in metabolic engineering to 
enhance active site proximity and allow for better substrate channeling. This process not 
only helps prevent diffusive loss between steps of the pathway but also keeps the 
substrates from being diverted into competing pathways, thereby resulting in higher 
fermentation yields. For instance, yeast YPH499 was engineered with HMG1 and a 
double fusion of ERG20–BTS1 to achieve GGOH production with titer yields of 138 
mg/L in a 5L fermenter, although with concomitant production of squalene at 60 mg/L.6
This same group later reported titer yields of 3.3 g/L under optimal fermentation 
conditions for YPH499 overexpressing HMG1 and the two double fusions BTS1–DPP1 
and BTS1–ERG20.7  
We attempted similar double fusion strategies not only in the reported YPH499 
background strain, but also in the yeast ATCC200589 carrying the AUR1C mutation, 
which was previously reported to produce 2.3 mg/L of GGOH when engineered with 
additional HMG1.8 Note that yeast strain with the AURC1 mutation has not previously 
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been engineered beyond additional HMG1. We introduced the AURC1 mutation into 
ATCC200589 using CRISPR, resulting in strain AN159Y.  
We found that co-expression of the two double fusions DPP1–BTS1 and BTS1–
ERG20 on the same plasmid together with tHMG1 on a second plasmid led to GGOH 
titers of ~5 mg/L (Figure 5) in the background strain YPH499 (strain AN-GG1-T3), but 
no production in AN159Y.  
Figure 5. GGOH fermentation titers 
4.3   Triple Enzyme Fusion Advent 
To date, only double fusions of enzymes have been reported. We hypothesized 
that a triple fusion of DPP1–BTS1–ERG20 could improve substrate channeling to a 
greater extent, thus leading to higher titer yields (Figures 4). We found that this triple 
fusion construct along with tHMG1 in the background strain AN159Y (strain AN-GG2-
T3) leads to GGOH production titers of ~13 mg/L with no detectable levels of squalene 
despite no ERG9 repression (Figure 5). This outcome is likely due to less FPP and GGPP 
being diverted into the competing ergosterol pathway (Figure 4), suggesting that the 
triple fusion, if properly expressed, is effective in substrate channeling for GGOH 
production. To our knowledge, this report is the first successful use of a triple fusion 
enzyme for metabolic engineering.  
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Some geranyllinalool (GLOH), the tertiary allylic alcohol isomer of GGOH, was 
sometimes produced, with more acidic media leading to increased GLOH content. This 
outcome is similar to reports of farnesol production often being accompanied by its 
















Figure 6. Comparison of GGOH, FOH, NOH and squalene yields in various strains. **Data 
plotted on log scale to capture full range of production values. D-B: DPP1-BTS1 double enzyme 
fusion.  B-E: BTS1-ERG20 double enzyme fusion.  D-B-E: DPP1-BTS1-ERG20 triple fusion. 
Numbers in bracket represent For each strain, the number in brackets indicates the number of 
independent transformant colonies tested, except for AN159Y/tHMG1/D-B-E (AN-GG2-T3), 
where five independent colonies derived from a streak of one original transformant colony were 





4.4   Fusion Constructs in Opposite Backgrounds 
Surprisingly, the triple fusion construct in YPH499 (AN-GG1-T4) and the double 
fusion constructs in AN159Y (AN-GG2-T5) did not produce detectable levels of GGOH 
(Figure 6). This outcome could be due to our small sample size. Furthermore, we 
observed a generally low transformation efficiency with the triple fusion plasmids (only 
four colonies for AN-GG2-T3 and two for AN-GG1-T4). And out of the four colonies for 
AN-GG2-T3, only one led to GGOH production. This result could be due to high 
metabolic burden imposed on the cell given that the plasmid is high copy and the triple 
fusion is expressed from a strong, constitutive PGK1 promoter. There could also be 
problems with the folding of the enzyme fusion constructs. In the future, these could be 
remediated by growing the strain at a lower temperature or using promoter libraries to 
tune the expression levels of the fusion constructs.  
Still, the triple fusion engineered strain (AN-GG2-T3) consistently produced 
GGOH across multiple runs and scales.  
4.5   Enzyme Order in the Fusion Constructs 
In deciding on the enzyme order in the fusion, we noted that reports of double 
fusion enzymes have shown that constructs where the later enzyme in the pathway came 
first in the fusion led to greater titer yields of the target compound, suggesting that the 
fused enzymes’ active sites are in closer proximity in those constructs.10 Given time 
constrains, we decided to focus on such enzyme order for our constructs.   
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4.6   Bench Scale Production Optimizations Without Appropriate Fermenter 
As was the case with our large scale fermentation of Z,E-FOH (see Chapter 2), 
our 3L-scale fermentation of GGOH led to dramatically lower titer yields (6 mg/L) from 
13.5 mg, which is likely due to our less than ideal large scale fermentation conditions. It 
is likely that when grown in better fermentative conditions with more favorable aeration, 
pH, mixing, nutrients, and evaporation control, that our strains would produce GGOH in 
higher titers.  
In Chapter 2, we discussed how overproduction of prenyl alcohols is deleterious 
to the organism. As such, the addition of a surfactant to the fermentation culture helps 
isolate the product from the organism preventing not only toxicity but also feedback 
inhibition. With our engineered yeast strains, we found that the addition of 2.5% decane 
content by volume helped increase geranylgeraniol production. Higher contents of decane 
were toxic, leading to inhibited growth.  
4.7   Titer Yield Calculation 
Our production yields are based on mg/L of growth media and not on the organic 
extract. Furthermore, our yields have not been adjusted to account for the efficiency of 
the extraction process. It is known that a significant portion of prenyl alcohols (farnesol 
and geranylgeraniol among others) remain bound within the cell membrane even with the 
addition of soybean oil as a surfactant.11 Therefore, our actual production yields could in 
fact be higher even in our less than ideal fermentation conditions.  
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4.8   Conclusion 
We engineered yeast with a set of fusion enzyme constructs, including a first of 
its kind triple fusion enzyme construct, which led to geranylgeraniol production with no 
squalene side product despite not repressing squalene synthase (ERG9). With this triple 
fusion-engineered strain, we produced 27 mg of isolated GGOH in a very rudimentary, 
homemade fermentor.  
**I would like to note that the following people contributed to the work in this chapter:
Yao Zong Ng: strain construction and fermentation 
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4.10 Experimental Section 
Strain construction 
The yeast (Saccharomyces cerevisiae) strain ATCC200589 and YPH499 
(ATCC76625) were obtained from the American Type Culture Collection, Rookville. 
AN159Y which contains mutations (F158Y and A240C) in the AUR1C gene of 
ATCC2005898 was constructed by the CRISPR method.12 In brief, pAN70 (a kind gift 
from the Church lab) containing yeast codon-optimized Cas9 under a constitutive TEF1p 
promoter was transformed into ATCC200589. A guide RNA (gRNA) plasmid, pAN151, 
was constructed to target Cas9 to AUR1C. A repair fragment (for homology-directed 
repair) containing the desired mutations was created by PCR of AUR1C in 3 parts using 
ATCC200589 genomic DNA as template and the following primer pairs: AUR1C-a: 
AN627/AN628; AUR1C-b: AN629/AN630; AUR1C-c: AN631/AN632. The three parts 
were fused by PCR using the external primers AN627/AN632. pAN151 (500ng) and the 
repair fragment (2µg) were transformed into the previously obtained 
ATCC200589/pAN70-Cas9 colonies and plated on SC agar plates lacking histidine, 
tryptophan and uracil. Correct clones were confirmed by PCR of genomic DNA (YeaStar 
Genomic DNA Kit, Zymo Research). PCR was performed using Phusion polymerase 
(NEB). 
The other strains used in this study (see Table S1) were constructed by transforming 
various combinations of plasmids (see Table S2) into either of the background strains 
AN159Y or YPH499. For yeast transformations, 30mL of selective SC media in a 250mL 
flask was inoculated with a starter culture to an OD600 of 0.1. When the culture reached 
an OD600 of 1, 300µL of 2.5M dithiothreitol was added, and the culture left to shake for 
20 min. The cells were then pelleted by centrifugation, washed twice with E buffer and 
resuspended in 30µL E buffer. 80µL of cells was mixed with 2µg of the plasmid to be 
transformed and electroporated at 1500V. The cells were allowed to recover for 2h in 
YPD (30ºC, 230rpm) and the transformants were selected on SC agar plates lacking 
specific amino acids to select for the auxotrophic markers on the plasmids. For other 
details on yeast media and the electroporation protocol, please see Ostrov et al.13
Plasmid construction 
The strategy adopted for the construction of the yeast expression plasmids pAN117, 
pAN119, pAN127 and pAN128 (see Table S2) was: (a) PCR of the individual parts (see 
Table S3 for primers and parts), (b) fusion PCR (external primers AN409/AN412 for 
pAN117/pAN119; AN568/AN569 for pAN127/pAN128) to create a transcriptional unit 
(TU) composed of the promoter, ORF and terminator, (c) Gibson assembly (NEB, 
E2611S) to insert the TU into the cut plasmid backbone (pRS42614 digested with SacI 
and KpnI for pAN117/pAN119; pRS424 digested with SacI and KpnI for 
pAN127/pAN128), (d) transformation of the Gibson mixture into electro-competent E. 
coli TG1 cells followed by selection on LB/ampicillin plates, (e) testing of colonies by 
amplification in LB/ampicillin media overnight followed by plasmid extraction 





pAN120 was constructed by gibson assembly of the vector pAN117 (digested with 
KpnI) and PCR products of PGK1 (AN536/AN540) and BTS1-ERG20 (AN541/AN537) 
using pAN119 as a template. pAN151 was constructed by PCR of SNR52p 
(AN318/AN625) and SUP4t (AN626/AN321) using a CAN1-gRNA plasmid12 as 
template (kind gift from the Church lab), followed by fusion pcr, restriction digestion 
(SacI/XhoI) and ligation into SacI/XhoI-digested pRS426. 
 
Small-scale fermentation trials 
Yeast prenyl alcohol production was performed in sterilized, 50 ml Erlenmeyer 
flasks (VWR) in an incubator shaker (New Brunswick, Innova 43R) at 30ºC and 230rpm 
for a total of 7 days. On Day 1, 0.3ml of saturated, overnight culture grown in selective 
SD media was added to 2.7ml of SD or YPD media. On Day 2, 3ml of YPD and 150µl of 
decane (final concentration of 2.5%) were added. On Day 3, 4ml of YPD and 100µl of 
decane were added. Cultures were harvested on Day 8 after incubation for 7 days. As a 
measure of cell growth, the final optical density (OD600) was determined by 10-fold 
dilution of the culture broth with YPD. 
 
Bench-scale production 
Bench-scale production was performed in a 6L vessel (L/P Vessel W/4 S/A, 6L, 
Bellco Glass). The vessel was incubated in a water bath set at a temperature of 30ºC. 
Filtered air was supplied via a sparger, and vented via an exit port with a moisture trap. 
Mixing was performed solely by the sparged air. There was no control of dissolved 
oxygen, pH or nutrient availability. On Day 1, 100mL of starter culture grown for 2 days 
was added to 2L of YPD to start the fermentation. On Day 2, 1L of YPD and 50mL of 
decane were added. On Day 3 and Day 6, another 1L of YPD and 100mL decane were 
added. The culture was harvested on Day 8 (1 week). 
 
Extraction of prenyl alcohols 
For small-scale fermentation trials, 1ml of the final culture broth was removed for 
pH and OD600 measurements. The remainder of the culture (~8.4ml) was transferred into 
a 15ml falcon tube. 1ml of brine and 2ml of hexane were added. The tube was placed 
horizontally in an incubator shaker (230rpm) for 1 hour to mix. The mixture was 
centrifuged at 3200rpm for 10min and the top hexane layer was filtered and transferred 
into a glass GC-MS vial for analysis. 
For bench-scale production, 8.4ml of the broth was sampled as above and analyzed 
by GC-MS after 7 days. The remainder of the broth was mixed in batches with ethyl 
acetate and transferred into a 2L-separating funnel. The organic layer was collected, dried 
(MgSO4) and concentrated under reduced pressure. The resulting concentrate was 
purified on silica gel to yield an oil, which was weighed and its identity further confirmed 
by 1H-NMR. 
 
Analysis of prenyl alcohols 
Geranylgeraniol (GGOH), farnesol (E,E-FOH), nerolidol (NOH) and squalene were 
analyzed using a ThermoFinnigan PolarisQ GC-MS (Agilent J&W column, #CP8907, 
VF-1ms 15m X 0.25mm x 0.25µm). GC-MS runs were carried out with the following 




ml/min, inlet temperature 225ºC, initial column temperature 50ºC, hold 2.5 minutes, raise 
at 17ºC/min to 285ºC, hold 3.5 minutes. For quantitative analysis, undecanol was used as 
an internal standard. The selected ion peak area (67 mass fragment) of 25 mg/l undecanol 
to that of 25 mg/l of authentic standards of GGOH (Sigma, G3278), E,E-FOH (Sigma, 
277541), NOH (Sigma, 18143) and squalene (Sigma, S3626) were used as a standard 
ratio. The amount of prenyl alcohol in a sample was determined by comparison of this 






Fig. S1. GGOH extracted yield from engineered yeast strains. 
D-B: DPP1-BTS1 double enzyme fusion.  B-E: BTS1-ERG20 double enzyme fusion.  D-
B-E: DPP1-BTS1-ERG20 triple fusion.  Extracted yields are reported in mg/L of growth 
media.  For each strain, the number in brackets indicates the number of independent 






































































































five independent colonies derived from a streak of one original transformant colony were 
tested.  Error bars = ±1 standard deviation. 
 
 
Fig. S2. Comparison of GGOH, FOH, NOH and squalene yields of various strains. 
Data is plotted on a log scale to capture the full range of production values. Strains are 


















































































































Fig. S3 GC-MS analysis of yeast fermentation extracts and authentic GGOH 
standard. 
(A) GC chromatographs of (i) authentic GGOH standard; GGOH produced from small-




production of AN-GG2-T3.  The undecanol internal standard is present in each trace at 
retention time (RT) ~7.68 min. RT of E,E-FOH is ~10.08 min. RT of GGOH is ~12.72 










Strains used in this study. 
 
Name Genotype/Plasmids-insert Source 
YPH499 
(ATCC76625) 
MATa ura3-52 lys2-801 ade2-101 trp1-Δ63 his3-Δ200 
leu2-Δ1 ATCC 
ATCC200589 MATalpha can1 leu2 trp1 ura3 aro7 ATCC 
AN159Y ATCC200589/AUR1C This study,8 
AN-CP4-S1 YPH499/pAN127-tHMG1 This study 
AN-CP2-S4 AN159Y/pAN127-tHMG1 This study 
AN-GG1-T3 YPH499/pAN127-tHMG1/pAN120-DPP1-BTS1/BTS1-ERG20 This study 
AN-GG1-T4 YPH499/pAN127-tHMG1/pAN119-DPP1-BTS1-ERG20 This study 
AN-GG2-T3 AN159Y/pAN127-tHMG1/pAN119-DPP1-BTS1-ERG20 This study 






Plasmids used in this study. 
 





pAN70 CEN, yeast TRP1 TEF1p-Cas9-CYC1t 
Gift from Di Carlo, 
Church lab 
pAN151 2µ, yeast URA3 SNR52p-cr17-gRNA-SUP4t 
CRISPR gRNA 
plasmid to create 
AUR1C mutation 
pAN127 2µ, yeast TRP1 TEF1p-tHMG1-ACT1t Truncated HMG1 
pAN128 2µ, yeast TRP1 TEF1p-HMG1-ACT1t Wild-type HMG1 
pAN117 2µ, yeast URA3 PGK1p-DPP1-BTS1-ADH1t 
Double fusion DPP1-
BTS1 









Two double fusions 
DPP1-BTS1/BTS1-







Primers used in this study. 
 
Name Plasmid Template Sequence (5’ – 3’) 
AN318 pAN151 SNR52p-F ctaaagggaacaaaagctgGAGCTCTCTTTGAAAAGATAATG 
AN625 pAN151 SNR52p-R 
GCTCTAAAACaaatgaaatagtccgtacggGATCATTT
ATCTTTCACTGCGGAGAAG 
AN626 pAN151 SUP4t-F ccgtacggactatttcatttGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAG 
AN321 pAN151 SUP4t-R gacataactaattacatgaCTCGAGAGACATAAAAAACAAAAAAAG 
AN627 NA AUR1a-F ATGGCAAACCCTTTTTCGAGATGG 
AN628 NA AUR1a-R GAAATAGTCCGTACGGTAACCATGC 
AN629 NA AUR1b-F cattttagcatggttaccgtacggactatttcattaTGGGGCCCCATTTGTCGTTG 
AN630 NA AUR1b-R gcaccgaaaatgacggaggaatttgaaaaacaTGTAGTATACATATTAATACCGAG 
AN631 NA AUR1c-F TTTTTCAAATTCCTCCGTCATTTTCG 
AN632 NA AUR1c-R TTAAGCCCTCTTTACACCTAGTGAC 
AN569 pAN127/pAN128 TEF1p-F 
CACTAAAGGGAACAAAAGCTGGAGCTATAG
CTTCAAAATGTTTCACT1TCC 
AN387 pAN127 TEF1p-R GTTTTCACCAATTGGTCCATAAACTTAGATTAGATTGCTATGCT 
AN388 pAN127 tHMG1-F tagcaatctaatctaagtttATGGACCAATTGGTGAAAACTGAAG 
AN401 pAN127/pAN128 tHMG1-R 
tacgcgcacaaaagcagagaTTAGGATTTAATGCAGGT
GACGG 
AN402 pAN127/pAN128 ACT1t-F tcacctgcattaaatcctaaTCTCTGCTTTTGTGCGCG 
AN568 pAN127/pAN128 ACT1t-R 
gactcactatagggcgaattgggtacACACTATGATATATA
AATATAATAGTTTTTCG 
AN571 pAN128 TEF1p-R cttgaatagcggcggcatAAACTTAGATTAGATTGCTATGCT 






AN420 pAN117/pAN119 PGK1p-R 
ttttaataaacgaaactctgttcatTTGTTTTATATTTGTTGT
AAAAAGTAGATAATTAC 
AN421 pAN117/pAN119 DPP1-F 
actttttacaacaaatataaaacaaATGAACAGAGTTTCGT
TTATTAAAACG 






AN442 pAN117/pAN119 BTS1-F 
catcctttgtccgatgaaggtatgggtggtggttctATGGAGGCC
AAGATAGATGAG 
AN443 pAN117 BTS1-R aaatcataaatcataagaaattcgcTCACAATTCGGATAAGTGGTCTA 






AN445 pAN119 BTS1-R taatttctttttctgaagccatagaaccaccaccCAATTCGGATAAGTGGTCTATTATAT 
AN446 pAN119 ERG20-F aatagaccacttatccgaattgggtggtggttctATGGCTTCAGAAAAAGAAATTAGG 
AN424 pAN119 ERG20-R aaatcataaatcataagaaattcgcCTATTTGCTTCTCTTGTAAACTTTG 
AN425 pAN119 ADH1t-F caaagtttacaagagaagcaaatagGCGAATTTCTTATGATTTATGATTTTTAT 
AN536 pAN120 PGK1p(RC)-F 
tacgactcactatagggcgaattgggtaccGAAGTACCTTCA
AAGAATGGGGTC 
AN540 pAN120 PGK1p(RC)-R 
tcatctatcttggcctccatTTGTTTTATATTTGTTGTAA
AAAGTAGATAATTAC 
AN541 pAN120 BTS1(RC)-F 
ctttttacaacaaatataaaacaaATGGAGGCCAAGATAG
ATGAG 




















Tocotrienols in a Single Step from Biosynthetic Geranylgeraniol 
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5.1   Introduction 
Vitamin E and its synthetic analogs are prime, lipid-soluble antioxidants whose 
roles extend beyond radical scavenging to numerous other benefits, including as 
cardioprotective agents.1-3 The natural vitamin E family comprises the tocopherols (1), 
the tocotrienols (2), the recently discovered α-tocomonoenol (3) and cold-water adapted 
Marine Derived Tocopherol (MDT, 4).4  
       
Figure 1. A) Natural vitamin E family. B) Vitamin E biosynthetic pathway. 
 
Tocopherols and tocotrienols represent the major constituents of the natural 
vitamin E family. Between these two classes, the tocotrienols have drawn much less 











1: Tocopherols (most widely distributed in nature)
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possessing anti-cancer, neuro-protective, radioprotective and hypocholesteromic 
properties to boot.5,6  
This dearth of appreciation of the tocotrienols as compared to the tocopherols may 
be due to the tocotrienols’ scarcity in nature. Furthermore, their unsaturated farnesyl side 
chain, which grants them their greater activity, renders their synthetic preparation non-
trivial. Whereas racemic α-tocopherol is produced industrially in a single step 
condensation of racemic isophytol (5) with trimethylhydroquinone (TMHQ, 6), an 
analogous direct synthesis of α-tocotrienol through the condensation of geranyllinalool 
(GLOH, 7) with TMHQ has not been reported given the challenging regioselective 
cycloetherification that must be achieved with additional sensitive olefins present. As 
such, nearly all of the reported racemic5,7,8 as well as asymmetric9-11 tocotrienol 
preparation methods involve the assembly of the molecule in different stages—first the 
construction of the chroman skeleton (8), followed by addition of the polyene chain in an 
overall arduous process as illustrated in Figure 3.   
  
Figure 2. A) Current industrial production of α-tocopherol. B) lack of analogous method for the 



































Figure 3. Selected tocotrienol syntheses. A) Racemic synthesis by Pearce et al.5 B) Asymmetric 
synthesis by Couladouros et al.11 
 
With the aim to make the tocotrienols and their analogs more readily accessible, 
we set out to achieve a direct synthesis of the tocotrienols that would be analogous to the 
current industrial tocopherol synthesis. Namely, a one-pot/tandem C-C coupling of the 
geranylgeranyl chain to TMHQ along with the regioselective cycloetherification of the 3-




















































































































vinyl of the polyene to arrive at tocotrienol. Furthermore, we believe that a hybrid 
strategy, in which metabolic engineering is drawn upon to procure the terpenoid portion 
of the molecule in the form of geranylgeraniol (GGOH, 24, see Chapter 4), may represent 









5.2   Designing the Catalyst System 
Our idea resided in the formation of an amphiphathic catalyst structure with 
microenvironments where polar reacting groups and non-participating, non-polar chains 
partition to drive the desired Friedel–Crafts C–C coupling and regioselective 
cycloetherification while concomitantly leaving the rest of the reactive polyene chain 
intact. We elected to employ a phase transfer catalyst (PTC, 26) as the framework for this 
system. We also considered the use of long chain nitroalkanes such as nitrodecane (27), 
but we ultimately focused on PTCs not only because they are more readily available in a 





















Figure 5. A) Schematic of amphipathic system allowing for regioselective cyclization. B) 




5.3   Choosing a Catalyst: Improving the In(III)-Promoted Synthesis of Tocopherol: 
from Phytyl Acetate to Phytyl Trifluoroacetate 
For the choice of catalyst needed to achieve the envisioned single step synthesis 
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α-tocopherol. We started with Indium triflate [In(OTf)3], which was recently reported to 
catalyze the condensation of phytyl acetate (28) with TMHQ to produce α-tocopherol 
with low catalyst loading.12 However, in this report, 16 hours of reaction time and 10 
equivalents of TMHQ were required for every equivalent of phytyl acetate. We improved 
on this method by modulating the reactivity of the phytyl group down to match that of 
TMHQ through the use of a trifluoroacetate group instead (29). This allowed for 
increased yields (quantitative), shorter reaction times (a few minutes when heated to 
reflux), and many fewer equivalents (1) of TMHQ while using the same catalyst loading 
originally reported. Similar yields are achieved overnight at room temperature with 1 
equivalent of TMHQ to 29 in MeNO2. 
 
 
Figure 6. A) Previous report. B) Improved method (this work). 
 
 
5.4   Synthesis of Polyprenyl-chromans, including α-Tocotrienol 
We tested the amphiphatic catalyst concept in the coupling of geranyl 
trifluoroacetate (30) with TMHQ towards prenyl-chroman 7 with a tetrabutylammonium 
bromide (34)–In(OTf)3 system. Pleasingly, we found that 7 could be obtained when a 
non-polar solvent such as hexane, heptane, mesitylene, or decane was employed, with 





















1,2-DCE, 80oC, 10 min
99%29: (R,R)-Phytyl trifluoroacetate
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and CH2Cl2 led to practically no regioselectivity. Taken together, we decided to focus on 
decane as the choice solvent for the reaction. 
Figure 7. Optimized single step synthesis of polyprenyl-benzopyrans/chromans 
Catalyst Conversion (%) Yield of α−2 (%) 
In(Otf)3 100 0 
35 0 0 
In(OTf)3−35 100 90 
Table 1. Importance of PTC in the catalyst system 
% Alkyl ether in 
decane 
Time to full 
conversion (min) 7 
Product Yield (%)* 
36 α−2 
100 5 0 N/A N/A 
50 5 0 N/A N/A 
20 5 40 N/A N/A 
10 5 50 0 N/A 
5 10 94 0 N/A 
2 10 95 45 55 
n-Butyl
ether
0.5 20 96 65 85 
0 120 92 55 75 
2.5 20 N/A 95 91 n-Octyl
ether 5 15 N/A 85 N/A 
Table 2. Effect of alkyl ether additive on reaction yield and time to completion. *Includes




















30 (n = 1), 31 (n = 2), 32 (n = 3)
33 (n = 3)
7 (n = 1), 36 (n = 2), α-2 (n = 3)
10% 35-In(OTf)
0.5% nButylether:Decane
or 2.5% nOctylether: Decane






In our efforts to improve the catalyst system, we found that a much shorter 
reaction time, greater yields and near-perfect purity were achieved in the synthesis of 7 
with an N-[4-(Trifluoromethyl)benzyl]cinchoninium bromide (35)–In(OTf)3 system in 
0.5% dibutyl ether:decane at 100oC (see Table 2). This doping of the decane solvent with 
dibutyl ether was helpful to achieve greater solubility of TMHQ, leading to higher yields 
of the Friedel–Crafts C–C coupling step while still maintaining a sufficient non-polar 
environment to achieve the regioselective cycloetherification. Generally, we found that 
greater portions of dibutyl ether led to speedier reactions and greater conversions, but 
lower regioselectivity of the cycloetherification, further pointing to the importance of 
maintaining a non-polar solvent environment. Additionally, we found that it was key that 
the trifluoroacetylated prenyl alcohol be added last to the reaction mixture to prevent the 
generation of side products.  
With the same catalyst and solvent system, we successfully synthesized geranyl-
chroman (36) by condensing farnesyl trifluoroacetate (31) with TMHQ. Likewise, we 
derived racemic α-tocotrienol (α-2) from geranylgeranyl trifluoroacetate (32) or 
geranyllinalyl trifuoroacetate (33). With these longer polyene chains, dioctyl ether proved 
a superior additive for the regioselective cycloetherification. Moreover, we found that 
applying a slight vacuum to the reaction flask was helpful not only in keeping oxygen 
out, but also in removing all the trifluoacetic acid (TFA) side product, further preventing 
it from reacting with the polyene side chain.
It is worth noting that NMR spectra evidences the presence of a small, inseparable 
side product in these reactions. This side product could potentially be overcyclized 
product. Efforts to employ LC-MS to unmask its identity has so far led to inconclusive 
results.   
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Figure 8: Analogous single step synthesis of α-tocotrienol. A) Industrial α-tocopherol synthesis.  
B) This work.
With this system, and in demonstration of the hybrid approach, we derived 29.6 
mg (0.070 mmol) of α-2 from 27 mg (0.093 mmol) of biosynthetic GGOH (24, see 
Chapter 4) in a 75% overall yield. We also showed in a pilot study that the TFA 
protection step could be combined with the condensation step to produce α-tocotrienol in 
a two-step-single-purification process from GGOH or GLOH. Taken together, the 
amphiphatic acid catalyst concept developed here is poised to be applied for a scalable 
production of α-tocotrienol similar to the current industrial production of α-tocopherol.   
5.5   Accessing the Rest of the Tocotrienol Family: Effect of Deactivating 
        Protection Groups 
To access the rest of the tocotrienol class, namely β-, ɣ-, and δ-tocotrienols (2), a 
deactivating group was necessary to prevent over-alkylation of the additional open arene 
positions, leading to complex product formation. With an acetyl group on the 1-OH 






















small portion of the product is cyclized into tocotrienol acetate (2-Ac), with the bulk of 
the obtained product being the non-cyclized 3-geranylgeranyl-hydroquinone acetate (37–
39), potentially due to the lower nucleophilicity of the 4-OH.   
 
 
Figure 9: Synthesis of β-, ɣ-, and δ-tocotrienols by the type I acid catalyst system: effect of an 






5.6   Next Generation Approach: Type II Adanve Acids 
To cyclize 37, 38, and 39 into their corresponding tocotrienol acetates, we turned 
to the Bronsted acid version of the catalyst system (41–47), which has an acid moiety 
directly attached to an ammonium or phosphonium within the confines of a large 
framework. With these acids, we were able to cyclize 37, 38, and 39 respectively into β-, 
ɣ-, and δ-tocotrienol acetates (2-Ac) at room temperature in polar solvents such as 
CH2Cl2 or 1,2-dichloroethane. We observed that 39 had a lower conversion rate than 37 
and 38, which in turn have a lower conversion rate than geranylgeranyl-TMHQ-acetate 
(40). This outcome is likely due to the lower phenol nucleophilicity stemming from the 
lower methyl substitution. 
 
R1, R2 = Μe, H  
           =   H, Me 
           =   H,  H









































Figure 10: Synthesis of β-, ɣ-, and δ-tocotrienols by the type II acid catalyst system. 
 
Still, it was noteworthy that the type II Adanve acids (41–47) could cyclize these 
substrates (37–40) into the benzopyrans at room temperature in 1,2-dichloroethane 
whereas camphorsulfonic acid (CSA, 48) and its derivatives (49, 50) failed to do so in the 
same conditions. This phenomenon is likely explained not only by the higher 
complexation capacity of the type II acids, but also by the lower pKa of their sulfonic acid 
group as a result of the neighboring quaternary ammonium/phosphonium. With amino 
acids, it is known that a positively charged ammonium lowers the pKa of carboxylic acids 
(from 4.76 for acetic acid to 2.34 for glycine).13 By analogy, a similar effect could be 









































O41: Adanve-C-S1-OH, R3 = H, R4 = H, n = 1
42: Adanve-C-S2-OH, R3 = H, R4 = H, n = 2
43: Adanve-HQ-S2-OClBz, R3 = ClBz, R4 = 
OMe, n = 2

























































R1, R2 = Me, Me (α); Μe, H (β); H, Me (γ); H, H (δ)
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Moreover, we noted that the dimeric catalysts (45–47) were especially active 
beyond their obvious carrying of two acid moieties, pointing to a possible synergistic 
effect of the two sulfonic acids. This point will be discussed further in Chapter 6.  
Unlike the type I catalyst system, the type II Adanve acids were unfortunately not 
catalytic with this particular substrate unless heated to 100 °C with accompanying 
lowering of the regioselectivity. We hypothesize that this result is due to product 
inhibition. On the positive side, this binding of the tocotrienols to the Adanve acids keeps 
them stable in solution in ambient air when they are known to be prone to oxidation. 
Another advantage of the type II acids, as with the type I system, is that most of them are 
solid allowing for easy manipulation and easy recovery for reuse. Moreover, they are 
readily synthesized from cheap starting materials in a modular process, which allows for 
ready variation of not only the chain length of the acid moiety, but also of the overall 































5.7   Conclusion 
We developed a single step process for the production of α-tocotrienol that is 
analogous to the current industrial process for α-tocopherol. To make the process more 
renewable, we devised a semi-synthetic route that harnesses the power of bioengineering 
to produce the terpenoid portion of the tocotrienol molecule in yeast through a novel 
triple fusion enzyme construct. To access the rest of the tocotrienols, a deactivating group 
is necessary on the 1-OH of the hydroquinone, which deactivates the 4-OH, leading to 
most of the product remaining non-cyclized. By engaging the Bronsted acid version of 
our catalyst system, we achieved the regioselective cycloetherification of these 3-
geranylgeranyl-hydroquinone intermediates into β-, ɣ-, and δ-tocotrienol acetates in mild 
conditions. Together, these new acid catalysts offer mild reaction conditions, low catalyst 
loading, and ease of manipulation and recovery owing to their solid state. Even in cases 
where the catalysts are soluble in CH2Cl2 or 1,2-dichloroethane, the addition of hexanes 
results in their crashing out of solution.  
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5.9   Experimental Section 
 
General procedures:  All reactions were carried out under argon atmosphere with dry 
solvents under anhydrous conditions, unless otherwise stated. Reagents were purchased 
from commercial vendors at the highest available purity and used without further 
purification.  
Dry dichloromethane (CH2Cl2), diethyl ether (Et2O), and tetrahydrofuran (THF) were 
purchased from Sigma-Aldrich. All reactions were stirred magnetically and monitored by 
TLC performed on 0.25 mm E. Merck silica gel plates (60F-254) using UV light as the 
visualizing agent or cerium ammonium molybdate (CAM) and heat as the developing 
agent. Silica gel (SiliCycle 60, academic grade) was used to carry out flash column 
chromatography. Unless otherwise recorded, yields refer to purified materials with 
spectroscopically (1H and 13C NMR) homogeneity. NMR spectra were recorded on 
Bruker DRX-300, DRX-400, and DRX-500 instruments calibrated using residual 
undeuterated solvents as internal reference. Multiciplicities were represented by the 
following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
AB = AB quartet, br = broad. IR spectra were recorded on a Perkin Elmer Spectrum 
Two® FT-IR spectrometer, and High-resolution mass spectra (HRMS) were recorded in 
the Columbia University Mass Spectral Core facility on a Waters XEVO G2XS QToF 
mass spectrometer using electrospray ionization (ESI), atmospheric solids analysis probe 
(ASAP) and atmospheric pressure chemical ionization (APCI) techniques.   
       
 
Abbreviations: CH2Cl2 = dichloromethane, PLE = pig liver esterase, DIPEA = 
diisopropyl ethyl amine, MgSO4 = Magnesium sulfate, Et2O = diethyl ether, TMHQ = 
trimethylhydroquinone, (NH4)2SO4 = Ammonium sulfate, NH4Cl = ammonium chloride, 
EtOH = ethanol, MeOH = methanol, DI = distilled, HCl = hydrogen chloride, RT = room 
temperature, DCE = 1,2-dichloroethane, TeCE = 1,1,2,2-tetrachloroethane, EtOAc = 
ethyl acetate, Et3N = triethyl amine, TLC = thin layer chromatography, CAM = cerium 
ammonium molybdate 
 
A. Terpenoid precursors preparation 
Geranyltrifluoroacetate (30): To a solution of geraniol (4 g, 26 mmol, 1 equiv) and 
Et3N (7.2 mL, 52 mmol, 2 equiv) in CH2Cl2 (50 mL) at 0oC was added dropwise TFAA 
(4.68 mL, 33.8 mmol, 1.3 equiv). The resulting mixture was stirred for 1 hour at 0oC, 
whereupon it was quenched with cold water (75 mL). The organic fraction was recovered 
and the aqueous fraction further extracted with CH2Cl2 (2 X 50 mL). The pooled organic 
fractions were washed with brine, dried with MgSO4 and concentrated to afford a crude 
orange oil. This oil was eluted through a silica plug already impregnated with 50% 
EtOAc-hexanes to afford the pure product after concentration as light orange/greenish oil 
(6.3 g, 97%). Rf =  0.70 (silica gel, 15% EtOAc:hexanes); IR (film) 2971, 2920, 2860, 
1782, 1669, 1450, 1386, 1220, 1142, 910, 428; 1H NMR (500 MHz, CDCl3) δ 5.39 (t, J 
= 7.3 Hz, 1H), 5.06 (t, J = 6.0 Hz, 1H), 4.85 (d, J = 7.4 Hz, 2H), 2.16 – 2.04 (m, 4H), 1.75 
(s, 3H), 1.67 (s, 3H), 1.59 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 158.3, 158.0, 157.7, 
157.3, 146.0, 132.4, 123.7, 116.4, 116.1, 113.8, 65.1, 39.84, 26.4, 25.8, 17.9, 16.8; 




molecular ion.  
 
E,E-Farnesyltrifluoroacetate (31): Light oil with slight green tinge. Rf =  0.67 (silica 
gel, 15% EtOAc:Hexanes); IR (film) 2971, 2919, 2857, 1782, 1670, 1448, 1219, 1139, 
909, 428; 1H NMR (500 MHz, CDCl3) δ 5.39 (t, J = 7.3 Hz, 1H), 5.09 (t, J = 6.2 Hz, 
2H), 4.85 (d, J = 7.4 Hz, 2H), 2.12 – 2.03 (m, 7H), 1.99 (d, J = 7.7 Hz, 2H), 1.76 (s, 3H), 
1.67 (s, 3H), 1.60 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 158.0, 157.7, 157.3, 146.1, 
136.1, 131.6, 124.6, 123.6, 116.3, 116.1, 113.8, 65.1, 40.0, 39.8, 27.0, 26.4, 25.9, 17.9, 
16.8, 16.3; HRMS (ASAP) calcd for C17H25F3O2+ [M]+ 318.1807, found 318.1815.  
 
E,E,E-Geranyltrifluoroacetate (32): Yellow tinged oil. Rf = 0.67  (silica gel, 15% 
EtOAc:Hexanes); IR (film) 2971, 2919, 2858, 1781, 1671, 1449, 1219, 1139, 910, 428; 
1H NMR ( 500 MHz, CDCl3) δ 5.40 (t, J = 7.1 Hz, 1H), 5.11 (br s, 3H), 4.85 (d, J = 7.4 
Hz, 2H), 2.20  2.03 (m, 9H), 2.02  1.94 (m, 4H), 1.76 (s, 3H), 1.68 (s, 3H), 1.61 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ 158.0, 157.7, 146.1, 136.1, 135.3, 131.6, 124.7, 124.5, 
123.6, 116.3, 116.1, 113.8, 65.1, 40.1, 40.0, 39.9, 27.1, 26.9, 26.4, 26.0, 18.0, 16.9, 16.3, 
16.3; HRMS (ASAP) calcd for C22H33F3O2+ [M]+ 386.2433, found 386.2439.  
 
E,E-Geranyllynalyltrifluoroacetate (33): Yellow tinged oil. Rf = 0.75 (silica gel, 15% 
EtOAc:Hexanes); IR (film) 2918, 2919, 2856, 1781, 1450, 1368, 1217, 1156, 989, 832, 
776, 680, 453; 1H NMR (500 MHz, CDCl3) δ 5.98 (ddd, J = 17.2, 11.0, 5.9 Hz, 1H), 
5.35 – 5.22 (m, 3H), 5.11 (br s, 3H), 2. 15 – 1.92 (m, 12H), 1.91 – 1.83 (m, 1H), 1.74 – 
1.57 (6 s, 16H); 13C NMR (125 MHz, CDCl3) δ 156.3, 155.9, 139.3, 139.3, 136.7, 136.6, 
136.5, 135.8, 135.6, 135.5, 135.4, 131.8, 131.6, 125.3, 125.1, 124.7, 124.7, 124.6, 124.4, 
124.3, 124.0, 123.8, 123.1, 115.9, 115.8, 113.6, 89.2, 89.1, 53.7, 40.3, 40.1, 40.1, 40.0, 
39.7, 32.5, 32.3, 32.3, 32.2, 27.1, 27.0, 27.0, 26.8, 26.8, 26.8, 27.0, 26.0, 26.0, 23.7, 23.6, 
23.4, 23.3, 22.4, 22.3, 22.3, 17.9, 17.9, 16.3, 16.2, 16.2; HRMS (ASAP) calcd for 
C22H33F3O2+ [M]+ 386.2433, found 386.2429.  
 
 
B. Hydroquinone precursors preparation 
2,3,6-Trimethylhydroquinone-1-acetate (S1): To a solution of 2,3,5-
trimethylhydroquinone (2g, 13.1 mmol, 1 equiv) in CH2Cl2 (11 mL) at RT was added 
DIPEA (6 ml, 34.2 mmol, 2.6 equiv) followed by Ac2O (3 mL, 32 mmol, 2.4 equiv). The 
mixture was stirred overnight when it was diluted with EtOAc (100 mL) and washed with 
(NH4)2SO4 (aq, 100 mL), water (100 mL) and brine (100 mL). Upon drying (MgSO4) and 
solvent evaporation, a reddish solid (3.1 g, trimethylhydroquinone di-acetate) was 
obtained.  
2g (8.5 mmol, 1 equiv) of this solid was dissolved into EtOH:H2O (10:1, 15.4 mL), 
Na2S2O4 (3.7 g, 21.2 mmol, 2.5 equiv) added, and under vigorous stirring at RT, titrated 
with a concentration aqueous solution of NaOH (monitored by TLC). At completion, the 
reaction mixture was quenched with (NH4)2SO4 (aq, 100 mL), brine (50 mL) and 
extracted with Et2O (3 X 50 mL). The pooled organic fractions were washed with brine, 
dried (MgSO4), and concentrated to yield a reddish brown solid (1.64 g, 99%). Rf = 0.45  
(silica gel, 30% EtOAc:hexanes); IR (film) 3457, 2926, 1730, 1589, 1366, 1318, 1242, 




2.34 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
170.7, 151.6, 141.7, 129.7, 127.5, 121.8, 114.9, 20.8, 16.4, 13.3, 12.1; HRMS (ESI) 
calcd for C11H14O3Na [M + Na]+ 217.0841, found 217.0848.     
 
2,5-Dimethylhydroquinone-1-acetate (S2): was made according to method for S1 from 
2,5-dimethyl-1,4-benzoquinone (2.5 equivalent of Na2S2O4 was added into the di-acetate 
formation reaction) followed by purification on silica gel (10% EtOAc:hexanes). White 
solid; Rf = 0.44 (silica gel, 30% EtOAc:hexanes); IR (film) 3423, 3242 (br), 2929, 1722, 
1631, 1522, 1463, 1411, 1369, 1241, 1174, 1151, 925, 584, 516; 1H NMR (500 MHz, 
CDCl3) δ 6.74 (s, 1H), 6.57 (s, 1H), 4.80 (s, 1H), 2.29 (s, 3H), 2.17 (s, 3H), 2.07 (s, 3H); 
13C NMR (125 MHz, CDCl3) δ 170.4, 151.8, 142.8, 128.6, 124.1, 122.6, 117.4, 21.1, 
16.1, 15.7; HRMS (ESI) calcd for C10H12O3Na [M + Na]+ 203.0684, found 203.0685.     
 
2,3-Dimethylhydroquinone-1-acetate (S3): was made according to method for S1 from 
2,3-dimethylhydroquinone. Light brown solid; Rf = 0.44 (silica gel, 30% 
EtOAc:hexanes); IR (film) 3452, 2928, 1733, 1589, 1486, 1458, 1372, 1240, 1223, 1046, 
1011, 822, 613; 1H NMR (500 MHz, CDCl3) δ 6.66 (d, J = 8.6 Hz, 1H), 6.46 (d, J = 8.6 
Hz, 1H), 5.48 (br s, 1H), 2.32 (s, 3H), 2.11 (s, 3H), 2.05 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 171.0, 151.9, 142.9, 130.0, 124.6, 119.4, 113.3, 21.2, 13.2, 12.3; HRMS (ESI) 
calcd for C10H12O3Na [M + Na]+ 203.0684, found 203.0688.     
 
3-Methylhydroquinone-1-acetate (S4): To a solution of 2-methylhydroquinone (1g, 
8.06 mmol, 1 equiv) in CH2Cl2 (74 mL) at 0oC was added dropwise DIPEA (1.47 mL, 
8.46 mmol, 1.05 equiv) followed by Ac2O (0.76 mL, 8.06 mmol, 1 equiv). Upon stirring 
for 4 hours at this temperature, the reaction mixture was washed with aqueous NH4Cl 
(100 mL) and water (100 mL). After drying (MgSO4) and concentration, the crude solid 
was purified on silica gel (10% EtOAc:hexanes) to yield 0.79 g (63%) of the the mono-
acetate as a white solid. Rf = 0.44 (silica gel, 30% EtOAc:hexanes); IR (film) 3463, 
3433, 2926, 1733, 1507, 1430, 1371, 1229, 1179, 1102, 1016, 910, 817, 597, 508, 447; 
1H NMR (500 MHz, CDCl3) δ 6.82 (s, 1H), 6.74 (d, J = 8.6 Hz, 1H), 6.64 (d, J = 8.6 Hz, 
1H), 5.17 (s, 1H), 2.27 (s, 3H), 2.19 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 170.9, 
152.0, 144.1, 125.6, 123.9, 119.9, 115.8, 21.4, 16.2; HRMS (ESI) calcd for C9H10O3Na 
[M + Na]+ 189.0528, found 189.0529.         
 
 
C. Geranylgeranyl-hydroquinone precursors 
6-Geranylgeranyl-2,3,5-trimethylhydroquinone (S5): Trimethylhydroquinone (0.5 g, 
3.29 mmol, 1 equiv) and geranyllynalool (1.24 g, 4.27 mmol, 1.3 equiv) were dissolved 
into 1,4-dioxane (14 mL) at room temperature. To this mixture, BF3.Et2O (0.1 mL, 0.82 
mmol, 0.25 equiv) was added dropwise with stirring. The resulting reaction mixture was 
heated at 65oC for 1 hour, the dioxane removed under reduced pressure, and the crude 
brownish paste dissolved in ether (60 mL). After washing the resulting solution 
successively with NaHCO3 (aq., 75 mL), Na2S2O4 (aq., 50 mL X 2), brine (50 mL) and 
drying it (MgSO4), the solvent was removed to yield a brown paste. This material was 
triturated in hexanes, cooled to -65oC, centrifuged cold for 3 minutes and the hexanes 




oily solid (darkens upon drying under high vac) is obtained. NMR spectra showed that 
this material still contained some trimethylhydroquinone contaminant, however, given 
the material’s susceptibility to oxidation, we chose to refrain from any further 
purification.  
 Rf = 0.27 (silica gel, 15% EtOAc:hexanes); IR (film) 3368 (br), 2968, 2920, 2863, 1645, 
1448, 1326, 1211, 1075, 1045, 593; 1H NMR (500 MHz, CDCl3) δ 5.16 – 5.02 (m, 4H), 
4.70 (s, 1H), 4.26 (s, 1H), 3.38 (d, J = 6.5 Hz, 2H), 2.22 – 2.13 (m, 17H), 1.98 (br s, 3H), 
1.84 – 1.80 (2 s, 3H), 1.69 (s, 6H), 1.64 – 1.56 (m, 7H); 13C NMR (125 MHz, CDCl3) δ 
147.3, 146.7, 146.2, 146.0, 135.8, 125.4, 124.8, 124.7, 124.5, 124.1, 122.4, 122.3, 121.2, 
114.7, 40.3, 40.1, 40.0, 32.3, 27.1, 27.0, 26.9, 26.8, 26.8, 26.7, 26.5, 26.0, 23.7, 18.0, 
18.0, 16.6, 16.5, 16.4, 16.2, 12.6, 12.5, 12.3; HRMS (ESI) calcd for C29H44O2Na+ [M + 
Na]+ 447.3239, found 447.3235. 
 
5-Geranylgeranyl-2,3,6-trimethylhydroquinone-1-acetate (40): was made from S1 and 
geranyllynalool according to the method described for S5 but without the centrifugation. 
Following silica gel purification (5% EtOAc:hexanes), 40 was obtained as a viscous oil.  
Rf = 0.31 (silica gel, 15% EtOAc:hexanes); IR (film) 3494 (br), 2968, 2920, 2856, 1742, 
1449, 1370, 1206, 1074, 1051, 941, 832, 501; 1H NMR (300 MHz, CDCl3) δ 5.17 – 5.04 
(m, 5H), 3.37 (d, J = 6.7 Hz, 1H), 2.34 (s, 3H), 2.15 (s, 3H), 2.09 – 2.03 (2 s, 14H), 2.04 
– 1.95 (m, 3H), 1.82 (s, 3H), 1.69 (s, 6H), 1.61 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 
170.0, 150.8, 150.7, 141.9, 138.7, 138.6, 136.1, 136.0, 135.9, 135.8, 135.6, 135.5, 135.3, 
135.2, 131.8, 131.6, 127.4, 125.9, 125.4, 125.3, 124.8, 124.7, 124.7, 124.6, 124.4, 124.0, 
123.9, 123.7, 121.9, 121.8, 40.3, 40.3, 40.1, 40.0, 32.6, 32.3, 27.1, 27.0, 27.0, 26.9, 26.9, 
26.8, 26.7, 26.7, 26.5, 26.0, 23.7, 20.8, 18.0, 17.9, 16.6, 16.5, 16.5, 16.4, 16.3, 16.3, 13.4, 
13.2, 12.4; HRMS (ESI) calcd for C31H46O3Na+ [M + Na]+ 489.3345, found 489.3349. 
 
3-Geranylgeranyl-2,5-dimethylhydroquinone-1-acetate (37): obtained as the major 
product (70%; 20% is cyclized to β-tocotrienol acetate) in the reaction of S2 and 32 (or 
33) catalyzed by the N-[4-(Trifluoromethyl)benzyl]cinchoninium bromide–In(OTf)3 
system in 2% n-octyl ether-decane (see below for a representative procedure with the 
difference that GGOTFA (32) was added nearly immediately after adding S2 given the 
better solubility). Silica gel purification (3% EtOAc:hexanes) yields 37 as a clear oil.            
Rf = 0.30 (silica gel, 15% EtOAc:hexanes); IR (film) 3494 (br), 2964, 2919, 2854, 1742, 
1476, 1447, 1369, 1206, 1076, 511; 1H NMR (500 MHz, CDCl3) δ 6.68 (s, 1H), 5.16 – 
5.03 (m, 5H), 3.38 (d, J = 6.5 Hz, 2H), 2.30 (s, 3H), 2.18 (s, 3H), 2.11 – 1.95 (m, 15H), 
1.82 (d, J = 4.2 Hz, 3H), 1.69 (s, 6H), 1.61 (s, 6H), 1.23 – 1.17 (m, 1H); 13C NMR (125 
MHz, CDCl3) δ 170.3, 151.0, 142.7, 138.6, 135.8, 126.6, 125.4, 124.7, 124.4, 124.0, 
122.9, 121.7, 121.7, 121.5, 40.3, 40.1, 40.0, 32.3, 27.0, 27.0, 26.9, 26.7, 26.5, 26.0, 23.7, 
21.1, 18.0, 16.6, 16.5, 16.4, 16.2, 12.9; HRMS (ESI) calcd for C30H44O3Na+ [M + Na]+ 
475.3188, found 475.3188. 
 
5-Geranylgeranyl-2,3-dimethylhydroquinone-1-aceate (38): obtained as the major 
product (88%) in the reaction of S3 and 32 (or 33) as with 37. Silica gel purification (3% 
EtOAc:hexanes) yields 38 as a clear oil. Rf =  0.30 (silica gel, 15% EtOAc:hexanes); IR 
(film) 3489, 2965, 2922, 2852, 1766, 1742, 1448, 1373, 1206, 1070, 906, 831, 499; 1H 




5.04 (m, 3H), 3.31 (d, J = 7.1 Hz, 2H), 2.30 (s, 3H), 2.16 (s, 3H), 2.14 – 2.05 (m, 6H), 
2.04 (s, 6H), 2.01 – 1.95 (m, 3H), 1.78 (d, J = 5.2 Hz, 3H), 1.68 (s, 6H), 1.62 – 1. 59 (2 s, 
6H); 13C NMR (125 MHz, CDCl3) δ 170.4, 150.9, 142.6, 139.7, 139.6, 136.3, 136.0, 
135.5, 135.4, 131.8, 131.6, 128.0, 125.4, 125.3, 124.9, 124.7, 124.7, 124.6, 124.6, 124.4, 
123.9, 122.4, 121.8, 121.6, 120.1, 40.3, 40.3, 40.1, 40.0, 32.6, 32.3, 30.6, 30.3, 27.1, 27.1, 
27.0, 26.9, 26.8, 26.7, 26.4, 26.1, 26.0, 23.7, 21.1, 18.0, 18.0, 16.6, 16.5, 16.4, 16.3, 13.1, 
12.5; HRMS (ESI) calcd for C30H44O3Na+ [M + Na]+ 475.3188, found 475.3187.  
 
5-Geranylgeranyl-3-methylhydroquinone-1-acetate (39): obtained as the major 
product (80%) in the reaction of S4 and 32 (or 33) as with 37 and 38. Silica gel 
purification (3% EtOAc:hexanes) yields 39 as a clear oil. Rf =  0.30 (silica gel, 15% 
EtOAc:hexanes); IR (film) 3406 (br), 2964, 2920, 2854, 1767, 1447, 1376, 1203, 912; 1H 
NMR (300 MHz, CDCl3) δ 6.72 (s, 1H), 6.68 (s, 1H), 5.31 (t, J = 6.7 Hz, 1H), 5.15 – 
5.05 (m, 4H), 3.33 (d, J = 7.1 Hz, 2H), 2.23 (s, 3H), 2.21 (s, 3H), 2.14 – 1.95 (m, 12H), 
1.77 (d, J = 1.7 Hz, 2H), 1.69 (s, 6H), 1.61 (s, 6H), 0.92 – 0.84 (m, 2H); 13C NMR (125 
MHz, CDCl3) δ 170.5, 150.9, 143.7, 139.6, 135.5, 127.3, 125.8, 124.7, 121.9, 121.6, 
120.4, 40.3, 40.0, 39.6, 32.3, 30.5, 27.0, 26.6, 26.0, 23.7, 21.4, 18.0, 16.6, 16.3; HRMS 
(ESI) calcd for C29H42O3Na+ [M + Na]+ 461.3032, found 461.3027. 
 
Type I Adanve Acids general preparation method: A suspension of Lewis acid (1 equiv) 
and PTC (1.3 equiv) in decane (or mixture of alkyl ether:decane) is heated with stirring at 
100oC for 10 minutes. The resulting white solid can be used directly (reactants added to 
the suspension) or filtered and stored to be used at a later time.  
 
Prenyl-chroman (7)—representative procedure for the single step Friedel-Crafts and 
regioselective cycloetherification:   
To a stirring suspension of N-[4-(Trifluoromethyl)benzyl]cinchoninium bromide–
In(OTf)3, 37 mg, 9.5 mol%) in 0.5% n-Butyl ether:decane (3 mL) at 100oC was added 
TMHQ (92 mg, 0.61 mmol, 2 equiv). The resulting suspension was stirred for 20 
minutes, then geranyl trifluoroacetate (30, 76 mg, 0.3 mmol, 1 equiv) in 1 mL of 0.5% n-
butyl ether:decane is added all at once and the reaction mixture put under house vacuum. 
The reaction mixture continued to be stirred and heated under this light vacuum for 15 
minutes when TLC showed complete conversion of 30. At this point, following filtering 
out of excess TMHQ, the reaction mixture was directly purified on silica gel (3% 
EtOAc:hexanes) to yield 7 as a clear oil (84.4 mg, 96% based on 30).  Rf =  0.33 (silica 
gel, 15% EtOAc:hexanes); IR (film) 3457 (br), 2925, 2857, 1720, 1452, 1377, 1256, 
1167, 1086, 1038, 926; 1H NMR (300 MHz, CDCl3) δ 5.13 (t, J = 7.1 Hz, 1H), 4.16 (s, 
1H), 2.62 (t, J = 6.9 Hz, 1H), 2.20 – 2.05 (m, 14H), 1.86 – 1.73 (m, 2H), 1.72 – 1.49 (m, 
9H), 1.25 (s, 2H), 1.14 (s, 1H), 1.01 (s, 1H), 0.93 (s, 1H); 13C NMR (125 MHz, CDCl3) δ 
145.8, 144.9, 131.7, 124.9, 123.0, 121.4, 118.8, 117.7, 75.7, 74.6, 48.7, 42.1, 40.3, 39.9, 
33.7, 32.4, 31.9, 26.0, 24.0, 22.7, 22.3, 21.1, 20.9, 20.2, 20.1, 17.9, 12.5, 12.2, 12.1, 11.6; 
HRMS (ASAP) calcd for C19H28O2+ [M]+ 288.2089, found 288.2088.  
 
Geranyl-chroman (36): Synthesized from 31 and TMHQ in 95% yield according to the 
procedure described for 7 with the difference that the solvent in this case was 2.5% n-




3456 (br), 2925, 2856, 1719, 1452, 1377, 1255, 1166, 1086, 1037, 926; 1H NMR (300 
MHz, CDCl3) δ 5.18 – 5.06 (m, 2H), 4.18 (s, 1H), 2.66 – 2.57 (m, 2H), 2.17 (s, 4H), 2.12 
(s, 7H), 2.07 – 1.93 (m, 4H), 1.85 – 1.74 (m, 2H), 1.67 (br s, 4H), 1.65 – 1.51 (4 s, 8H), 
1.28 – 1.20 (m, 4H), 1.01 (s, 1H), 0.96 – 0.82 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 
145.8, 144.9, 135.4, 131.7, 125.5, 124.7, 124.7, 123.6, 122.9, 121.4, 120.2, 118.8, 117.6, 
74.6, 40.2, 40.0, 39.8, 31.9, 27.4, 27.0, 26.0, 24.0, 23.6, 22.5, 21.1, 19.9, 18.0, 16.2, 12.5, 
12.1, 11.6; HRMS (ASAP) calcd for C24H36O2+ [M]+ 356.2715, found 356.2723.  
 
 
α-Tocotrienol (α-2): Synthesized from 32 (or 33) and TMHQ in an average yield of 91% 
according to the procedure described above for 7 with the difference that the solvent in 
this case was 2.5% n-octyl ether:decane). 1H NMR shows the presence of an inseparable 
side product.  
Note that from  mg (0.083 mmol, 89%) of α-2 was derived from 27 (0.093) mg of 
biosynthetic GGOH (24).  
Two-step-single purification from GGOH (24): 100 mg (0.34 mmol) of 24 was 
trifluoroacetylated as described above to yield 32. CH2Cl2 was then removed under 
reduced pressure. This non-purified material was resuspended in 2.5% n-octyl 
ether:decane and reacted with TMHQ as before to yield 79.4 mg (0.19 mmol, 55% yield) 
of α-2. 
Colorless viscous oil; Rf = 0.33 (silica gel, 15% EtOAc:hexanes); IR (film) 3457 (br), 
2924, 2855, 1719, 1451, 1376, 1257, 1166, 1086, 1038, 925; 1H NMR (300 MHz, 
CDCl3) δ 5.17 – 5.07 (m, 3H), 4.15 (s, 1H), 2.61 (t, J = 6.5 Hz, 1H), 2.16 (s, 4H), 2.11 (s, 
8H), 2.04 (br s, 6H), 2.00 – 1.94 (m, 3H), 1.84 – 1.73 (m, 2H), 1.68 (s, 8H), 1.60 (s, 9H), 
1.53 (s, 3H), 1.29 – 1.18 (m, 6H), 0.94 – 0.80 (m, 3H); 13C NMR (125 MHz, CDCl3) δ 
145.7, 144.8, 135.3, 131.8, 125.3, 124.6, 122.9, 121.2, 118.7, 117.5, 74.5, 68.4, 40.2, 
40.0, 39.7, 32.2, 31.8, 29.9, 27.0, 26.8, 26.6, 26.0, 24.0, 23.7, 22.5, 22.3, 21.0, 17.9, 17.9, 




Adanve-C-S1-OH (41)—representative procedure for the preparation of type II 
Adanve Acids:  A suspension of sodium bromomethanesulfonate# (500 mg, 2.54 mmol, 
1 equiv) and cinchonine (784.5 mg, 2.67 mmol, 1.05 equiv) in DMF (4 mL) is heated 
with stirring at 130oC overnight. The solvent is then removed under reduced pressure, and 
the left over brown residue is dissolved in EtOH (10 mL) and cooled to 0oC. An ethanoic 
solution of HCl (1.25 M, 6.1 mL, 7.6 mmol, 3 equiv) is then added dropwise, and the 
resulting reaction mixture stirred at RT for 3 hours. At this point, the white precipitate 
(NaCl) is filtered out, and solvent removed under reduced pressurefrom the filtrate to 
yield a brown paste. Et2O (5 mL) is added to this material and removed under reduced 
pressure to yield a brown solid, which is dried under high vacuum for 24 hours (1.28 g, 
99%). (Note: proton NMR shows evidence of trace DMF that is hard to remove).  IR 
(film) 3131 (br), 2950, 2775, 2526 (br), 2286, 2054, 1982, 1893, 1662, 1627, 1599, 1542, 
1229, 1182, 1037, 838, 762, 571, 514, 464, 411; 1H NMR (500 MHz, DMSO) δ 11.51 (s, 
1H), 9.24 (d, J = 5.4 Hz, 1H), 8.84 (d, J = 7.7 Hz, 1H), 8.45 – 8.33 (m, 1H), 8.11 (dd, J = 




(ddd, J = 17.4, 10.3, 7.2 Hz, 1H), 5.20 – 5.05 (m, 2H), 3.96 (s, 1H), 3.90 – 3.77 (m, 1H), 
3.51 (t, J = 9.2 Hz, 1H), 3.41 (t, J = 11.4 Hz, 1H), 3.29 (t, J = 11.1 Hz, 1H), 3.15 (dd, J = 
20.4, 10.4 Hz, 1H), 2.42 (d, J = 1.2 Hz, 2H), 2.24 – 2.14 (m, 1H), 1.86 (s, 1H), 1.74 – 
1.72 (m, 1H), 1.65 – 1.60 (m, 1H), 1.14 – 1.11 (m, 1H), 1.01 – 0.72 (2 t, 1H); 13C NMR 
(125 MHz, DMSO) δ 162.3, 144.8, 137.7, 134.1, 130.0, 125.3, 125.0, 122.0, 119.7, 
116.8, 66.3, 59.0, 48.3, 47.1, 43.0, 36.2, 35.8, 34.1, 30.8, 26.6, 22.5, 17.1, 11.4; HRMS 
(ESI) calcd for C20H24N2O4SNa [M – HBr – HCl + Na]+ 411.1354, found 411.1349.  
 
Adanve-C-S2-OH (42): Made from sodium bromoethanesulfonate and cinchonine 
according to the procedure described above for 41. Light brown solid; IR (film) 3171 
(br), 2954, 2916, 2774, 2527 (br), 2055, 1982, 1627, 1599, 1430, 1216, 1167, 1038, 853, 
761, 518, 412; 1H NMR (500 MHz, DMSO) δ 11.62 (s, 1H), 9.27 (d, J = 5.6 Hz, 1H), 
8.88 (d, J = 8.6 Hz, 1H), 8.45 (d, J = 8.5 Hz, 1H), 8.16 – 8.06 (m, 2H), 7.94 (t, J = 7.7 Hz, 
1H), 7.87 (s, 1H), 7.05 (br s, 1H), 6.65 (s, 1H), 6.35 (dd, J = 16.8, 10.1 Hz, 1H), 5.98 
(ddd, J = 17.4, 10.2, 7.3 Hz, 1H), 5.52 (d, J = 16.8 Hz, 1H), 5.23 – 5.06 (m, 2H), 3.91 – 
3.80 (m, 1H), 3.51 (t, J = 9.3 Hz, 1H), 3.41 (t, J = 11.2 Hz, 1H), 3.32 – 3.23 (m, 1H), 3.22 
– 3.08 (m, 1H), 2.43 (s, 2H), 2.26 – 2.15 (m, 1H), 1.86 (s, 1H), 1.80 – 1.70 (m, 1H), 1.69 
– 1.60 (m, 1H), 1.16 – 1.12 (m, 1H), 0.8 (t, J = 7.2 Hz, 1H); 13C NMR ( 126 MHz, 
DMSO) δ 162.3, 158.3, 144.4, 142.9, 137.7, 137.5, 134.3, 130.1, 125.3, 125.1, 121.5, 
119.7, 116.8, 116.2, 66.3, 59.0, 48.3, 47.0, 36.2, 35.8, 34.1, 30.8, 26.7, 24.4, 23.9, 22.5, 
17.0, 11.4; HRMS (ESI) calcd for C21H27N2O4S [M – HBr – HCl + H]+ 403.1692, found 
403.1685.  
 
Adanve-HC-S2F-OH (44): Made from sodium 2-chloro-1,1,2-trifluoroethanesulfonate14 
and hydrocinchonine according to the procedure described above for 41 with the 
modification that NaBr (1.05 equiv) was added to the initial reaction mixture. 
Amorphous, dark brown solid; IR (film) 3167, 2915, 2614, 2502 (br), 2022, 1626, 1599, 
1542, 1454, 1419, 1382, 1278, 1225, 1080, 991, 942, 838, 774, 760, 936, 554, 530, 410; 
1H NMR (500 MHz, DMSO) δ 10.78 (s, 1H), 9.29 (d, J = 4.4 Hz, 1H), 8.77 (d, J = 8.2 
Hz, 1H), 8.35 (d, J = 8.1 Hz, 2H), 8.15 (dd, J = 15.7, 6.0 Hz, 2H), 7.98 – 7.91 (m, 2H), 
7.87 (s, 2H), 6.83 (dd, J = 46.0, 14.2 Hz, 3H), 6.50 (s, 1H), 3.64 – 3.55 (m, 1H), 3.51 (t, J 
= 8.3 Hz, 1H), 3.40 (t, J = 10.4 Hz, 1H), 3.35 – 3.26 (m, 1H), 3.20 – 3.10 (m, 1H), 3.08 
(s, 1H), 2.50 – 2.41 (2 s, 2H), 2.23 – 2.12 (m, 1H), 1.83 (br s, 1H), 1.80 – 1.71 (m, 1H), 
1.70 – 1.58 (m, 2H), 1.54 – 1.40 (m, 2H), 1.19 – 0.80 (m, 1H), 0.81 (t, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, DMSO) δ 162.5, 158.6, 144.7, 137.4, 134.6, 130.4, 125.4, 125.1, 
121.5, 119.9, 116.8, 116.6, 114.6, 114.3, 112.3, 112.1, 98.5, 98.3, 98.2, 98.0, 96.5, 96.3, 
96.3, 96.1, 66.6, 59.3, 49.1, 48.6, 36.0, 34.3, 34.2, 30.9, 24.5, 23.9, 23.1, 17.1, 11.5; 19F 
NMR (282 MHz, DMSO) δ -109.54 (dd, J = 248.1, 15.6 Hz, 1F), -121.12 – -123.21 (m, 
1F), -147.30 (dt, J = 46.1, 16.2 Hz, 1F). HRMS analysis was attempted, but 
fragmentation of the fluoroalkyl sulfonate prevented observation of the molecular ion.  
 
Adanve-P-R2 (45): Derived from sodium bromoethanesulfonate and (R)-DTBM-
Segphos® according to the the procedure described for 41 with the modification that 2 
equivalents of sodium bromoethanesulfonate were used. Sticky, off white solid; IR (film) 
3355 (br), 2957, 2912, 2866, 1670, 1591, 1446, 1408, 1390, 1363, 1261, 1228, 1183, 




(500 MHz, CDCl3) δ 9.24 (s, 2H), 7.68 – 6.42 (m, 15H), 5.83 – 5.50 (m, 2H), 3.80 – 3.54 
(m, 11H), 3.38 (s, 2H), 2.61 (t, J = 5.3 Hz, 6H), 1.39 – 1.21 (m, 90H); 13C NMR ((125 
MHz, CDCl3) δ 163.8, 37.9, 36.2, 35.2, 32.6, 32.0, 32.0, 31.9, 31.8, 31.8, 30.3, 30.2, 
30.0; HRMS analysis was attempted, but fragmentation of the fluoroalkyl sulfonate 
prevented observation of the molecular ion.  
 
Adanve-HQ-R2-OBzCl (S6, pseudoenantiomer of 43):  Derived from sodium 
bromoethanesulfonate and O-(4-Chlorobenzoyl)hydroquinine according to the procedure 
described for 41. Dark, viscous oil; IR (film) 3425 (br), 2933, 2768, 2443 (br), 1729, 
1664, 1601, 1495, 1462, 1430, 1385, 1260, 1171, 1086, 1012, 851, 755, 684, 529; 1H 
NMR (500 MHz, CDCl3) δ 12.53 (s, 1H), 9.01 – 8.95 (2 br s, 3H), 8.45 (d, J = 8.7 Hz, 
1H), 8.16 (s, 1H), 8.00 (s, 2H), 7.75 (s, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 5.7 Hz, 
2H), 4.16 (s, 3H), 3.86 (s, 1H), 3.78 – 3.69 (m, 1H), 3.68 – 3.46 (2 br s, 2H), 3.27 (br s, 
1H), 2.61 (s, 6H), 2.51 – 2.37 (br s, 1H), 2.30 – 1.86 (3 br s, 4H), 1.33 (s, 2H), 0.77 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 163.6, 163.2, 162.0, 150.9, 141.3, 140.0, 139.1, 
134.3, 131.4, 129.7, 129.1, 128.3, 126.6, 123.5, 120.9, 119.4, 102.8, 70.3, 58.8, 58.3, 
57.0, 53.8, 43.7, 38.7, 37.2, 35.2, 35.1, 32.0, 26.9, 25.2, 24.7, 20.4, 11.7; HRMS (ESI) 
calcd for C29H34N2O6SCl [M – HCl + H]+ 573.1826, found 573.1819.  
 
 
Standard procedure for regioselective cycloetherification of Geranylgeranyl-
hydroquinones to Tocotrienols using Type II Adanve Acids: All of the Type II Adanve 
Acids were effective in promoting the regioselective cycloetherification of 3-
geranylgeranyl-hydroquinones to tocotrienols in halogenated solvents such as DCE, 
CH2Cl2, or TeCE.  
Typically, the appropriate 3-geranylgeranyl-hydroquinone starting material is dissolved 
into DCE (0.12 M) followed by the addition of the type II Adanve Acid (3 equiv for 
monomeric forms, 1 equiv for dimeric forms or super acid variant 44). The resulting 
reaction mixture is stirred at room temperature and monitored by TLC.  
 
α-Tocotrienol (α-2): 75% conversion/yield after 2 days with Adanve-P-R2 (45) in DCE 
at room temperature.  
 
α-Tocotrienol acetate (α-2-Ac): 65% conversion/yield after 2 days with Adanve-P-R2 
44) in DCE at RT. 35% conversion/yield after 2 days with Adanve-S2-OH (42) at RT. 
Purification by silica gel (4% EtOAc:hexanes), colorless oil. Rf = 0.37 (silica gel, 15% 
EtOAc:hexanes); IR (film) 2927, 2862, 1758, 1453, 1369, 1208, 1167, 1111, 1079; 1H 
NMR (400 MHz, CDCl3) δ 5.16  5.06 (s, 3H), 2.60 (t, J = 6.1 Hz, 2H), 2.32 (s, 3H), 2.09 
(d, J = 3.3 Hz, 4H), 2.02 (s, 4H), 1.98 (s, 5H), 1.68 (s, 6H), 1.60 (d, 5H), 1.54 (s, 4H), 
1.26 – 1.22 (m, 5H), 0.92 – 0.830 (m, 3H)  ; 13C NMR (100 MHz, CDCl3) δ 170.1, 
149.7, 140.9, 135.5, 127.0, 125.3, 124.7, 123.4, 117.7, 75.2, 40.3, 40.1, 32.3, 31.4, 30.1, 
26.9, 26.0, 23.8, 22.5, 22.4, 20.9, 18.0, 16.2, 13.3, 12.4, 12.2, 1.4; HRMS (ESI) calcd for 
C31H46O3Na+ [M + Na]+ 489.3345, found 489.3341.  
 
β-Tocotrienol acetate (β-2-Ac): 40% conversion/yield after 4 days with Adanve-S2-OH 




0.36 (silica gel, 15% EtOAc:hexanes); IR (film) 2927, 2862, 1758, 1650, 1474, 1373, 
1207, 1165, 1085, 1013, 927; 1H NMR (400 MHz, CDCl3) δ 6.64 (s, 1H), 5.18 – 5.04 
(m, 3H), 2.61 (t, J = 6.4 Hz, 2H), 2.29 (s, 3H), 2.12 (d, J = 3.6 Hz, 4H), 2.09 – 1.95 (m, 
10H), 1.83 – 1.49 (m, 20H), 1.26 (s, 3H), 0.95 – 0.80 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ 170.4, 150.1, 141.5, 135.5, 125.8, 125.4, 124.9, 124.7, 124.6, 121.4, 120.3, 
75.2, 40.3, 40.1, 34.6, 32.3, 31.3, 30.1, 27.0, 26.9, 26.7, 26.0, 24.2, 23.7, 22.5, 21.2, 21.0, 
18.0, 16.3, 12.2; HRMS (ESI) calcd for C30H44O3Na+ [M + Na]+ 475.3188, found 
475.3184. 
 
ɣ-Tocotrienol acetate (ɣ-2-Ac): 39% conversion/yield after 4 days with Adanve-S2-OH 
(42) in DCE at RT. Purification by silica gel (4% EtOAc:hexanes), colorless oil. Rf = 
0.36 (silica gel, 15% EtOAc:hexanes); IR (film) 2927, 2859, 1759, 1447, 1369, 1206, 
1103, 1076, 936; 1H NMR (400 MHz, CDCl3) δ 6.57 (s, 1H), 5.2 – 5.05 (m, 3H), 2.73 – 
2.67 (m, 2H), 2.11 (d, J = 3.5 Hz, 4H), 2.07 – 1.93 (m, 11H), 1.81 – 1.51 (m, 18H), 1.29 
– 1.23 (m, 5H), 0.97 – 0.80 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 170.5, 152.3, 149.9, 
142.0, 135.6, 135.5, 127.4, 126.2, 125.4, 124.7, 124.6, 123.4, 119.2, 118.7, 76.1, 40.4, 
32.3, 31.4, 30.1, 27.0, 26.0, 24.5, 23.8, 22.6, 22.5, 21.2, 18.0, 16.3, 13.0, 12.3; HRMS 
(ESI) calcd for C30H44O3Na+ [M + Na]+ 475.3188, found 475.3195. 
 
 δ-Tocotrienol acetate (δ-2-Ac): 26% conversion/yield after 4 days with Adanve-S2-OH 
(42) in DCE at RT. Purification by silica gel (4% EtOAc:hexanes), colorless oil. Rf = 
0.36 (silica gel, 15% EtOAc:hexanes); IR (film) 2927, 2855, 1759, 1474, 1454, 1370, 
1205, 1018; 1H NMR (400 MHz, CDCl3) δ 6.66 (s, 1H), 6.61 (s, 1H), 5.16 – 5.04 (m, 
3H), 2.75 – 2.70 (m, 2H), 2.25 (s, 3H), 2.16 – 1.90 (m, 14H), 1.77 – 1.49 (m, 21H), 1.30 
– 1.16 (m, 7H), 0.97 – 0.83 (m, 5H); 13C NMR (100 MHz, CDCl3) δ 170.6, 142.9, 127.7, 
121.5, 121.3, 121.2, 120.8, 119.4, 76.4, 40.2, 37.3, 31.3, 30.1, 26.1, 24.5, 23.8, 23.4, 22.8, 
22.5, 21.4, 18.0, 17.0, 16.9, 16.5, 16.3; HRMS (ESI) calcd for C29H42O3Na+ [M + Na]+ 
461.3032, found 461.3038.  
 
Improved method for α-tocopherol production 
α-Tocopherol (α-1): Trimethylhydroquinone (6, 200 mg, 1.31 mmol) and In(OTf)3 (22 
mg, 0.039 mmol, 3 mol%) were dissolved in DCE and heated to 80ºC with stirring. 
Phytyltrifluoroacetate (29, 514 mg, 1.21 mmol, 1 equiv) was then added. After 10 
minutes, the reaction mixture was filtered through a silica plug and concentrated to yield 
## mg (558.7 mg, 1.3 mmol, 99% yield) of α-1 as a clear oil. 
Alternatively, the reagents were combined as above in MeNO2 and stirred at room 
temperature overnight to yield α-1 in 95% yield.  
 Rf = 0.34 (silica gel, 15% EtOAc:hexanes); IR (film) 3567 (br), 2924, 2866, 1458, 1377, 
1260, 1211, 1159, 10583, 1058, 1009, 918, 647; 1H NMR (300 MHz, CDCl3) δ 2.61 (t, J 
= 6.8 Hz, 1H), 2.16 (s, 2H), 2.12 (s, 3H), 1.79 (dq, J = 13.5, 6.6 Hz, 1H), 1.62 – 1.00 (m, 
13H), 0.90 – 0.82 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 145.9, 144.9, 123.0, 121.3, 
117.7, 100.3, 74.9, 40.25, 40.18, 39.7, 37.9, 37.8, 37.8, 37.7, 37.6, 33.2, 33.1, 31.9, 31.9, 
28.3, 25.2, 24.8, 24.1, 23.1, 23.0, 21.4, 21.1, 20.1, 12.1, 11.6; HRMS (ASAP) calcd for 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Novel Chiral Acid for Asymmetric Proton Transfer: Adanve Acids Applied to 
Chiral Vitamin E Synthesis 
214
6.1   Introduction 
 Asymmetric synthesis is a key cornerstone in the broader sphere of synthetic 
chemistry. A well-established set of asymmetric induction tools are chiral Lewis acid 
catalysts whereby a Lewis acidic metal is combined (typically in situ) with a chiral Lewis 
basic ligand to form a chiral complex with net Lewis acidic character.1 The substitution 
of the metal for a proton, the smallest Lewis acid, is an attractive objective given that 
Bronsted acids typically have lower cost, better environmental friendliness, and superior 
handling, storage, and stability properties. Several reports have shown the effectiveness 
of such chiral Bronsted acid catalysts to impact enantioselectivity.1-8 
 
Figure 1. A) Examples of early chiral Bronsted acids (used in enzymatic resolution). B) 




























































































 But there are only a few examples of such chiral Bronsted acids, headlined by the 
binaphtol-derived phosphoric acids (1). Moreover, most are weak acids.3,9 To expand the 
arsenal of this emerging chiral Bronsted acid catalysis field, we developed the Adanve 
acids II (examples 2 – 4) described in the last chapter. As discussed there, the type II 
Adanve acids are readily synthesized, highly tunable chiral acids with levers of control at 
the linker chain length, the scaffold’s size and architecture, the acid moiety strength and 
character, as well as the counterion size and reactivity. Given the large library of known 
chiral bases, by reversing their polarity (Figure 2), a large diversity of chiral Bronsted 
acids could in principle be synthesized. The integration of a charged ammonium or 
phosphonium at the system’s center could impact interesting reaction enhancing 
properties. In addition to their ready, modular synthesis, these novel chiral acids are easy 
to handle given their solid state with positive implication for their recovery from reaction 
mixtures. Lastly, outside of their use as chiral proton shuttles, we envision the use of 
super acid variants such as 4 as chiral diflate counterions for Lewis acidic metals. 
 
Figure 2. A) Ready, modular synthesis of the Adanve acid as demonstrated on cinchona 











z = H, F, Cl
n = 1 - 3
X = Cl, Br, I, HSO4, etc.
R = H, alkyl, aryl, 
Adanve acid II, 
polymer, etc.




























We undertook an early exploration of the ability of the type II Adanve acids to 
induce asymmetric cyclization to chiral chromans. Chromans are hydrobenzofuran motifs 
that constitute the core of many bioactive natural and synthetic molecules (Figure 3).10 
The vitamin E family and their synthetic analogs represent the most recognizable 
chromans. In addition to their wide-spread use as lipid-soluble anti-oxidant and radical 
scavenger, they have been shown to have cardioprotective, hypocholesteromic and anti-
cancer properties.11-13  
Furthermore, studies have shown that the stereochemistry at C2 of the chroman 
ring is key in determining the biopotency of vitamin E. That is, natural vitamin E isomers 
with an R configuration at the C2 position of the chroman ring possess far greater activity 
as they are preferentially accumulated by mammalian organisms.14,15 As such, significant 
efforts have been made to achieve the asymmetric synthesis of vitamin E.13,16 Most of the 
asymmetric methods to Vitamin E involve the asymmetric production of the chroman 
core by various means (chiral resolution,17-21 enzymatic resolution,22-26 chiral auxiliary,27-
29 metal-mediated asymmetric catalysis,30-33 and organic catalyst-mediated asymmetric 
catalysis34) before appending the appropriate terpenoid tail (Figure 4A-B). One method, 
that of the Woggon group, stands out in its creative use of a chiral auxiliary directly 
attached to the chroman core to affect asymmetric proton transfer in pseudo bio-mimicry 
of the natural vitamin E cyclase (Figure 4C).35,36         
While all of these asymmetric approaches to vitamin E synthesis are ingenious, 
they have not yet proven amenable to large-scale production, which largely explains why 
current industrial production of vitamin E remains racemic. Therefore, the development 









































Figure 3. Chiral chromans in important molecules. A) Natural vitamin E. B) Vitamin E 
analogs. C) Tocopherol cyclase’s asymmetric proton transfer mechanism. D) Selected molecules 































































   
Figure 4. A) Typical multi-stage approach to asymmetric vitamin E. B) Selected asymmetric 
strategies to the chroman core. C) Reported biomimetic method to vitamin E. D) Our direct 
biomimetic approach to vitamin E using our novel chiral acid system. 
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With the type II Adanve acids, we aimed to achieve a direct asymmetric synthesis 
of vitamin E in a mimic of the natural vitamin E cyclases where a combination of 
asymmetric proton transfer and binding of the reactive intermediate by the chiral 
environment of the catalyst would be in effect (Figure 4D). Chiral phosphoric acids are 
not strong enough to perform this envisioned cyclization. Figure 5 shows a representative 
set of the Adanve acids investigated.  
 
 
Figure 5. Representative examples of Adanve acids investigated. A) Linker length effects. B) 
Pseudoenantiomer effects. C) C3 and C6’ substitutient effects (includes 17). D) C9-OH 

























































4: Adanve-HC-S2F-OH Br, X = Br 































































































9: Adanve-C-S2-OH Br, X = Br
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6.2   Cyclization Conditions: Effects of Solvent, Substrate Concentration, Catalyst 
Loading, and Temperature on Product Yield and Enantioselectivity  
Using phytyl-TMHQ (23H) as the substrate, we first screened for conditions for 
the successful transformation of this starting material into α-tocopherol (24H) by the 
Adanve acids. Some of these factors are discussed below. At this stage, we chose 14C-
NMR as a convenient method to determine the product’s enantioselective excess 
(e.e.).37,38 While some e.e. was seemingly evident by this method (see Figure 7), the low 
signal to noise ratio of the acquired spectra, a result of the small reaction scales, do not 
permit us to draw a concrete conclusion.  
Figure 6. Enantioselective cyclization efforts 
Solvents 
We found that the Adanve acids performed best in halogenated solvents such as 
CH2Cl2, 1,2-DCE, and 1,1,2,2-tetrachloroethane (TeCE). While CH2Cl2 and TeCE led to 





























We found that a substrate concentration of at least 0.1M was helpful in achieving 
considerable conversion to product in the face of the competing oxidation of 23-H to 25. 
Going forward, we opted for a substrate concentration of 0.15M. 
Temperature 
Most of the sulfonic acid-based Adanve acids were active between 0 and 100 ºC, 
the reaction becoming catalytic (less than stochiometric amount of acid required) at 
higher temperatures but with no enantioselectivity by 14C-NMR.   
Adanve acids equivalents  
This factor proved to be dependant on the type of Adanve acid II used and on the 
reaction temperature. For the typical monomers (3 for example) at room temperature and 
below, more than stochiometric amounts (typically 3 equivalents) are required for 
considerable substrate conversion to the product (24H). The substituents on the catalyst 
scaffold factor into this matter as they may make the catalyst more soluble, thus requiring 
less of it. For example, catalysts with C6’-OMe were typically more soluble, thus more 
active. The counterion also plays a role. For example, 20 with an iodide counterion, was 
much more active than 9, which has a bromide counterion. The acid strength is another 
factor. For example, 4 and 21 were very active, nearly catalytic even at cold 
temperatures. 3 was a little more active than 9, which was in turn a lot more active than 
10.  
The dimeric Adanve acids (2 and 22) were more active beyond their obvious 
carrying of two sufonic acids moieties. With these dimers, often 1 equivalent was enough 
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to achieve complete cyclization when two equivalents of the monomer types did not yield 
the same results. This outcome points to a possible synergistic effect of the two sulfonic 
groups in proximity or to the enhancing effects of clusters of charged groups.  
Lastly, with the cinchona-based acids, we observed that those with S 
configuration (cinchonine) were generally more active than those with R configuration 
(cinchonidine). This observation is in line with literature reports that cinchonine and 
quinidine are more active than cinchonidine and quinine in spurring various 
processes.39,40  
Solvent Cat. (mol eq.) 
[23-H] 
(M) Δ (ºC) Time Outcome 
DCE 3 (3) 0.15 25 3 d *(S)-24H, 60% y 
CH2Cl2 3 (3) 0.15 25 2 d (rac)-24H, 85% y 
TeCE 3 (3) 0.15 25 2 d (rac)-24H, 80% y 
DCE 3 (3) 0.15 0 4 d mostly 25, little 24H 
DCE 3 (2) 0.15 50 8 h (rac)-24H, 70% y 
DCE 3 (0.5) 0.15 100 8 h (rac)-24H, 90% y 
DCE 9 (4) 0.15 25 2.5 d *(R)-24H, 50% y 
DCE 10 (6) 0.15 50 10 h mostly 25, little 24H 
DCE 11 (4) 0.15 25 5 d *(R)-24H, 57% y 
DCE 12 (4) 0.15 25 5 d *(S)-24H, 50% y 
DCE 13 (6) 0.15 25 5 d *(S)-24H, 28% y 
DCE 14 (3) 0.15 25 3 d *(S)-24H, 62% y 
DCE 15 (3) 0.15 25 2 d (rac)-24H, 50% y 
DCE 16 (3) 0.15 25 2 d *(S)-24H, 65% y 
DCE 17 (3) 0.15 25 2 d *(R)-24H, 63% y 
DCE 18 (3) 0.15 25 2 d *(S)-24H, 50% y 
DCE 19 (4) 0.15 50 2 d (rac)-24H, 20% y 
DCE 4 (0.9) 0.15 0 8 h (rac)-24H, 70% y 
DCE 20 (1) 0.15 25 10 h (rac)-24H, 90% y 
DCE 22 (1.2) 0.15 25 2 d (rac)-24H, 66% y 
Table 1. Summary of exploration with 23H. **diastereomer determination only denotes a 
qualitative excess as determined by diastereomeric C1’ peak heights in 14C-NMR spectra
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Figure 7. Qualitative determination of 24H diastereomers by 13C-NMR. A) Commercial (R)-
24H. B) Ambo-24H. C) 24H from the reaction of 23H with 9. D) 24H from the reaction of 23Ac 



















As summarized in Table 1, it appears that with the cinchona-based Adanve acids, 
the linker chain length, the C6’ substitution on the quinoline, and the counterion for the 
ammonium were the primary factors affecting asymmetric determination in the chroman 
formation. As such, we decided to focus on Adanve-C-S2-OH (9) to further explore other 
means to increase the diastereoselectivity, namely through modifications to the substrate 
23. We expected that once a modification of 23 was identified to achieve high
diastereomic excess with 9, that the opposite diastereomer could be achieved with 3 or 
16.  
6.3   Substrate Modifications: 1-OH Protecting Group Effects 
On the hypothesis that the nature of the substituent on the 1-OH of 23 could play 
a role in setting the stereochemistry at C2, we synthesized 23Ac, 23Bz, 23CPN, and 
23Ms.  
With the acetyl, benzoyl and mesyl groups of 23Ac, 23Bz and 23Ms respectively, 
we anticipated that their electron withdrawing effect would lower the nucleophilicity of 
the 4-OH, which may give enough time for the charged reactive intermediate to match 
the chiral environment provided by the catalyst before 4-OH attack of the tertiary 
carbocation at C2. With 23CPN, we hoped that the bulky (S)-camphanoyl group (CPN) 
occupying one face of the proto-chroman would force the acid catalyst to only approach 
from the other side, thereby donating the proton from only that side. Furthermore, we 
anticipated that specific asymmetric interactions between the two chiral groups 
(camphanoyl and cinchona)41 could enhance the diastereselectivity of the chroman 
formation. 
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Interestingly, the (S)-camphanoyl group led to zero diastereoselectivity (as 
comfirmed by both chiral HPLC and qualitative 14C-NMR). The benzoyl group also led 
to practically no diastereoselectivity despite its electron-withdrawing effect. Meanwhile, 
the mesyl group (not only electron-withdrawing but also “stickier”) seemed to lead to 
slightly higher diastereoselectivity (4.5%, however this result cannot yet be fully 
confirmed as the chiral separation by HPLC suffered from overlapping peaks with the 
conditions tried so far).  
Taken together, these results pointed to a possible interaction between the 
“sticky” group on the 1-OH and the hydrogen-bond-network42 of the Adanve acid, i.e., 
the stickier the group, the higher the stereoselectivity, which would explain why the 
bulkier groups led to no diastereoselectivity given their higher sterics. As such, we 
decided to explore such “sticky” groups further. More importantly, we hypothesized that 
such a group on the side chain itself (figure 7B, 26) instead of on the 1-OH, would have a 
positive effect on the enantioselectivity.   




23Ac 9 (4) 25 5 (S)-24Ac, 50% y, 2% e.e. 
23Bz 9 (4) 25 5 (S)-24Bz, 55% y, 2% e.e. 
23CPN 9 (4) 25 5 (rac)-24CPN, 48% y, 0% e.e. 
23Ms 9 (4) 25 7 24Ms, 40% y, e.e. (TBC, overlap) 
23Ms 20 (2) 25 2 24Ms, 80% y, e.e. (TBC, overlap) 
Table 2. Substrate modification effects: 1-OH protecting group. All experiments performed in 
DCE with a substrate concentration of 0.15M. a) Isolated yields; b) Diastereomer determination 
was performed by chiral HPLC; TBC = to be confirmed 
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6.4   Substrate Modifications: “Sticky” Side Chain Effects 
To investigate our hypothesis that a “sticky” group on the pro-chroman tail would 
allow for the fixation on the side chain through interactions with the hydrogen-bond-
network of the Adanve acid, this “fixation” in turn enhancing asymmetric proton delivery 
to the vinyl (see Figure 8), we decided to start with carboxylic acid 26. The cyclization of 
26 would lead to the commercially relevant, water-soluble vitamin E analog Trolox® 
(27).  
Figure 8. “Sticky” side chain interaction with hydrogen-bond-network of the Adanve 
acid 
Unfortunately, when subjected to the Adanve acids, oxidation of 26 to quinone 28 
and other side decomposition reactions take precedence over proton-induced cyclization. 
Adding zinc dust or sodium dithionite to the reaction only lead to starting material 
decomposition.   
To mitigate these side reactions, we decided to protect the radical generation 
prone 1-OH with a methyl group. When carboxylic acid 29 is subjected to the acids in 
CH2Cl2, Trolox methyl ether (30) is obtained in about 40% conversion after 10 days. The 


















deactivating effect of the neighboring carboxylic acid group. As to the enantioselectivity 
of the cyclization, the key goal here, efforts are ongoing to develop a chiral separation 
method for compound 30.  
Figure 9. Early “sticky” side chain investigations 
Substrate Catalyst (mol eq.) Δ (ºC) 
Time 
(d) Outcome
26 9 (4) RT 2 28, decomposition 
26 2 (1) RT 2 28, decomposition 
29 9 (4) RT 10 30 (40% y, e.e. TBD) 
29 3 (4) RT 10 30 (43% y, e.e. TBD) 
Table 3. Substrate modification effects: “sticky” side chain. **All experiments were performed in 
CH2Cl2 with a substrate concentration of 0.15M. TBD = to be determined 
 A note about the synthesis of 26 and 29
 En route to 26, the hydrolysis of ester 32 could only be achieved with pig liver 






















decomposition of the starting material. This outcome is likely due to the very labile 
benzylic protons given the neighboring α,β-unsaturated system. Furthermore, the 
successfully obtained 26 was very sensitive and quickly oxidized to quinone 28.  
For the synthesis of 29, the initial methylation of the starting material 31 was only 
successful with the trimethyloxonium tetrafluoroborate and proton-sponge® conditions.45 
All other methylation conditions (MeI or MeOTf with K2CO3 or Ag2O) led to starting 
material decomposition. Furthermore, hydrolysis of ester 34 only responded to PLE when 
an organic solvent additive such as methyl tert-butyl ether was added to the reaction. 
Chemical hydrolysis methods led to the compound’s decomposition. 
It would also be interesting to cyclize ester 34 (Figure 9B) by the Adanve acids 
although we do not anticipate great enantioselectivity given the bulky ethyl and lack of a 
proton to participate in the catalyst’s hydrogen-bond-network.  































































6.5   Additional Chiral Acids Synthesized and Explored  
Similar to the type I catalyst system (Chapter 5), we synthesized contructs 
combining a strong organic Bronsted acid (PTSA) with chiral phase transfer catalysts 
(37–39). In an early investigation of these constructs’ ability to induce asymmetric proton 
transfer, we found that they could cyclize 23H to 24H with slight enantioselectivity (13C 
NMR). Similarly, we synthesized and investigated 40 with a combination of PTSA with 
very slight asymmetric success.  
Furthermore, we synthesized CSA derivatives 41 and 42. Given their structural 
similarity to the cinchona-based Adanve acids, we thought they would be good model 
systems to investigate the enhancing effect of the ammonium group in the chiral acid. 41 
and 42 failed to convert 23H to 24H. The implications of these results were discussed in 
Chapter 5.  





















































6.6   Conclusion 
In the hope to help expand the arsenal of the exciting chiral Bronsted acid 
catalysis field, we developed a new class of chiral Bronsted acids (Adanve acids), 
materials that are highly tunable, easy to synthesize, and easy to handle as well as 
recover. In a preliminary exploration of the ability of these chiral acids to induce 
asymmetric proton transfer, we investigated their usage to impart asymmetric formation 
of chromans, namely the important vitamin E family.  
Our early findings suggest that a host of factors play a role in the ability of this 
novel acid catalyst system to induce asymmetric chroman formation. A more rigorous 
screening of solvent, concentration, temperature, and pressure conditions could reveal 
favorable conditions to achieve asymmetric formation of vitamin E by these acids. 
Furthermore, a type II Adanve acid with a more constraining chiral scaffold to limit the 
conformational freedoms of the docked subrates could be advantageous.  
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6.8   Experimental Section 
 
General procedures:  All reactions were carried out under argon atmosphere with dry 
solvents under anhydrous conditions, unless otherwise stated. Reagents were purchased 
from commercial vendors at the highest available purity and used without further 
purification.  
Dry dichloromethane (DCM), diethyl ether (Et2O), and tetrahydrofuran (THF) were 
purchased from Sigma-Aldrich. All reactions were stirred magnetically and monitored by 
TLC performed on 0.25 mm E. Merck silica gel plates (60F-254) using UV light as the 
visualizing agent or cerium ammonium molybdate (CAM) and heat as the developing 
agent. Silica gel (SiliCycle 60, academic grade) was used to carry out flash column 
chromatography. Unless otherwise recorded, yields refer to purified materials with 
spectroscopically (1H and 13C NMR) homogeneity. NMR spectra were recorded on 
Bruker DRX-300, DRX-400, and DRX-500 instruments calibrated using residual 
undeuterated solvents as internal reference. Multiciplicities were represented by the 
following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
AB = AB quartet, br = broad. IR spectra were recorded on a Perkin Elmer Spectrum 
Two® FT-IR spectrometer, and High-resolution mass spectra (HRMS) were recorded in 
the Columbia University Mass Spectral Core facility on a Waters XEVO G2XS QToF 
mass spectrometer using electrospray ionization (ESI), atmospheric solids analysis probe 
(ASAP) and atmospheric pressure chemical ionization (APCI) techniques.   
       
 
Abbreviations: DCM = dichloromethane, PLE = pig liver esterase, DIPEA = diisopropyl 
ethyl amine, MgSO4 = Magnesium sulfate, Et2O = diethyl ether, TMHQ = 
trimethylhydroquinone, (NH4)2SO4 = Ammonium sulfate, NH4Cl = ammonium chloride, 
EtOH = ethanol, MeOH = methanol, DI = distilled, HCl = hydrogen chloride, RT = room 
temperature, DCE = 1,2-dichloroethane, TeCE = 1,1,2,2-tetrachloroethane, EtOAc = 




Hydroquinone precursors preparation 
2,3,6-Trimethylhydroquinone-1-acetate (S1): see section 5.9 of Chapter 5. 
 
2,3,6-Trimethylhydroquinone-1-benzoyl (S2): was synthesized according to the 
method of for S1 described in Section 5.9, Chapter 5. Light yellow solid; Rf = 0.50 (silica 
gel, 30% EtOAc:hexanes); IR (film) 3456, 2927, 1708, 1585, 1451, 1417, 1314, 1271, 
1190, 1084, 1071, 708, 595; 1H NMR (300 MHz, CDCl3) δ 8.26 (d, J = 7.2 Hz, 1H), 
7.70 – 7.60 (m, 1H), 7.53 (t, J = 7.7 Hz, 1H), 6.48 (s, 1H), 2.14 (s, 3H), 2.09 (s, 3H), 2.08 
(s, 3H); 13C NMR (125 MHz, CDCl3) δ 165.7, 151.7, 141.9, 133.9, 133.2, 130.5, 130.5, 
130.2, 129.9, 129.7, 129.0, 128.8, 128.7, 128.0, 121.8, 115.0, 16.6, 13.5, 12.2; HRMS 
(ESI) calcd for C16H16O3Na [M + Na]+ 279.0997, found 279.1004.     
 
 
Phytyl-hydroquinone precursors preparation 
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6-Phylty-2,3,5-trimethylhydroquinone (23H): Made from trimethylhydroquinone and 
natural R,R-phytol according to the method described for the synthesis of geranylgeranyl-
trimethylhydroquinone in Section 5.9, Chapter 5. In this case, the centrifugation 
procedure yielded the clean product as an oily white solid that darkens slightly in storage. 
Rf = 0.25 (silica gel, 15% EtOAc:hexanes); IR (film) 3363 (br), 2953, 2924, 2866, 1460, 
1379, 1325, 1246, 1078, 1046, 557; 1H NMR (500 MHz, CDCl3) δ 5.14 (t, J = 6.6 Hz, 
1H), 4.77 (s, 1H), 4.33 (s, 1H), 3.40 (d, J = 6.7 Hz, 2H), 2.22 (s, 3H), 2.19 (s, 7H), 1.84 
(s, 2H), 1.55 (td, J = 13.3 Hz, 6.7 Hz, 1H), 1.43 – 1.03 (m, 18H), 0.92 – 0.88 (2 s, 7H), 
0.88 – 0.84 (m, 5H); 13C NMR (125 MHz, CDCl3) δ 146.7, 146.0, 139.0, 138.6, 123.9, 
122.6, 121.9, 121.6, 121.2, 119.8, 114.7, 40.3, 39.7, 37.8, 37.7, 37.6, 37.4, 37.0, 33.1, 
33.1, 33.0, 32.6, 28.3, 26.6, 26.4, 25.7, 25.1, 24.8, 23.8, 23.1, 23.0, 20.1, 16.5, 16.2, 12.6, 
12.5, 12.3; HRMS (ASAP) calcd for C30H44O2+ [M + H]+ 431.3889, found 431.3880. 
 
5-Phytyl-2,3,6-trimethylhydroquinone-1-acetate (23Ac): Synthesized from S1 and 
natural phytol according to the method described Section 5.9, Chapter 5 but without the 
centrifugation step. Instead, after purification on silica gel (5% EtOAc:hexanes), 23Ac 
was obtained as a viscous oil. Rf = 0.28 (silica gel, 15% EtOAc:hexanes); IR (film) 3496 
(br), 2925, 2866, 1743, 1459, 1369, 1206, 1073, 940, 735, 501; 1H NMR (300 MHz, 
CDCl3) δ 5.14 (t, J = 6.5 Hz, 1H), 5.07 (s, 1H), 3.37 (d, J = 6.7 Hz, 2H), 2.33 (s, 3H), 
2.15 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.02  1.96 (m, 2H), 1.81 (s, 2H), 1.74 – 1.71 (m, 
1H), 1.57 – 1.00 (m, 22H), 0.90 – 0.83 (m, 13H); 13C NMR (125 MHz, CDCl3) δ 170.0, 
150.8, 141.9, 139.2, 127.5, 125.9, 123.7, 121.9, 121.4, 40.3, 39.7, 37.8, 37.7, 37.6, 37.0, 
33.1, 33.0, 28.3, 26.7, 25.6, 25.1, 24.8, 23.1, 23.0, 20.9, 20.1, 20.0, 16.6, 13.4, 13.2, 12.4; 
HRMS (ESI) calcd for C31H52O3Na+ [M + Na]+ 495.3814, found 495.3818. 
 
5-Phytyl-2,3,6-trimethylhydroquinone-1-benzoyl (23Bz)15: Synthesized from S2 and 
natural phytol according to the method described Section 5.9, Chapter 5 minus the 
centrifugation step. After purification on silica gel (5% EtOAc:hexanes), 23Bz was 
obtained as a yellow oily solid. Rf = 0.32 (silica gel, 15% EtOAc:hexanes); IR (film) 
3467, 2924, 2867, 1710, 1599, 1454, 1378, 1274, 1236, 1109, 1095, 713; 1H NMR (300 
MHz, CDCl3) δ 8.27 (d, J = 7.1 Hz, 2H), 7.68 – 7.61 (m, 1H), 7.54 (t, J = 7.5 Hz, 2H), 
5.21 – 5.10 (m, 2H), 3.41 (d, J = 6.7 Hz, 2H), 2.19 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H), 
2.02 (t, J = 7.5 Hz, 2H), 1.83 (s, 2H), 1.76 – 1.40 (m, 1H), 1.59 – 1.02 (m, 22H), 0.91 – 
0.85 (m, 13H); 13C NMR (125 MHz, CDCl3) δ 165.4, 150.8, 142.0, 139.1, 133.8, 130.5, 
129.9, 128.9, 127.7, 126.2, 123.9, 121.9, 121.5, 40.3, 39.7, 37.8, 37.7, 37.6, 37.0, 33.1, 
33.0, 28.3, 26.7, 25.6, 25.1, 24.8, 23.0, 23.0, 20.1, 20.0, 16.6, 13.5, 13.3, 12.4; HRMS 
(ESI) calcd for C36H54O3Na+ [M + Na]+ 557.3971, found 557.3979.  
 
5-Phytyl-2,3,6-trimethylhydroquinone-1-methanesulfonate (23Ms): To a stirring 
solution of Ms2O (161.8 mg, 0.92 mmol, 1 equiv) in DCM (4 mL) at 0oC was added 23H 
(400 mg, 0.92 mmol, 1 equiv). Upon dissolution of 23H, DIPEA (0.22 mL, 1.2 mmol, 1.3 
equiv) was added dropwise followed by a small grain of DMAP. When 23H was fully 
converted (TLC), the reaction mixture was poured into NH4Cl (aq, 20 mL) and extracted 
with DCM (3 X 14 mL). The pooled organic fractions were washed with brine (20 mL), 
dried (MgSO4) and concentrated to yield, following silica gel purification (5% 
EtOAc:hexanes), 23Ms as a white solid (206 mg, 44%). Rf = 0.22 (silica gel, 15% 
235
EtOAc:hexanes); IR (film) 2954, 2921, 2869, 1718, 1607, 1460, 1376, 1252, 1175, 1047, 
967, 862, 795, 515; 1H NMR (500 MHz, CDCl3) δ 5.20 (br s, 1H), 5.12 (t, J = 6.6 Hz, 
1H), 3.37 (d, J = 6.6 Hz, 2H), 3.24 (s, 3H), 2.30 (s, 3H), 2.26 (s, 3H), 2.15 (s, 3H), 2.00 
(br s, 1H), 1.81 (s, 2H), 1.73 (s, 1H), 1.52 (td, J = 13.2, 6.6 Hz, 1H), 1.46 – 0.99 (m, 
23H), 0.90 – 0.81 (m, 15H); 13C NMR (500 MHz, CDCl3) δ 96.0, 93.3, 93.1, 90.5, 90.1, 
89.1, 88.7, 88.7, 88.5, 88.3, 68.0, 67.9, 67.7, 67.4, 67.4, 67.4, 67.2, 66.2, 66.2, 65.0, 64.6, 
64.3, 64.2, 64.1, 63.7, 63.7, 63.0, 62.9, 62.1, 61.7, 61.6, 61.1; HRMS (ESI) calcd for 
C30H52O4SNa+ [M + Na]+ 531.3484, found 531.3478. 
 
5-Phytyl-2,3,6-trimethylhydroquinone-1-(S)-camphanoyl (23CPN): Synthesized from 
23H and (S)-Camphanic chloride in 36% yield according to the method described for 
23Ms. White solid; Rf = 0.22 (silica gel, 15% EtOAc:hexanes); IR (film) 3474 (br), 
2953, 2925, 2869, 1795, 1755, 1461, 1378, 1311, 1165, 1095, 1057, 990, 958, 795, 730, 
509; 1H NMR (500 MHz, CDCl3) δ 5.15 (s, 1H), 5.13 – 5.07 (m, 1H), 3.72 (s, 1H), 3.36 
(d, J = 6.6 Hz, 2H), 2.62 – 2.53 (m, 1H), 2.29 – 2.17 (m, 2H), 2.14 (s, 4H), 2.12 (s, 1H), 
2.08 (s, 3H), 2.05 (s, 4H), 2.02 – 1.96 (m, 3H), 1.80 (s, 3H), 1.72 (s, 1H), 1.70 (s, 1H), 
1.52 (td, J = 13.2, 6.6 Hz, 1H) 1.44 – 1.21 (m, 15H), 1.20 – 1.14 (3 s, 14H), 1.10 – 1.00 
(m, 5H), 0.90 – 0.80 (m, 16H); 13C NMR (125 MHz, CDCl3) δ 178.3, 166.5, 151.0, 
141.4, 139.3, 127.0, 125.5, 123.9, 122.0, 121.9, 121.3, 91.4, 55.2, 54.5, 43.8, 40.3, 39.7, 
37.7, 37.7, 37.61, 37.0, 33.1, 33.0, 33.0, 31.8, 29.3, 28.3, 26.62, 25.6, 25.1, 24.8, 23.0, 
22.9, 20.1, 20.0, 17.3, 17.2, 16.5, 13.6, 13.4, 12.4, 10.0; HRMS (ESI) calcd for 
C39H62O3Na+ [M + Na]+ 633.4495, found 633.4498. 
 
3-(Ethyl-trans-2’,3’-dimethylacrylate)-2,5,6-trimethylhydroquinone (32): To a 
vigorously stirring solution of 5-Hydroxy-4,6,7-trimethyl-2(3H)-benzofuranone47, 48 (31, 
285mg, 1.48 mmol, 1 equiv) in DCM (15 mL) at -78oC was added dropwise a 1 M 
solution of DIBAL-H in heptane (3.7 mL, 3.7 mmol, 2.5 equiv). The resulting reaction 
mixture was subsequently stirred vigorously for 15 minutes, then 1 M HCl (10 mL) was 
poured into it at -78oC. The resulting mixture was warmed to room temperature and 
extracted with ether (3 X 30 mL). After washing the pooled organic fractions with brine 
and drying over MgSO4, the solvent was removed under reduced pressure to yield white 
flakes.  
This material was dissolved in DCM (15 mL) followed by the addition of 
(Carbethoxyethylidene)triphenylphosphorane (1.1 g, 2.96 mmol, 2 equiv). After stirring 
for 3 hours at RT, the solvent was removed and the resulting sticky solid extracted with 
50% Ether:hexane to yield, after silica gel purification (5% EtOAc:hexanes), a mixture of 
32 and its quinone as an oil (307 mg, 75%). 32 quickly converts into its quinone in 
chloroform-d; the following characterization data is for the quinone form.  Rf = 0.70 
(silica gel, 30% EtOAc:Hexanes); IR (film) 2987, 2854, 1680, 1636, 1426, 1374, 1309, 
1276, 1265, 1210, 862, 741, 422; 1H NMR (300 MHz, CDCl3) δ 6.51 (td, J = 7.3, 1.5 
Hz, 1H), 4.29 – 4.11 (m, 4H), 3.38 (d, J = 7.2 Hz, 2H), 2.05 – 2.01 (3 s, 10H), 1.98 (d, J = 
1.2 Hz, 3H), 1.53 (s, 8H), 1.35 – 1.22 (m, 6H); 13C NMR 125 MHz, CDCl3) δ 141.3, 
140.2, 137.0, 61.0, 34.3, 26.5, 22.9, 14.6, 13.2, 13.0, 12.9, 12.8; HRMS (ESI) calcd for 
C16H20O4Na+ [M + Na]+ 299.1259, found 299.1264. 
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3-(trans-2’,3’-dimethylacrylic acid)-2,5,6-trimethylquinone (28): To a suspension of 
32 (250 mg, 0.9 mmol, 1 equiv) in 0.1 M phosphate buffer (20 mL, pH 7) was added PLE 
(100 mg) and CH3CN (2 mL). The suspension was stirred vigorously for 8 hours 
whereupon it was diluted with NH4Cl (aq., 40 mL) and extracted with ether (4 X 25 mL, 
centrifugation was helpful in breaking the emulsion). The pooled organic fractions were 
dried over MgSO4 and concentrated to yield 28 as an off white solid (223 mg, 99%).  Rf 
= 0.51 (silica gel, 5% MeOH:DCM); IR (film) 2918 (br), 2849 (br), 2652 (br), 2562 (br), 
1686, 1635, 1428, 1372, 1302, 1275, 1260, 1208, 863, 740, 715, 421; 1H NMR (400 
MHz, CDCl3) δ 6.65 (td, J = 7.3, 1.4 Hz, 1H), 3.41 (d, J = 7.3 Hz, 2H), 2.04 (s, 3H), 2.02 
(s, 6H), 2.00 (s, 3H), 1.25 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 187.7, 186.8, 171.4, 
149.1, 142.0, 141.1, 140.9, 140.9, 139.8, 128.6, 30.0, 26.7, 12.8, 12.8, 12.7, 12.7; HRMS 
(ESI) calcd for C14H16O4Na+ [M + Na]+ 271.0946, found 271.0949. 
 
3-(trans-2’,3’-dimethylacrylic acid)-2,5,6-trimethyl-1-methoxyhydroquinone (29): A 
slurry of 31 (0.7 g,  mmol, 1 equiv),  [Me3OBF4] (3 equiv), and proton-sponge® (3.3 
equiv) in CH2Cl2 was stirred vigorously overnight at room temperature. The reaction 
mixture was then directly applied to a silica gel column and eluted with 2% EtOAc in 
hexanes to yield 33 as a white solid that turns pink upon standing. 29 was derived from 
33 according to the same DIBAL-H followed by Wittig olefination process outlined 
above for 32. The resulting ester 34 was hydrolyzed with PLE in a 1:1 mixture of 
phosphate buffer and t-butyl methyl ether over four days at room temperature to yield 29 
as a white powder. Rf = 0.35 (silica gel, 30% EtOAc:Hexanes); IR (film) 3660, 2960, 
2920, 2850, 1705, 1460, 1400, 1370, 1350, 1025; 1H NMR (400 MHz, CDCl3) δ 6.82 (t, 
J = 6.7 Hz, 1H), 3.62 (s, 3H), 3.55 (d, J = 7.1 Hz, 2H), 2.20 (s, 6H), 2.13 (s, 3H), 2.01 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 172.4, 151.0, 148.3, 143.2, 128.7, 127.9, 127.1, 
122.3, 120.3, 60.8, 27.4, 13.2, 12.7, 12.6, 12.5; HRMS (ESI) calcd for C15H19O4- [M - 
H]- 263.1283, found 263.1285.  
 
Type II Adanve Acids preparation: See Section 5.9 of Chapter 5 for synthesis and 
characterization data for selected type II Adanve acids. 
 
Standard procedure for enantio-selective cycloetherification to chiral chromans using 
Type II Adanve Acids: Same as in the regioselective cycloetherification of 
geranylgeranyl-hydroquinones described in Section 5.9 of the preceding chapter.  
 
α-Tocopherol (24H): See Table 1. Purification by silica gel gel (4% EtOAc:hexanes); 
clear viscous oil. Rf = 0.34 (silica gel, 15% EtOAc:hexanes); IR (film) 3567 (br), 2924, 
2866, 1458, 1377, 1260, 1211, 1159, 10583, 1058, 1009, 918, 647; 1H NMR (300 MHz, 
CDCl3) δ 2.61 (t, J = 6.8 Hz, 1H), 2.16 (s, 2H), 2.12 (s, 3H), 1.79 (dq, J = 13.5, 6.6 Hz, 
1H), 1.62 – 1.00 (m, 13H), 0.90 – 0.82 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 145.9, 
144.9, 123.0, 121.3, 117.7, 100.3, 74.9, 40.25, 40.18, 39.7, 37.9, 37.8, 37.8, 37.7, 37.6, 
33.2, 33.1, 31.9, 31.9, 28.3, 25.2, 24.8, 24.1, 23.1, 23.0, 21.4, 21.1, 20.1, 12.1, 11.6; 
HRMS (ASAP) calcd for C29H51O2+ [M + H]+ 431.3889, found 431.3894; HPLC 
(Chiralcel OD-H, 0.5% 2-propanol in hexanes, 1.0 mL/min, 25 ºC, 220 nm): t(2R, 4’R,8’R) = 
9.5 min, t(2S, 4’R,8’R) = 10.6 min. 
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α-Tocopherol acetate (24Ac): See Table 2. Purification by silica gel (4% 
EtOAc:hexanes); clear viscous oil that crystallizes at 0 ºC. Rf = 0.40 (silica gel, 15% 
EtOAc:hexanes); IR (film) 2925, 2866, 1758, 1459, 1367, 1205, 1160, 1077, 849, 680, 
617, 484; 1H NMR (300 MHz, CDCl3) δ 2.59 (t, J = 6.7 Hz, 2H), 2.33 (s, 3H), 2.09 (s, 
3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.87 – 1.68 (m, 2H), 1.60 – 1.55 (m, 1H), 1.53 (s, 2H), 
1.52 – 1.26 (m, 10H), 1.24 (s, 4H), 1.22 – 1.00 (m, 7H), 0.92 – 0.81 (m, 12H); 13C NMR 
(100 MHz, CDCl3) δ 170.0, 149.8, 140.9, 127.0, 125.2, 123.4, 117.7, 75.4, 39.7, 37.8, 
37.6, 33.1, 33.1, 31.4, 28.3, 25.1, 24.8, 23.1, 23.0, 21.4, 20.9, 20.9, 20.1, 20.0, 13.3, 12.4, 
12.2; HRMS (ESI) calcd for C31H52O3Na+ [M + Na]+ 495.3814, found 495.3812; HPLC 
(Chiralcel OD-H, 0.02% 2-propanol in hexanes, 1.0 mL/min, 25 ºC, 220 nm): t(2R, 4’R,8’R) 
= 25.9 min, t(2S, 4’R,8’R) = 28.8 min. 
 
 
α-Tocopherol mesylate (24Ms): See Table 2. Purification by silica gel (4% 
EtOAc:hexanes), viscous oil that crystallizes into an off white solid upon storage at 0 ºC.  
Rf = 0.30 (silica gel, 15% EtOAc:hexanes); IR (film) 2926, 2856, 1743, 1461, 1409, 
1342, 1176, 1106, 1056, 967, 909, 872, 730, 649, 517; 1H NMR (500 MHz, CDCl3) δ 
5.40  5.32 (m, 1H), 3.23 (s, 3H), 2.60 (t, J = 6.7 Hz, 2H), 2.32 (t, J = 7.4 Hz, 1H), 2.25 (s, 
3H), 2.22 (s, 3H), 2.10 (s, 3H), 2.08 – 2.00 (m, 1H), 1.87  1.73 (m, 2H), 1.64 – 1.03 (m, 
32H), 0.92  0.85 (m, 14H); 13C NMR (125 MHz, CDCl3) δ 150.5, 139.9, 130.5, 130.3, 
128.9, 128.4, 128.2, 127.5, 124.1, 118.4, 75.7, 69.2, 62.4, 40.3, 39.7, 39.0, 37.8, 37.7, 
37.7, 37.6, 34.3, 33.1, 33.0, 31.8, 31.3, 30.1, 30.0, 29.9, 29.7, 29.5, 29.4, 28.3, 27.5, 26.0, 
25.1, 24.8, 24.2, 23.0, 22.95, 22.9, 21.3, 21.0, 20.1, 20.0, 14.8, 14.4, 14.4, 14.0, 12.2  ; 
HRMS (ESI) calcd for C30H52O4SNa+ [M + Na]+ 531.3484, found 531.3483; HPLC 
([Chiralcel OD-H, 0.05% 2-propanol in hexanes, 1.0 mL/min, 25 ºC, 220 nm] has given 
the best separation so far but still with some overlap). 
 
 
Methyl-Trolox® (30): See Table 3.  IR (film) 3240, 2963, 2919, 2852, 1705, 1461, 1402, 
1371, 1349, 1020 1H NMR (400 MHz, CDCl3) δ 3.62 (s, 3H), 2.71 – 2.53 (m, 2H), 2.42 
– 2.32 (m, 1H), 2.19 (s, 3H), 2.15 (s, 3H), 2.12 (s, 3H), 2.02 – 1.90 (m, 1H), 1.62 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 176.5, 151.0, 146.8, 145.4, 128.9, 126.5, 123.1, 117.8, 
60.7, 30.1, 24.6, 20.7, 12.9, 12.2, 12.0; HRMS (APCI) calcd for C15H19O4- [M - H]- 
263.1283, found 263.1290; HPLC (ongoing).  
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